

ESU course 1 - Oligometastatic treatment in genitourinary tumors (bladder, renal, prostate)

ESU Course 1

**02 November
2023
09:00 - 12:00**

**Location
Chair**

Morgiou
G. Gandaglia, Milan (IT)

09:00 - 09:05

European School of Urology: A unique possibility for urological education

G. Gandaglia, Milan (IT)

09:05 - 09:25

Definitions and biology of oligometastases

R. Flippot, Villejuif (FR)

09:25 - 09:55

Role of imaging modalities

G. Gandaglia, Milan (IT)

09:55 - 10:05

Break

10:05 - 10:45

Radiotherapeutic management of oligometastases in genitourinary tumors

N. Sanmamed, Madrid (ES)

10:45 - 11:10

Salvage surgical treatment in oligometastatic disease

G. Gandaglia, Milan (IT)

11:10 - 11:40

Role of systemic therapy in oligometastatic disease

R. Flippot, Villejuif (FR)

11:40 - 11:55

Discussion

11:55 - 12:00

Take home messages and closure

Welcome and Introduction

ESUI Welcome and introduction

**02 November
2023
09:00 - 09:10**

**Location
Chair**

Callelongue
F. Sanguedolce, Barcelona (ES)

The future of prostate cancer screening programme in EU: Evidence, technologies and strategies

ESUI Plenary session 1

**02 November
2023
09:10 - 10:50**

**Location
Chairs**

Callelongue
F. Sanguedolce, Barcelona (ES)
L. Budäus, Hamburg (DE)

09:10 - 09:30	EU recommendations on PCa screening programme: What we expect in the next 5 years H. Van Poppel, Leuven (BE)
09:30 - 09:50	Strategies to screen population
09:30 - 09:40	Challenges of MRI in (any) screening programmes I.G. Schoots, Rotterdam (NL)
09:40 - 09:50	The lung cancer screening model T.G. Blum, Berlin (DE)
09:50 - 10:10	Prostate cancer screening: The PSA/biomarker implemented pathway
09:50 - 10:00	The GOTEBORG-2 trial J. Hugosson, Gothenburg (SE)
10:00 - 10:10	ProSa V. Panebianco, Rome (IT)
10:10 - 10:30	Prostate cancer screening: The MRI only pathway
10:10 - 10:20	Prostagram Trial D. Eldred-Evans, London (GB)
10:20 - 10:30	Re-Imagine Trial S. Punwani, London (GB)
10:30 - 10:50	Q&A and discussion

YAU session

YAU Plenary Session 1

**02 November
2023
10:00 - 11:00**

**Location
Chairs**

Sormiou
J. Gómez Rivas, Madrid (ES)
L.A. 't Hoen, Rotterdam (NL)

10:00 - 10:15

YAU overview

J. Gómez Rivas, Madrid (ES)

10:15 - 10:30

Update of the non-oncology groups

A. Pietropaolo, Southampton (GB)

10:30 - 10:45

Update of the uro-oncology groups

C.D. Fankhauser, Lucerne (CH)

10:45 - 11:00

Q & A

YAU/Y-ESTRO/Y-ESMO session

YAU Plenary session 2

**02 November
2023
11:00 - 12:30**

Location Sormiou
Chair J. Gómez Rivas, Madrid (ES)

11:00 - 11:30

Best paper / project 2022

11:00 - 11:10

Best paper by YAU 2022: Three-dimensional Model-assisted Minimally Invasive Partial Nephrectomy: A Systematic Review with Meta-analysis of Comparative Studies

Presenter F. Piramide, Turin (IT)

11:10 - 11:20

Best paper / project by Y-ESMO 2022: Availability and accessibility of biomolecular technologies in oncology in Europe

Presenter A. Bayle, Villejuif (FR)

11:20 - 11:30

Best paper / project by Y-ESTRO 2022 – Genomic Classifiers in Genomic Classifiers in Personalized Prostate Cancer Radiation Therapy Approaches: A systematic Review and Future Perspectives Based on International Consensus

Presenter S.K.B. Spohn, Freiburg (DE)

11:30 - 12:15

Soft Skills Session

11:30 - 11:37

Talent Incubator Programme
J. N'Dow, Aberdeen (GB)

11:37 - 11:45

Career development within the EAU
J. N'Dow, Aberdeen (GB)

11:45 - 12:00

Y-ESTRO: Diversity, Equity and inclusion within the Radiation
A. Abravan, Manchester (GB)

12:00 - 12:15

Y-ESMO: Mentorship and Professional Development opportunities
M. Kfoury, Marseille (FR)

12:15 - 12:30

Q & A

Other imaging modalities – updates for PCa diagnostic

ESUI Plenary session 2

**02 November
2023
11:10 - 11:50**

Location Callelongue
Chairs V. Scattoni, Milan (IT)
M. Mischi, Eindhoven (NL)

11:10 - 11:20

Ultrasound based – mpUS trial
T. Loch, Flensburg (DE)

11:20 - 11:30

PSMA based (DEPROMP trial)
M. Ritter, Bonn (DE)

11:30 - 11:40

Artificial Intelligence/MRI based: The ProCancer-I project
J. Almeida, Lisbon (PT)

11:40 - 11:50

Machine Learning/3D-US based: PCaVision trial
H. Wijkstra, Amsterdam (NL)

Latest evidence in imaging trials and their clinical implications

ESUI Plenary session 3

**02 November
2023
11:50 - 12:30**

Location Callelongue
Chairs V. Kasivisvanathan, London (GB)
G. Lughezzani, Milan (IT)

11:50 - 12:00

**ZIRCON – Girentuximab-PET/CT
in RCC phase III trial**

**Case
presenter** P. Mulders, Nijmegen
(NL)

12:00 - 12:03

Discussion

12:03 - 12:13

**PRIME – BiParametric MRI
phase III trial**

**Case
presenter** V. Kasivisvanathan,
London (GB)

12:13 - 12:16

Discussion

12:16 - 12:26

**PRECISE trial: MRI features
predicting active surveillance
failure**

**Case
presenter** A. Stabile, Milan (IT)

12:26 - 12:29

Discussion

12:29 - 12:30

Conclusion

Welcome and introduction

ESUP Welcome and introduction

**02 November
2023
13:30 - 13:35**

Location Chairs

Sormiou
M. Colecchia, Milan (IT)
K. Junker, Homburg (DE)

Biomarkers and molecular tests in bladder urothelial carcinoma

ESUP session 1

**02 November
2023
13:35 - 15:15**

**Location
Chairs**

Sormiou
M. Colecchia, Milan (IT)
K. Junker, Homburg (DE)
G.P. Paner, Chicago (US)

13:35 - 14:00

Molecular Differences between Primary bladder Tumors and metastasis and differences in PDL-1 expression
M. Eckstein, Erlangen (DE)

14:00 - 14:30

G.P. Paner, Chicago (US)
M.B. Amin, Los Angeles (US)
Proposal of a new grading in non-muscle invasive bladder cancer

**Case
presenter**

M. Colecchia, Milan (IT)

14:30 - 15:00

Artificial Intelligence in uro pathology
M.B. Amin, Los Angeles (US)

15:00 - 15:15

Discussion

ESU Course 2 - Neoadjuvant and adjuvant treatments in genitourinary tumors

ESU Course 2

**02 November
2023
14:00 - 17:00**

Location Morgiou
Chair R. Campi, Florence (IT)

14:00 - 14:05	European School of Urology: A unique possibility for urological education R. Campi, Florence (IT)
14:05 - 14:35	Neoadjuvant/adjuvant treatment in renal cancer R. Campi, Florence (IT)
14:35 - 14:55	Clinical cases in high-risk localized renal cancer R. Campi, Florence (IT)
14:55 - 15:05	Break
15:05 - 15:35	Neoadjuvant/adjuvant treatment in bladder cancer B. Szabados, London (GB)
15:35 - 15:50	Clinical cases in bladder cancer B. Szabados, London (GB)
15:50 - 16:20	Neoadjuvant/adjuvant treatment in high-risk localized prostate cancer T. Zilli, Bellinzona (CH)
16:20 - 16:40	Clinical cases in high-risk localized prostate cancer T. Zilli, Bellinzona (CH)
16:40 - 16:55	Discussion
16:55 - 17:00	Closing remarks R. Campi, Florence (IT)

Imaging-guided surgery and interventions

Industry sponsored session

**02 November
2023
14:00 - 14:45**

**Location
Chairs**

Callelongue
P. Martino, Bari (IT)
F. Sanguedolce, Barcelona (ES)

14:00 - 14:30

**The future of targeted therapies: What's in the pipeline for
theranostics in GU cancers**

14:00 - 14:15

Theranostics in prostate cancer

Presenter J. Walz, Marseille (FR)

14:15 - 14:30

**Theranostics in renal and
bladder cancers**

Presenter F. Ceci, Milano (IT)

14:30 - 14:45

**Novel clinical applications of
blue light in bladder cancer**

Presenter M.C. Kriegmair,
Mannheim (DE)

Joint Session ESUI-ESUR: the role of NGI in the management of bladder cancer

ESUI-ESUR Joint session 4

**02 November
2023
14:45 - 15:45**

Location Callelongue
Chair M. Rouprêt, Paris (FR)

14:45 - 15:00

Current role of NGI in bladder cancer

V. Panebianco, Rome (IT)

15:00 - 15:15

Clinical case in NMI of bladder tumour (guided by Delphi process)

Case presenter
Provoker

M. Pecoraro, Rome (IT)

M.C. Kriegmair,
Mannheim (DE)

15:15 - 15:30

Clinical case in MI of bladder tumour (guided by Delphi process)

Case presenter
Provoker

A.W. Postema,
Amsterdam (NL)

M. Rouprêt, Paris (FR)

15:30 - 15:45

Q&A and discussion

New and old controversies in urothelial carcinoma

ESUP session2

**02 November
2023
15:15 - 16:45**

Location Sormiou
Chairs M. Colecchia, Milan (IT)
K. Junker, Homburg (DE)
G.P. Paner, Chicago (US)

15:15 - 15:45

M.B. Amin, Los Angeles (US)
M. Colecchia, Milan (IT)
G.P. Paner, Chicago (US)
pT1 substaging in bladder carcinoma

Case presenter M.R. Raspollini,
Florence (IT)

15:45 - 16:00

Nectin-4 expression in metastatic urothelial carcinoma and therapeutic correlations
N. Klümper, Bonn (DE)

16:00 - 16:30

Results of ISUP Consensus Conference the pathology of urachal neoplasms and glandular lesions of the urinary bladder
G.P. Paner, Chicago (US)

16:30 - 16:45

Discussion

Nuclear medicine in urology: Lessons learnt and new horizons

ESUI Plenary session 5

**02 November
2023
16:10 - 17:10**

Location Callelongue
Chairs G. Salomon, Hamburg (DE)
J. Walz, Marseille (FR)

- 16:10 - 16:25** **Enhancing access to radiotheranostics for cancer care, worldwide – the Oncidium initiative**
A. Viana, Auderghem (BE)
- 16:25 - 16:40** **Current challenges of PSMA PET/CT in Prostate cancer**
D. Oprea-Lager, Amsterdam (NL)
- 16:40 - 16:55** **Different tracers for different indication (every cancer)**
A. Chiti, Milan (IT)
- 16:55 - 17:10** **Q&A and discussion**

Closing remarks

ESUP Closing remarks

**02 November
2023
16:45 - 17:00**

**Location
Chairs**

Sormiou
M. Colecchia, Milan (IT)
K. Junker, Homburg (DE)

Closing remarks

ESUI Closing remarks

**02 November
2023
17:10 - 17:15**

**Location
Chair**

Callelongue
F. Sanguedolce, Barcelona (ES)

Welcome and introduction

Welcome and introduction

**03 November
2023
08:45 - 09:00**

**Location
Chairs**

Auditorium
C. Porta, Bari (IT)
P. Hoskin, Northwood (GB)
A. Stenzl, Tübingen (DE)

Hands-on Training Course in MRI reading

HOT 1

**03 November
2023
09:00 - 12:30**

Location Sormiou
Chair V. Kasivisvanathan, London (GB)
Tutors M. Pecoraro, Rome (IT)
V. Panebianco, Rome (IT)
L. Budäus, Hamburg (DE)

09:00 - 09:05

Course Overview

V. Kasivisvanathan, London (GB)

09:05 - 09:15

Lecture: The importance of prostate MRI to the Urologist

L. Budäus, Hamburg (DE)

09:15 - 09:45

Lecture: Introduction to MRI sequences, scoring systems, PI-RADS

M. Pecoraro, Rome (IT)

09:45 - 10:15

Lecture: Interactive case discussion – reporting MRI using PI-RADS

V. Panebianco, Rome (IT)

10:15 - 10:20

Introduction to the MIM software for MRI interpretation

V. Kasivisvanathan, London (GB)

10:20 - 10:50

Diagnosis I: Practical MRI diagnosis

10:50 - 11:20

Review of the findings I

V. Panebianco, Rome (IT)

11:20 - 11:30

Diagnosis II: Practical MRI diagnosis

11:30 - 12:00

Review of the findings II

M. Pecoraro, Rome (IT)

12:00 - 12:30

Discussion, feedback, & closure

Genito-urinary cancer screening in 2023

Plenary Session 1

03 November
2023
09:00 - 10:30

Location Auditorium
Chairs H. Van Poppel, Leuven (BE)
H. Thoeny, Fribourg (CH)

09:00 - 09:10

Incidence, prevalence and mortality of GU tumours in 2023
To be confirmed

09:10 - 09:20

Risk-adapted strategy for screening and early detection in prostate cancer
H. Van Poppel, Leuven (BE)

09:20 - 09:30

Rationale for renal cell carcinoma screening
G.D. Stewart, Cambridge (GB)

09:30 - 09:40

Large-scale interception using personalised prevention algorithms - an opportunity for urothelial cancer screening
R. Flippot, Villejuif (FR)

09:40 - 10:00

Discussion

O07

Improved oncologic outcomes after radical prostatectomy and lymph node dissection in patients who received staging PSMA PET/CT: A propensity score matched analysis

Authors: [Ettema R.H.](#)¹, [Meijer D.](#)¹, [Mellema J.J.](#)¹, [van Leeuwen P.J.](#)², [Luining W.I.](#)¹, [van der Poel H.G.](#)², [Donswijk M.L.](#)³, [Nieuwenhuijzen J.A.](#)¹, [van den Bergh R.C.N.](#)⁴, [Oprea-Lager D.E.](#)⁵, [Vis A.N.](#)¹

Institutes: ¹Amsterdam University Medical Centre, Dept. of Urology, Amsterdam, The Netherlands, ²The Netherlands Cancer Institute, Dept. of Urology, Amsterdam, The Netherlands, ³The Netherlands Cancer Institute, Dept. of Nuclear Medicine, Amsterdam, The Netherlands, ⁴St. Antonius Hospital, Dept. of Urology, Nieuwegein, The Netherlands, ⁵Amsterdam University Medical Centre, Dept. of Radiology and Nuclear Medicine, Amsterdam, The Netherlands

O08

Intense surveillance for patients treated with radical prostatectomy and adverse pathologic features: early results from “easy-1 (early salvage radiotherapy-1) protocol”

Authors: [Tamburini S.](#)¹, [Bianchi L.](#)¹, [Mottaran A.](#)¹, [Droghetti M.](#)¹, [Piazza P.](#)¹, [Chessa F.](#)¹, [Catanzaro C.](#)¹, [Ntreta M.](#)², [Siepe G.](#)², [Schiavina R.](#)¹, [Morganti A.G.](#)², [Brunocilla E.](#)¹

Institutes: ¹IRCCS Azienda Ospedaliero-universitaria di Bologna, Dept. of Urology, Bologna, Italy, ²IRCCS Azienda Ospedaliero-Universitaria di Bologna, Dept. of Radiation Oncology, Bologna, Italy

10:20 - 10:30

Discussion

New horizons for high risk localised prostate cancer

Plenary Session 2

**03 November
2023
11:15 - 12:15**

Location Chairs

Auditorium
P. Hoskin, Northwood (GB)
J. Gómez Rivas, Madrid (ES)
D. Oprea-Lager, Amsterdam (NL)
H. Thoeny, Fribourg (CH)

11:15 - 11:25

Image guided LN dissection

T. Maurer, Hamburg (DE)

11:25 - 11:35

Lutetium and beyond

A. Chiti, Milan (IT)

11:35 - 11:45

MR guided radiotherapy and SABR

A. Tree, Sutton, Surrey (GB)

11:45 - 11:55

How systemic treatment should be used for men with high-risk localised prostate cancer in 2023?

S. Merler, Verona (IT)

11:55 - 12:15

Discussion

Multidisciplinary case discussion: Your next Monday morning prostate cancer challenging case

Plenary Session 3

**03 November
2023
12:15 - 12:45**

**Location
Moderator**

Auditorium
F. Sanguedolce, Barcelona (ES)

12:15 - 12:45

T. Zilli, Bellinzona (CH)
H. Thoeny, Fribourg (CH)
D. Oprea-Lager, Amsterdam (NL)
G. Gravis, Marseilles (FR)

**Case
presenter**

J. Gómez Rivas, Madrid
(ES)

Hands-on Training Course in MRI reading

HOT 2

**03 November
2023
14:00 - 17:30**

Location Sormiou
Chair F. Sanguedolce, Barcelona (ES)
Tutors L. Budäus, Hamburg (DE)
M. Pecoraro, Rome (IT)
I.G. Schoots, Rotterdam (NL)

14:00 - 14:05

Course Overview

F. Sanguedolce, Barcelona (ES)

14:05 - 14:15

Lecture: The importance of prostate MRI to the Urologist

F. Sanguedolce, Barcelona (ES)

14:15 - 14:45

Lecture: Introduction to MRI sequences, scoring systems, PI-RADS

14:45 - 15:15

Lecture: Interactive case discussion – reporting MRI using PI-RADS

15:15 - 15:20

Introduction to the MIM software for MRI interpretation

15:20 - 15:50

Diagnosis I: Practical MRI diagnosis

15:50 - 16:20

Review of the findings I

16:20 - 16:50

Diagnosis II: Practical MRI diagnosis

16:50 - 17:20

Review of the findings II

17:20 - 17:30

Discussion, feedback, & closure

Learning points from morbidity and mortality

Plenary Session 4

**03 November
2023
14:00 - 15:10**

**Location
Chairs**

Auditorium
U. Vogl, Bellinzona (CH)
T. Zilli, Bellinzona (CH)
A. Bex, London (GB)
B. Leigh, London (GB)

14:00 - 14:10

Introduction

B. Leigh, London (GB)

14:10 - 14:20

BCa

M.C. Mir Maresma, Valencia (ES)

14:20 - 14:30

Discussion

14:30 - 14:40

PCa

G. Gandaglia, Milan (IT)

14:40 - 14:50

Discussion

14:50 - 15:00

RCC (e.g T3 renal tumour...)

F. Mumtaz, London (GB)

15:00 - 15:10

Discussion

Innovative concepts and new modalities of treatment in urothelial carcinomas

Plenary Session 5

03 November
2023
15:40 - 17:00

Location Auditorium
Chairs J. Puente, Madrid (ES)
V. Achard, Fribourg (CH)
M. Rouprêt, Paris (FR)

15:40 - 15:50 **Systemic versus intravesical drug from high-risk NMIBC naive from BCG**

A.M. Kamat, Houston (US)

15:50 - 16:00 **Active surveillance in NMIBC: myth or reality?**

P. Gontero, Turin (IT)

16:00 - 16:20 **How to select my patients for conservative management for MIBC after neoadjuvant chemotherapy?**

Presenters V. Panebianco, Rome (IT)
G. Niegisch, Düsseldorf (DE)
N. Sanmamed, Madrid (ES)

16:20 - 16:30 **Discussion**

O09 **Comparison of the Genomic Alterations in Upper-tract and Bladder Urothelial Carcinoma**

Authors: Yekeduz E.¹, Saliby R.M.², Shah V.², Baca S.C.², Eid M.², Saad E.², Semaan K.², Bellmunt J.³, Choueiri T.K.³, Ürün Y.⁴

Institutes: ¹Ankara Etlik City Hospital, Dept. of Medical Oncology, Ankara, Turkey, ²Dana-Farber Cancer Institute, Dept. of Medical Oncology, Boston, United States of America, ³Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States of America, ⁴Ankara University School of Medicine, Dept. of Medical Oncology, Ankara, Turkey

O10 **The 3 year follow-up of the phase 1b-2 study on chemoradiotherapy combined with nivolumab monotherapy or ipilimumab and nivolumab in muscle-invasive bladder cancer**

Authors: Remmelink M.J.¹, Oddens J.R.¹, Nieuwenhuijzen J.A.¹, Voortman J.², de Reijke T.M.¹, Beerlage H.P.¹, van der Hulle T.³, Daniëls L.A.⁴, Bins A.D.²

Institutes: ¹Amsterdam UMC, Dept. of Urology, Amsterdam, The Netherlands, ²Amsterdam UMC, Dept. of Medical Oncology, Amsterdam, The Netherlands, ³Leiden University Medical Center, Dept. of Medical Oncology, Leiden, The Netherlands, ⁴Amsterdam UMC, Dept. of Radiotherapy, Amsterdam, The Netherlands

16:50 - 17:00 **Discussion**

Multidisciplinary case discussion: UTUC - from conservative to systemic treatment

Plenary Session 6

**03 November
2023
17:00 - 17:30**

Location Auditorium
Moderator M. Rouprêt, Paris (FR)

17:00 - 17:30

Y. Lorient, Villejuif (FR)
E. Laukhtina, Vienna (AT)
J.A. Hernández Mancera, Barcelona (ES)
E. Compérat, Paris (FR)
**UTUC - from conservative to
systemic treatment**

**Case
presenter** A. Galloli, Barcelona
(ES)

Game changing session

Plenary Session 7

**04 November
2023
08:45 - 10:05**

Location Auditorium
Chairs A.S. Merseburger, Lübeck (DE)
K. Fizazi, Villejuif (FR)
V. Fonteyne, Ghent (BE)

08:45 - 08:55	NEphron Sparing Treatment (NEST) for small renal masses M. Tran, London (GB)
08:55 - 09:00	Discussion
09:00 - 09:10	Update on PSMA targeting A. Farolfi (IT)
09:10 - 09:20	EMBARK S. Freedland, Los Angeles (US)
09:20 - 09:30	Update on TALAPRO-2 and PROpel F. Schlürmann, Brest (FR)
09:30 - 09:35	Discussion
09:35 - 09:45	EV-302/KEYNOTE-A39 trial T. Powles, London (GB)
09:45 - 09:55	THOR Trial Y. Loriot, Villejuif (FR)
09:55 - 10:05	Discussion

Hand-on Training Course in PSMA/PET image reading

HOT 3

**04 November
2023
09:00 - 12:30**

Location Sormiou
Tutors F. Sanguedolce, Barcelona (ES)
 V. Kasivisvanathan, London (GB)
 J. Walz, Marseille (FR)
 D. Oprea-Lager, Amsterdam (NL)
 R. Mei, Bologna (IT)

09:00 - 09:10	Importance of PSMA/PET imaging to the Urologist and introduction to the course	Tutor	V. Kasivisvanathan, London (GB)
09:10 - 09:25	Overview of PET-tracers and radioligands	Tutor	R. Mei, Bologna (IT)
09:25 - 09:40	Principles of PET reading in Prostate Cancer	Tutor	D. Oprea-Lager, Amsterdam (NL)
09:40 - 09:55	Current data on PET imaging in newly diagnosed prostate cancer for diagnosis & staging	Tutor	V. Kasivisvanathan, London (GB)
09:55 - 10:40	Review & Discussion of PSMA/PET images for initial prostate cancer staging	Tutor	R. Mei, Bologna (IT)
10:40 - 10:55	Current data on PET imaging in recurrent prostate cancer	Tutor	F. Sanguedolce, Barcelona (ES)
10:55 - 11:40	Review & Discussion of PSMA/PET images of prostate cancer recurrence	Tutor	D. Oprea-Lager, Amsterdam (NL)
11:40 - 11:55	Current data on the role of PET imaging for selection of radioligand therapy candidates in advanced prostate cancer	Tutor	J. Walz, Marseille (FR)

Scientific Programme - EMUC23

11:55 - 12:29

**Review & Discussion of
PSMA/PET images of advanced
prostate cancer**

Tutor

R. Mei, Bologna (IT)

12:29 - 12:30

Summary and Close

Tutor

F. Sanguedolce, Barcelona
(ES)

Multidisciplinary case discussions in kidney cancer

Plenary Session 8

**04 November
2023
10:35 - 11:35**

Location Auditorium
Moderator A. Bex, London (GB)

10:35 - 11:05

N. Sanmamed, Madrid (ES)
Y.Ü. Ürün, Ankara (TR)
A.S. Merseburger, Lübeck (DE)
H. Thoeny, Fribourg (CH)
K. Junker, Homburg (DE)
**Multidisciplinary case
discussion: Oligometastatic
clear-cell renal cell carcinoma**

**Case
presenter** R. Campi, Florence
(IT)

11:05 - 11:35

Y.Ü. Ürün, Ankara (TR)
A.S. Merseburger, Lübeck (DE)
H. Thoeny, Fribourg (CH)
M. Eckstein, Erlangen (DE)
K. Junker, Homburg (DE)
**Multidisciplinary case
discussion: Management of non
clear-cell renal cell carcinomas**

**Case
presenter** L. Marandino, Milan (IT)

Interdisciplinary challenges in penile and testicular cancer

Plenary Session 9

04 November
2023
11:35 - 12:45

Location Auditorium
Moderator J. Oldenburg, Oslo (NO)

11:35 - 12:05

C. Protzel, Schwerin (DE)
L. Varela, Marseille (FR)
A. Tran, Manchester (GB)
M. Colecchia, Milan (IT)
A. Tsili, Ioannina (GR)
Management of locally advanced (cN+ cM0) squamous cell carcinoma of the penis

Case presenter J.M. Gaya Sopena, Barcelona (ES)

12:05 - 12:35

S. Fischer, St. Gallen (CH)
A. Papachristofilou, Basel (CH)
C.D. Fankhauser, Lucerne (CH)
E. Comp erat, Paris (FR)
A. Tsili, Ioannina (GR)
Management of CSIIB seminoma

Case presenter C. Oing, Newcastle upon Tyne (GB)

O11

Post-chemotherapy retroperitoneal lymph node dissection for metastatic testicular cancer at a national referral center

Authors: Evmorfopoulos K.¹, Vlachostergios P.², Chasiotis G.¹, Karatzas A.¹, Zachos I.¹, Dimitropoulos K.³, Pisters L.⁴, Tzortzis V.¹

Institutes: ¹University of Thessaly, Faculty of Medicine School of Health Sciences University Hospital of Larissa, Dept. of Urology, Larissa, Greece, ²IASO Thessalias Hospital, Dept. of Medical Oncology, Larissa, Greece, ³University of Aberdeen Aberdeen Royal Infirmary NHS Grampian, Dept. of Urology, Aberdeen, United Kingdom, ⁴The University of Texas MD Anderson Cancer Center, Dept. of Urology, Houston, United States of America

Hands-on Training Course in MRI fusion biopsy

HOT 4

**04 November
2023
14:00 - 17:00**

Location Morgiou
Chair L. Budäus, Hamburg (DE)
Tutors J. Hanske, Herne (DE)
C. Wetterauer, Basel (CH)
C. Kastner, Cambridge (GB)
A.S. Rannikko, Helsinki (FI)
F. Sanguedolce, Barcelona (ES)
G. Lughezzani, Milan (IT)

14:00 - 14:05

Introduction

L. Budäus, Hamburg (DE)

14:05 - 14:20

Different MRI-Ultrasound technical approaches available

L. Budäus, Hamburg (DE)

14:20 - 14:50

Demonstration: How to perform a transperineal biopsy

L. Budäus, Hamburg (DE)

14:50 - 16:50

Hands-on training at stations

Tutors

F. Sanguedolce, Barcelona (ES)
L. Budäus, Hamburg (DE)
G. Lughezzani, Milan (IT)
C. Kastner, Cambridge (GB)
C. Wetterauer, Basel (CH)
J. Hanske, Herne (DE)
A.S. Rannikko, Helsinki (FI)

16:50 - 17:00

Discussion, Feedback, & Closure

L. Budäus, Hamburg (DE)

Research Foundation session

Plenary Session 10

**04 November
2023
14:00 - 14:15**

**Location
Chairs**

Auditorium
A.S. Bjartell, Malmö (SE)
W.P.J. Witjes, Arnhem (NL)

14:00 - 14:05

PRIME study
V. Kasivisvanathan, London (GB)

14:05 - 14:10

MINERVA and ROGUE-1 projects
D. D'Andrea, Vienna (AT)

14:10 - 14:15

Discussion

New opportunities in genito-urinary tumours

Plenary Session 11

**04 November
2023
14:15 - 15:30**

Location Auditorium
Chairs V. Fonteyne, Ghent (BE)
M. Rouprêt, Paris (FR)
C. Porta, Bari (IT)

14:15 - 14:25

What can we learn from other tumours?

C. Massard, Villejuif (FR)

14:25 - 14:35

Strategies for penile preservation in early penile cancer

A. Parnham, Manchester (GB)

14:35 - 14:45

Novel immune approaches in GU

Y. Loriot, Villejuif (FR)

14:45 - 14:55

Spatial transcriptomics/proteomics on tissue sections: the way to individualise (immune) therapy

M. Eckstein, Erlangen (DE)

14:55 - 15:05

De-escalation strategies in metastatic seminoma: ready for prime time?

A. Papachristofilou, Basel (CH)

15:05 - 15:30

Discussion

Individualised approaches to kidney cancer

Plenary Session 12

04 November
2023
16:00 - 17:30

Location Auditorium
Chairs P. Blanchard, Villejuif (FR)
M.C. Mir Maresma, Valencia (ES)
M. Colecchia, Milan (IT)

16:00 - 16:10

New imaging approaches in kidney cancer

A. Volpe, Novara (IT)

16:10 - 16:20

Clinical impact of the new WHO classification of KT

M.B. Amin, Los Angeles (US)

16:20 - 16:30

Indications of treating the primary in metastatic kidney cancer in the IO era

G. Pignot, Marseille (FR)

O12

Tumor Response by Baseline Metastases in Patients (Pts) With Renal Cell Carcinoma (RCC) Treated with Lenvatinib (L) Plus Pembrolizumab (P) vs Sunitinib (S): Post Hoc Analysis of the CLEAR Trial

Authors: Grünwald V.¹, McKay R.R.², Buchler T.³, Masatoshi E.⁴, Park S.H.⁵, Takagi T.⁶, Zanetta S.⁷, Keizman D.⁸, Suárez C.⁹, Négrier S.¹⁰, Lee J.L.¹¹, Santini D.¹², Bedke J.¹³, Staehler M.¹⁴, Kollmannsberger C.¹⁵, Choueiri T.¹⁶, Motzer R.¹⁷, Burgents J.¹⁸, Okpara C.¹⁹, Powles T.²⁰

Institutes: ¹University Hospital Essen, Interdisciplinary Genitourinary Oncology Clinic for Urology Clinic for Medical Oncology, Essen, Germany, ²University of California San Diego, Division of Hematology-Oncology, La Jolla, United States of America, ³First Faculty of Medicine Charles University and Thomayer University Hospital, Dept. of Oncology, Prague, Czech Republic, ⁴Kyushu University, Dept. of Urology, Fukuoka, Japan, ⁵Samsung Medical Center, Division of Hematology Oncology, Dept. of Medicine, Seoul, South Korea, ⁶Tokyo Women's Medical University, Dept. of Urology, Tokyo, Japan, ⁷Georges-François Leclerc Cancer Centre, Dept. of Oncology, Dijon, France, ⁸Tel-Aviv Sourasky Medical Center, Dept. of Oncology, Tel-Aviv, Israel, ⁹Vall d'Hebron Institute of Oncology Hospital Universitari Vall d'Hebron Vall d'Hebron Barcelona Hospital Campus, Dept. of Medical Oncology, Barcelona, Spain, ¹⁰Centre Léon Bérard, University of Lyon, Lyon, France, ¹¹University of Ulsan College of Medicine, Asan Medical Center, Dept. of Oncology and Internal Medicine, Seoul, South Korea, ¹²Policlinico Umberto 1 La Sapienza Università di Roma, Dept. of Medical Oncology A, Rome, Italy, ¹³Klinikum Stuttgart, Dept. of Urology, Stuttgart, Germany, ¹⁴University Hospital of Munich, Dept. of Urology, Munich, Germany, ¹⁵BC Cancer - Vancouver Cancer Centre, Dept. of Medical Oncology, Vancouver, Canada, ¹⁶Dana-Farber Cancer Institute, Dept. of Medical Oncology, Boston, United States of America, ¹⁷Memorial Sloan Kettering Cancer Center, Dept. of Medicine, New York, United States of America, ¹⁸Merck and Co. Inc., Dept. of Global Clinical Development, Rahway, United States of America, ¹⁹Eisai Ltd., Clinical Research, Hatfield, United Kingdom, ²⁰The Royal Free NHS Trust, Dept. of Oncology, London, United Kingdom

16:40 - 17:00

Discussion

17:00 - 17:20

Who is the best candidate for adjuvant therapy?

Clinical perspective

R. Pichler, Innsbruck (AT)

Research perspective

K. Junker, Homburg (DE)

17:20 - 17:30

Discussion

EMUC23 Networking and Abstract Discussion Session

Poster Session

04 November
2023
17:30 - 18:30

Location Les Goudes

- P001** **Programmed death-ligand (PD-L1) immunoexpression and clinical outcomes in Penile Squamous Cell Carcinoma**
Authors: Macedo Alves Peyroteo Gomes I.S.¹, Santos F.²
Institutes: ¹Portuguese Institute of Oncology in Lisbon, Dept. of Urology, Lisbon, Portugal, ²Portuguese Institute of Oncology in Lisbon, Dept. of Pathology, Lisbon, Portugal
- P002** **Saving more than just skin: A study of penile sparing approaches in cancer treatment**
Authors: Shaker G., Shaker M.
Institutes: Aneurin Bevan NHS health board, Dept. of Urology, Newport, United Kingdom
- P003** **The added value of systematic biopsy to targeted biopsy and selection of clinical variables in patients with PIRADS =3 lesions**
Authors: Riaza Montes M.¹, Aguirre Larracochea U.², Gascón Pérez M.², Gallego Sánchez J.A.¹
Institutes: ¹Galdakao-Usansolo Hospital, Dept. of Urology, Galdakao, Spain, ²Galdakao-Usansolo Hospital, Biostatistician Research Unit, Galdakao, Spain
- P004** **Utility of metastatic screening with computerized tomography and bone-scan after prostate cancer diagnosis**
Authors: Minguez Ojeda C.S., Fernandez Conejo G., Tagalos Munoz A., Mata Alcaraz M., Lopez Perez E., García Barreras S., Sanz Mayayo E., Rodriguez Patron R., Burgos Revilla F.J.
Institutes: Hospital Ramon y Cajal, Dept. of Urology, Madrid, Spain
- P005** **The accuracy and intra- and interobserver variability of PSMA PET/CT for the local staging of primary prostate cancer**
Authors: Donswijk M.L.¹, Ettema R.H.², Meijer D.², Wondergem M.¹, Cheung Z.¹, Bekers E.M.³, van Leeuwen P.J.⁴, van den Bergh R.C.N.⁵, van der Poel H.G.⁴, Vis A.N.², Oprea-Lager D.E.⁶
Institutes: ¹The Netherlands Cancer Institute - Antoni van Leeuwenhoek, Dept. of Nuclear Medicine, Amsterdam, The Netherlands, ²Amsterdam University Medical Centres, Dept. of Urology, Amsterdam, The Netherlands, ³The Netherlands Cancer Institute - Antoni van Leeuwenhoek, Dept. of Pathology, Amsterdam, The Netherlands, ⁴The Netherlands Cancer Institute - Antoni van Leeuwenhoek, Dept. of Urology, Amsterdam, The Netherlands, ⁵St. Antonius Hospital, Dept. of Urology, Nieuwegein, The Netherlands, ⁶Amsterdam University Medical Centres, Dept. of Radiology and Nuclear Medicine, Amsterdam, The Netherlands

- P006** **The additional value of 68Ga-PSMA PET/CT SUVmax in predicting ISUP GG=2 and ISUP GG=3 prostate cancer in biopsy**
Authors: Heetman J.G.¹, Paulino Pereira L.J.¹, Kelder J.C.², Soeterik T.F.W.¹, Wever L.¹, Lavalaye J.³, van der Hoeven E.J.R.J.⁴, Lam M.G.E.H.⁵, van Melick H.H.E.¹, van den Bergh R.C.N.¹
Institutes: ¹Sint Antonius Hospital, Dept. of Urology, Nieuwegein, The Netherlands, ²Sint Antonius Hospital, Dept. of Cardiology, Nieuwegein, The Netherlands, ³Sint Antonius Hospital, Dept. of Nuclear Medicine, Nieuwegein, The Netherlands, ⁴Sint Antonius Hospital, Dept. of Radiology, Nieuwegein, The Netherlands, ⁵University Medical Center Utrecht, Dept. of Radiology and Nuclear Medicine, Utrecht, The Netherlands
- P007** **Efficacy of Prostate Health Index for diagnosis of prostate cancer**
Authors: Chung J.H., Song W., Jeon S.S.
Institutes: Samsung Medical Center, Dept. of Urology, Seoul, South Korea
- P008** **Prostate-Specific Antigen (PSA) level and International Prostate Symptom Score (IPSS) as stratifiers for positive Magnetic Resonance Imaging (MRI) results in biopsy-naïve men**
Authors: Paulino Pereira L.J., Gravendeel S.I., Heetman J.G., Prinsen A.M.A., van Melick H.H., van den Bergh R.C.
Institutes: Sint Antonius Hospital, Dept. of Urology, Nieuwegein, The Netherlands
- P009** **The probability of metastases within different Prostate-Specific Antigen (PSA) ranges using Prostate-Specific Membrane Antigen (PSMA) positron emission tomography in patients with newly diagnosed prostate cancer**
Authors: Luining W.I.¹, Hagens M.J.², Meijer D.¹, Ettema R.H.¹, van Moorselaar R.J.A.¹, van Leeuwen P.J.², Oprea-Lager D.E.³, Vis A.N.¹
Institutes: ¹Amsterdam University Medical Center, Prostate Cancer Network the Netherlands, Dept. of Urology, Amsterdam, The Netherlands, ²Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Prostate Cancer Network the Netherlands, Dept. of Urology, Amsterdam, The Netherlands, ³Amsterdam University Medical Center, Dept. of Radiology and Nuclear Medicine, Amsterdam, The Netherlands
- P010** **Prostate-Specific Antigen Density (PSAD) in post-Magnetic Resonance Imaging (MRI) risk-stratification to avoid biopsies and detection of low-risk prostate cancer: Results of the MR-PROPER study**
Authors: Prinsen A.M.A.¹, Somford D.M.², Van den Bergh R.C.N.¹, Schoots I.G.³
Institutes: ¹St. Antonius Hospital, Dept. of Urology, Nieuwegein, The Netherlands, ²Canisius-Wilhelmina Hospital, Dept. of Urology, Nijmegen, The Netherlands, ³Erasmus MC University Medical Center, Dept. of Radiology and Nuclear Medicine, Rotterdam, The Netherlands
-

- O05** **Pre-magnetic resonance imaging (MRI) prostate-specific antigen density (PSAD) risk-stratification to avoid MRIs, biopsies and detection of low-risk prostate cancer: Results of the MR-PROPER study**
Authors: Prinsen A.M.A.¹, Somford D.M.², Van den Bergh R.C.N.¹, Schoots I.G.³
Institutes: ¹St. Antonius Hospital, Dept. of Urology, Nieuwegein, The Netherlands, ²Canisius-Wilhelmina Hospital, Dept. of Urology, Nijmegen, The Netherlands, ³Erasmus MC University Medical Center, Dept. of Radiology and Nuclear Medicine, Rotterdam, The Netherlands
- P012** **Telomere biology as a prognostic factor in radical prostatectomy**
Authors: Rubio Galisteo J.M.¹, Gómez Gómez E.¹, Carrasco Valiente J.¹, Cano Castineira R.¹, Esteban Lafuente L.², Najarro P.², De Pedro N.², Blanca Pedregosa A.¹
Institutes: ¹Reina Sofía University Hospital, IMIBIC, UCO, Dept. of Urology, Cordoba, Spain, ²LifeLength, Madrid, Spain
- P013** **Development and validation of deep-learning model to predict adverse pathology at radical prostatectomy: A focus on pre-surgical clinical variables**
Authors: Song S.H.¹, Chang D.E.², Byun S-S.¹
Institutes: ¹Seoul National University Bundang Hospital, Dept. of Urology, Seongnam, South Korea, ²Korea Advanced Institute of Science and Technology, School of Electrical Engineering, Daejeon, South Korea
- P014** **Diagnostic accuracy of next generation imaging tests for prostate cancer in clinical practice**
Authors: Gonzalo Balbas A., Guijarro A., De La Pena E., Sanchez-Rosendo L., Jiménez E., Hernández V., Pérez E., Llorente C.
Institutes: Hospital Universitario Fundación Alcorcón, Dept. of Urology, Alcorcón-Madrid, Spain
- P015** **Automated pelvic MRI measurements associated with urinary incontinence for prostate cancer patients undergoing radical prostatectomy**
Authors: van den Berg I.¹, Spaans R.N.², Wessels F.J.³, van der Hoeven E.J.R.J.⁴, Tutein Nolthenius C.J.⁴, van den Bergh R.C.N.², van der Voort van Zyp J.R.N.¹, van den Berg C.A.T.¹, van Melick H.H.E.²
Institutes: ¹University Medical Center Utrecht, Radiation Oncology, Utrecht, The Netherlands, ²St. Antonius Hospital, Urology, Nieuwegein, The Netherlands, ³University Medical Center Utrecht, Radiology, Utrecht, The Netherlands, ⁴St. Antonius Hospital, Radiology, Nieuwegein, The Netherlands
- P016** **PSMA PET/CT for the targeting of prostate biopsies: Additional value over MRI**
Authors: Morré C.J.W.M.¹, Boer J.J.², Rynja S.P.¹, Hagens M.J.³, Noordzij M.A.¹
Institutes: ¹Spaarne Gasthuis, Dept. of Urology, Hoofddorp, The Netherlands, ²Spaarne Gasthuis, Dept. of Nuclear Medicine, Hoofddorp, The Netherlands, ³Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital NCI-AVL, Dept. of Urology, Amsterdam, The Netherlands
-

- P017** **MRI/US fusion, transperineal prostate biopsy utilising electro-magnetic 'Vector' needle tracking, under local anesthesia**
Authors: De Santis M.¹, Fletcher P.², Barrett T.³, Kastner C.⁴
Institutes: ¹Università degli Studi di Roma Tor Vergata, Dept. of Medicine and Surgery, Rome, Italy, ²Cambridge University Hospitals, Dept. of Radiology, Cambridge, United Kingdom, ³GenesisCare Cambridge, Dept. of Radiology, Cambridge, United Kingdom, ⁴GenesisCare Cambridge, Dept. of Urology, Cambridge, United Kingdom
- P018** **Is multiparametric MRI always needed in biopsy-naïve patients with abnormal digital rectal examination? A single-institutional experience combining clinical and micro-ultrasonography based factors to optimize prostate cancer detection.**
Authors: Avolio P.P., Maffei D., Fasulo V., Paciotti M., Saitta C., De Carne F., Buffi N.M., Lazzeri M., Lughezzani G.
Institutes: Humanitas University, Dept. of Biomedical Science, Pieve Emauele, Italy
- P019** **A Cost-Benefit Comparison of Biparametric Magnetic Resonance Imaging Versus Conventional Prostate Cancer Screening**
Authors: Park K.K.
Institutes: Jeju National University, Dept. of Urology, Jeju, South Korea
- P020** **Reducing the number of prostate magnetic resonance imaging (MRI) in biopsy-naïve men with prostate-specific antigen (PSA) <6 ng/ml using PSA-density (PSAD) and digital rectal examination (DRE) risk stratification**
Authors: Paulino Pereira L.J., Prinsen A.M.A., Heetman J.G., van Melick H.H., van den Bergh R.C.
Institutes: Sint Antonius Hospital, Dept. of Urology, Nieuwegein, The Netherlands
- P021** **The value of PSMA-PET in Addition to mpMRI and Systematic Biopsies to Select Patients for Hemi-ablative Focal Therapy in Prostate Cancer**
Authors: Scheltema M.J.V.¹, Geboers B.¹, Meijer D.², Counter W.³, Thompson J.¹, Doan P.¹, Gondoputro W.¹, Katelaris A.¹, Haynes A.M.⁴, Delprado W.⁵, Vis A.², van Leeuwen P.⁶, Ho B.³, Liu V.³, Lee J.³, Donswijk M.⁷, Oprea-Lager D.⁸, Emmett L.³, Stricker P.¹
Institutes: ¹St. Vincents Prostate Cancer Research Centre, Dept. of Urology, Sydney, Australia, ²Amsterdam UMC, Dept. of Urology, Amsterdam, The Netherlands, ³St. Vincents Hospital, Dept. of Theranostic Medicine, Sydney, Australia, ⁴Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Dept. of Urology, Sydney, Australia, ⁵Douglas Hanly Moir Pathology, Dept. of Pathology, Sydney, Australia, ⁶Antoni van Leeuwenhoek Netherlands Cancer Institute, Dept. of Urology, Amsterdam, The Netherlands, ⁷Antoni van Leeuwenhoek Netherlands Cancer Institute, Dept. of Radiology, Amsterdam, The Netherlands, ⁸Amsterdam UMC, Dept. of Radiology and Nuclear Medicine, Amsterdam, The Netherlands

- P022** **Correlation of maximum standardized uptake value (SUVmax) on PSMA-ligand PET/CT and the numerical DROP-IN gamma probe signal for intraoperative identification of prostate cancer lesions**
Authors: Berrens A.C.¹, Sorbi M. A.¹, Donswijk M.L.², de Barros H. A.¹, Azargoshasb S.³, van Oosterom M. N.³, Rietbergen D. D. D.⁴, Bekers E.⁵, van der Poel H. G.¹, van Leeuwen F. W. B.³, van Leeuwen P. J.¹
Institutes: ¹Antoni van Leeuwenhoek Hospital, Dept. of Urology, Amsterdam, The Netherlands, ²Antoni van Leeuwenhoek Hospital, Dept. of Nuclear Medicine, Amsterdam, The Netherlands, ³Interventional Molecular Imaging Laboratory, Leiden University Medical Centre, Dept. of Radiology, Leiden, The Netherlands, ⁴Leiden University Medical Centre, Dept. of Nuclear Medicine, Leiden, The Netherlands, ⁵Antoni van Leeuwenhoek Hospital, Dept. of Pathology, Amsterdam, The Netherlands
- P023** **The Impact of Palliative Transurethral Resection of the Prostate on the Prognosis of no radical surgery indications Prostate Cancer Patients: A SEER Database Study**
Authors: Fanyu M., Fei Z., Hua S.
Institutes: The Affiliated BenQ Hospital of Nanjing Medical University, Dept. of Urology, Nanjing, China
- P024** **A randomized Phase 3 trial of Metformin in patients initiating androgen deprivation therapy as PRevention and Intervention of MEtabolic syndrome: The PRIME Study**
Authors: Elangovan A.¹, Eigl B.J.², Ghosh S.¹, Kim J.³, Thoms J.⁴, Bouchard M.⁵, Peacock M.⁶, Fleshner N.⁷, Campbell H.⁸, Vigneault E.⁹, Vincent F.¹⁰, So A.¹¹, Cury F.¹², Quon H.¹³, Carlson R.¹⁴, Lambert C.¹⁵, Klotz L.¹⁶, Chi K.², Brundage M.¹⁷, Pollak M.¹⁸, Usmani N.¹
Institutes: ¹Cross Cancer Institute, Dept. of Radiation Oncology, Edmonton, Canada, ²British Columbia Cancer Agency, Dept. of Medical Oncology, Vancouver, Canada, ³Max Rady College of Medicine, Dept. of Radiation Oncology, Winnipeg, Canada, ⁴Dr. H. Bliss Murphy Cancer Centre, Dept. of Oncology, St. John's, Canada, ⁵Centre Hospitalier Universitaire de Sherbrooke, Dept. of Radiation Oncology, Sherbrooke, Canada, ⁶British Columbia Cancer Agency, Dept. of Radiation Oncology, Vancouver, Canada, ⁷University of Toronto, Dept. of Urology, Toronto, Canada, ⁸Saint John Regional Hospital, Dept. of Radiation Oncology, Saint John, Canada, ⁹Centre de Recherche du CHU de Québec-Université Laval, Dept. of Radiation Oncology, Quebec, Canada, ¹⁰Centre Intégré Universitaire de Santé et de Services Sociaux de la Mauricie-et-du-Centre-du-Québec, Dept. of Radiation Oncology, Trois-Rivières, Canada, ¹¹University of British Columbia, Dept. of Urologic Sciences, Vancouver, Canada, ¹²McGill University Health Centre, Dept. of Radiation Oncology, Montreal, Canada, ¹³Tom Baker Cancer Centre, Dept. of Radiation Oncology, Calgary, Canada, ¹⁴Northeast Cancer Centre, Dept. of Radiation Oncology, Sudbury, Canada, ¹⁵Centre Hospitalier de l'Université de Montréal, Dept. of Radiation Oncology, Montreal, Canada, ¹⁶Sunnybrook Health Sciences Centre, Dept. of Radiation Oncology, Toronto, Canada, ¹⁷Kingston Regional Cancer Centre, Dept. of Oncology, Kingston, Canada, ¹⁸Jewish General Hospital, Dept. of Oncology, Montreal, Canada

- P025** **The role of DNA repair genes mutational status in prostate cancer treatment with androgen signaling blockade**
Authors: Stukan A.
Institutes: Clinical Oncology Dispensery 1, Drug Supply Coordination, Krasnodar, Russia
- P026** **Clinical aspects of prostate cancer in patients with germinal and somatic mutations in homologous recombination repair (HRR) genes**
Authors: Stukan A.
Institutes: Clinical Oncology Dispensery, Drug Supply Coordination, Krasnodar, Russia
- P027** **Stereotactic re-irradiation for local relapse after prostate/prostate-bed radiotherapy**
Authors: Giannini L.¹, Torrisi M.¹, Deantoni C.L.¹, Fodor A.¹, Broggi S.², Perna L.², Fiorino C.², Midulla M.¹, Villa S.L.¹, Dell'Oca I.¹, Del Vecchio A.², Arcangeli S.³, Di Muzio N.G.¹
Institutes: ¹IRCCS San Raffaele Scientific Institute, Dept. of Radiation Oncology, Milan, Italy, ²IRCCS San Raffaele Scientific Institute, Dept. of Medical Physics, Milan, Italy, ³IRCCS San Gerardo dei Tintori, Dept. of Radiation Oncology, Monza, Italy
- P028** **Evaluation of the influence of the cardiovascular risk score on survival in metastatic prostate cancer.**
Authors: Veloso Gonçalves M., Teixeira C.M., Lopes De Almeida C., Baptista Freitas M., C. Couto M., Lemos T., Marques Ribeiro M.J., Augusto I., Barbosa M., Meireles S.
Institutes: Sao Joao University Hospital Center, Dept. of Medical Oncology, Porto, Portugal
- P029** **The histomorphological dynamics of MRI-progressing prostate cancer lesions.**
Authors: Stavrinides V.¹, Trahearn N.², Eksi E.³, Haider A.⁴, Freeman A.⁴, Kirkham A.⁵, Allen C.⁵, Emberton M.⁶, Giganti F.⁵, Moore C.⁶
Institutes: ¹UCL, Dept. of Urology, London, United Kingdom, ²ICR, Cancer Evolution, London, United Kingdom, ³OHSU, CEDAR, Portland, United States of America, ⁴UCLH, Dept. of Pathology, London, United Kingdom, ⁵UCLH, Dept. of Radiology, London, United Kingdom, ⁶UCLH, Dept. of Urology, London, United Kingdom
- P030** **Mid-term follow up analysis of patients at suspicion of prostate cancer that avoided prostate biopsy after negative magnetic resonance imaging**
Authors: Tagalos Munoz A.C., Fernández Conejo G., López Plaza J.A., Fernández Mardomingo A., Mínguez Ojeda C., Mata Alcaraz M., Sanz Mayayo E., Rodríguez-Patrón Rodríguez R., García Barreras S., Fraile Poblador A., Burgos Revilla F.J.
Institutes: Hospital Universitario Ramón y Cajal, Dept. of Urology, Madrid, Spain
-

- P031** **Optimized detection of local recurrence of prostate cancer using a dual time point contrast-enhanced [18F]PSMA-1007 PET/CT and TOF+PSF reconstruction**
Authors: Mamlins E.¹, Novruzov E.¹, Dabir M.¹, Mattes-György K.¹, Schmitt D.¹, Kuhlmann J.¹, Beu M.¹, Antke C.¹, Cardinale J.¹, Radtke J.P.², Antoch G.³, Niegisch G.², Schimmöller L.⁴, Giesel F.L.¹
Institutes: ¹University Hospital Duesseldorf, Department of Nuclear Medicine, Duesseldorf, Germany, ²University Hospital Duesseldorf, Department of Urology, Duesseldorf, Germany, ³University Hospital Duesseldorf, Department of Diagnostic and Interventional Radiology, Duesseldorf, Germany, ⁴Marien Hospital Herne, Department of Diagnostic and Interventional Radiology and Nuclear Medicine, Herne, Germany
- P032** **Stereotactic prostate radiotherapy with or without androgen deprivation therapy: A phase III, multi-institutional randomized-controlled trial. The SPA trial**
Authors: Triggiani L.¹, Morelli V.¹, Tomasini D.¹, Francesco F.², Georgopoulos A.¹, Mataj E.¹, Domina A.O.¹, Granello L.¹, Francolini G.³, Albano D.⁴, Magli A.⁵, Arcangeli S.⁶, Bruni A.⁷, Ciccarelli S.⁸, Ghirardelli S.⁹, Guerini A.E.¹, Grazioli L.¹⁰, Lancia A.¹¹, La Mattina S.¹¹, Buglione di Monale e Bastia M.¹, Marvaso G.¹², Sepulcri M.¹³, Franzese C.¹⁴, Barbera F.², Bonù M.L.F.¹
Institutes: ¹Istituto del Radio O. Alberti - Spedali Civili di Brescia - University of Brescia, Dept. of Radiation Oncology, Brescia, Italy, ²Istituto del Radio O. Alberti - Spedali Civili di Brescia - University of Brescia, Dept. of Brachytherapy, Brescia, Italy, ³Azienda Ospedaliera Universitaria Careggi - University of Florence, Dept. of Radiation Oncology, Florence, Italy, ⁴Spedali Civili di Brescia - University of Brescia, Dept. of Nuclear Medicine, Brescia, Italy, ⁵AULSS 1 Belluno, Dept. of Radiation Oncology, Belluno, Italy, ⁶ASST Monza - University of Milan Bicocca, Dept. of Radiation Oncology, Monza, Italy, ⁷Azienda Ospedaliera Universitaria Policlinico di Modena, Dept. of Radiation Oncology, Modena, Italy, ⁸ASST - Cremona, Dept. of Radiation Oncology, Cremona, Italy, ⁹Humanitas Gavazzeni Hospital - Bergamo, Dept. of Radiation Oncology, Bergamo, Italy, ¹⁰ASST Spedali Civili di Brescia, Dept. of Radiology, Brescia, Italy, ¹¹Fondazione IRCCS Policlinico San Matteo, Dept. of Radiation Oncology, Pavia, Italy, ¹²Istituto Europeo di Oncologia - I.E.O. - University of Milan, Dept. of Radiation Oncology, Milan, Italy, ¹³Istituto Oncologico Veneto IOV-IRCCS, Dept. of Radiation Oncology, Padova, Italy, ¹⁴Humanitas Research Hospital - Rozzano, Dept. of Radiation Oncology, Milan, Italy
- P033** **Infectious rates comparison of targeted transrectal biopsy of the prostate and fiducial marker implantation in patients undergoing image-guided radiation therapy.**
Authors: Kapogiannis E., Apostolou T., Antoniou C., Karydakis P., Kalogeropoulos T.
Institutes: Hippokrateion General Hospital of Athens, Dept. of Urology, Athens, Greece

- P034** **Cardiovascular specific mortality in patients with primary prostate cancer: A population-based study of 171147 patients**
Authors: Alhadeethi A.¹, Atia A.², Alkhawaldeh I.M.³, Ahmed A.A.⁴, Afifi E.⁵, Elwekel A.⁶, Nouh A.⁷, Morsi M.H.⁸, Negida A.⁹
Institutes: ¹Ninaveh University, Medicine, MOSUL, Iraq, ²Cairo University, Medicine, cairo, Egypt, ³Mutah University, Medicine, mutah, Jordan, ⁴Menofia University, Medicine, cairo, Egypt, ⁵Benha University, Medicine, benha, Egypt, ⁶Al-Azhar University, Medicine, cairo, Egypt, ⁷Sohag University, Medicine, Sohag, Egypt, ⁸Misr University, Science and Technology, Giza, Egypt, ⁹Virginia Commonwealth University, Medicine, Virginia, United States of America
- P035** **Validation of diagnostic nomograms based on mass spectrometry-based urinary biomarkers to distinguish clinically significant prostate cancer: complementing MRI pathway**
Authors: Morillo Tejedor A.C.¹, Frantzi M.², Lendinez G.³, Blanca Pedregosa A.⁴, García Morales L.¹, López Ruíz D.⁵, Parada J.⁶, Heidegger I.⁷, Culig Z.⁷, López Beltrán A.⁸, Mora Ortiz M.⁴, Carrasco Valiente J.¹, Medina R.A.³, Mischak H.⁹, Gómez Gómez E.¹
Institutes: ¹Reina Sofía University Hospital, Dept. of Urology, Cordoba, Spain, ²Mosaiques diagnostics GmbH, Dept. of Biomarker Research, Hannover, Germany, ³Virgen del Rocio University Hospital, Dept. of Urology, Sevilla, Spain, ⁴Maimonides Institute of Biomedical Research of Cordoba, Dept. of Urology, Cordoba, Spain, ⁵Reina Sofía University Hospital, Dept. of Radiology, Cordoba, Spain, ⁶Virgen del Rocio University Hospital, Dept. of Radiology, Sevilla, Spain, ⁷Medical University of Innsbruck, Dept. of Urology, Innsbruck, Austria, ⁸University of Cordoba, Dept. of Pathology, Cordoba, Spain, ⁹University of Glasgow, Institute of Cardiovascular and Medical Science, Glasgow, United Kingdom

- P036** **Histopathological Concordance between Prostate Biopsies and Radical Prostatectomy Specimens – Implications of Transrectal and Transperineal Biopsy Approaches**
Authors: Hagens M.J.¹, Ribbert L.L.A.¹, Jager A.², Veerman H.¹, Barwari K.³, Boodt B.⁴, de Bruijn R.E.⁵, Claessen A.⁶, Leter M.R.⁷, van der Noort V.⁸, Smeenge M.⁹, Roeleveld T.A.¹⁰, Rynja S.P.¹¹, Schaaf M.¹², Weltings S.¹³, Vis A.N.², Bekers E.¹⁴, van Leeuwen P.J.¹, van der Poel H.G.¹
Institutes: ¹Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Dept. of Urology, Amsterdam, The Netherlands, ²Amsterdam University Medical Centers, Dept. of Urology, Amsterdam, The Netherlands, ³Andros Clinics, Dept. of Urology, Amsterdam, The Netherlands, ⁴Flevoziekenhuis, Dept. of Urology, Almere, The Netherlands, ⁵Ziekenhuis Amstelland, Dept. of Urology, Amstelveen, The Netherlands, ⁶Rode Kruis Ziekenhuis, Dept. of Urology, Beverwijk, The Netherlands, ⁷Dijklander Ziekenhuis, Dept. of Urology, Hoorn, The Netherlands, ⁸Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Statistics Department, Amsterdam, The Netherlands, ⁹St Jansdal Ziekenhuis, Dept. of Urology, Harderwijk, The Netherlands, ¹⁰Noordwest Ziekenhuisgroep, Dept. of Urology, Alkmaar, The Netherlands, ¹¹Spaarne Gasthuis, Dept. of Urology, Hoofddorp, The Netherlands, ¹²BovenIJ Ziekenhuis, Dept. of Urology, Amsterdam, The Netherlands, ¹³Zaans Medisch Centrum, Dept. of Urology, Zaandam, The Netherlands, ¹⁴Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Dept. of Pathology, Amsterdam, The Netherlands
- P037** **Risk of detecting prostate cancer based on the PSAD and PIRADS lesions in MRI in patients with a negative previous biopsy.**
Authors: Gonzalez De Gor Garcia Herrera V.¹, Aragón Chamizo J.¹, Herranz Del Amo F.¹, Barbas Bernardo G.², Luis Cardo A.³, Cancho Gil M.J.¹, Sánchez Ochoa M.A.¹, Bataller Monfort V.¹, Moreno Cortés J.C.¹, Cano Velasco J.¹, Mayor De Castro J.¹, Hernández Fernández C.¹
Institutes: ¹Hospital General Universitario Gregorio Marañón, Dept. of Urology, Madrid, Spain, ²Hospital Clínica Universidad de Navarra, Dept. of Urology, Madrid, Spain, ³Hospital General Universitario de Toledo, Dept. of Urology, Toledo, Spain
- P038** **Local anaesthesia transperineal (LATP) biopsy of the prostate: a new era for prostate cancer diagnosis?**
Authors: Lim P., Low J., Hurton E., Gallagher W., Rajjayabun P.
Institutes: Alexandra Hospital, Dept. of Urology, Redditch, United Kingdom

- P039** **Using PSMA PET to Guide Prostate Biopsies and Stage Men at High-Risk of Prostate Cancer**
Authors: Bodar Y.¹, Boevé L.M.S.², van Leeuwen P.J.³, Baars P.C.⁴, Nieuwenhuijzen J.A.¹, van Haarst E.P.², Oddens J.R.¹, Donswijk M.L.⁵, van Riel L.A.M.N.¹, Scheltema M.J.V.¹, Meijer D.¹, Hendrikse N.H.⁶, Oprea-Lager D.E.⁶, Vis A.N.¹
Institutes: ¹Amsterdam UMC, Dept. of Urology, Amsterdam, The Netherlands, ²OLVG, Dept. of Urology, Amsterdam, The Netherlands, ³Netherlands Cancer Institute, Dept. of Urology, Amsterdam, The Netherlands, ⁴OLVG, Dept. of Nuclear Medicine, Amsterdam, The Netherlands, ⁵Netherlands Cancer Institute, Dept. of Nuclear Medicine, Amsterdam, The Netherlands, ⁶Amsterdam UMC, Dept. of Nuclear Medicine, Amsterdam, The Netherlands
- P040** **Transperineal prostate biopsy: antibiotic prophylaxis needed?**
Authors: Westerhout S.F.¹, van Steenberg J.P.Z.², Rynja S.P.¹, Noordzij M.A.¹
Institutes: ¹Spaarne Gasthuis, Dept. of Urology, Hoofddorp, The Netherlands, ²Amsterdam UMC, Dept. of Urology, Amsterdam, The Netherlands
- P041** **LATP: Can we do less for more?**
Authors: Maniarasu S., Alex H., Dumitru S., Rahul M.
Institutes: Mersey and West Lancashire NHS Trust, Dept. of Urology, Southport, United Kingdom
- P042** **External Validation of the 2019 Briganti's and 2019 Draulans' nomograms for the identification of patients who should be considered for an extended pelvic lymph node dissection in a cohort of portuguese prostate cancer patients**
Authors: Oliveira J.P., Dias N., de Sousa T., Silva C., Morgado A.
Institutes: Centro Hospitalar e Universitário de Sao Joao, Dept. of Urology, Porto, Portugal
- P043** **Impact of Histological Re-evaluation of Biopsies on Upgrading of Radical Prostatectomy Specimens in Low-Risk Prostate Carcinoma Patients**
Authors: Da Silva Medeiros M., Brito Lança M., Vilma S., Quinto H., Campos Pinheiro L.
Institutes: University and Hospital Centre of Central Lisbon, Dept. of Urology, Lisbon, Portugal
- P044** **Free-hand transperineal prostate biopsy with MRI-fusion in an outpatient setting: single-centre experience in Brazil**
Authors: Teixeira Dias A.E., Ribeiro T., Santos T., Marroig B., Fortes H., Pedrosa J.A., Fortes M., Silva C.
Institutes: UroTarget, Dept. of Urology, Rio de Janeiro, Brazil
- P045** **Stereotactic Body Radiotherapy (sbrt) as salvage treatment for prostate cancer with exclusive local relapse**
Authors: Macias Lozano M.J., Fajardo Paneque I., Díaz Gómez L., Sayago Gil S., Jaén Olasolo J.
Institutes: Jerez Hospital (Cádiz), Radiotherapy Oncology Department, Jerez de la Frontera (Cádiz), Spain
- P046** **Salvage cryotherapy for prostate cancer**
Authors: Vieira E Brito D., Alberto J., Ferreira A., Pereira M.P., Jorge Pereira B.A., Godinho R., Peralta P., Rabaça C.
Institutes: Portuguese Institute of Oncology Coimbra, Dept. of Urology, Coimbra, Portugal

- P047** **Long-term results of LDR brachytherapy in localized prostate cancer**
Authors: Carl S.¹, Andreas J.¹, Meilinger M.¹, Carl N.²
Institutes: ¹Kreiskrankenhaus Emmendingen, Dept. of Urology, Emmendingen, Germany, ²University Hospital Heidelberg-Mannheim, Dept. of Urology, Mannheim, Germany
- P048** **Advantage in ADT combined with radiotherapy? Results**
Authors: Feltes N., Galdeano M., Paredes S., Lozano JL
Institutes: Hospital De Terrassa, Dept. of Radiation Oncology, Terrassa, Spain
- P049** **10-year experience of whole gland cryoablation: analysis of biochemical recurrence**
Authors: Reviriego Barrús A.¹, Martí Antonio M.², Miguélez Martínez L.¹, Gómez Sanz V.¹, Martínez Pinilla W.G.¹, Marfil Pena C.¹, Marrón Penón M.C.¹, Guinda Sevillano C.¹, Arnáiz Esteban J.F.¹
Institutes: ¹University Hospital Santa Bárbara, Dept. of Urology, Soria, Spain, ²University of Extremadura, Dept. of Mathematics, Plasencia, Spain
- P050** **Active surveillance in prostate cancer: PIRADS 3 lesions in confirmatory MRI and during active surveillance follow-up**
Authors: García Morales L.¹, Chamorro Castillo L.¹, García Manrique C.¹, Morillo Tejedor A.C.¹, Gómez Egea C.¹, Ruíz López D.², Carrasco Valiente J.¹, Anglada Curado F.J.¹, Gómez Gómez E.¹
Institutes: ¹Reina Sofía University Hospital, Dept. of Urology, Córdoba, Spain, ²Reina Sofía University Hospital, Dept. of Radiology, Córdoba, Spain
- P051** **Grade reclassification during active surveillance in low risk prostate cancer men selected with an MRI-informed biopsy**
Authors: Marenghi C.¹, Badenchini F.¹, Avuzzi B.², Catanzaro M.A.³, Claps M.¹, Casbarra A.², Noris Chiorda B.², Guadalupi V.¹, Stellato M.¹, Nazzani S.³, Stagni S.³, Cattaneo L.⁴, Casale A.⁵, Messina A.⁵, Villa S.², Macchi A.³, Torelli T.³, Verzoni E.¹, Procopio G.¹, Rancati T.⁶, Nicolai N.³
Institutes: ¹Fondazione IRCCS Istituto Nazionale Tumori, Dept. of Medical Oncology, Milan, Italy, ²Fondazione IRCCS Istituto Nazionale Tumori, Dept. of Radiation Oncology, Milan, Italy, ³Fondazione IRCCS Istituto Nazionale Tumori, Dept. of Oncologic Urology, Milan, Italy, ⁴Fondazione IRCCS Istituto Nazionale Tumori, Biobank Unit - Advanced Diagnostics Department, Milan, Italy, ⁵Fondazione IRCCS Istituto Nazionale Tumori, Dept. of Radiology, Milan, Italy, ⁶Fondazione IRCCS Istituto Nazionale Tumori, Dept. of Data Science, Milan, Italy
- P052** **Low-dose-rate brachytherapy as a primary treatment for localised and locally advanced prostate cancer: a systematic review of economic evaluations**
Authors: Stanberry B.¹, Parker L¹, Webber-Jones N.², Coffey B.³
Institutes: ¹Institute of Healthcare Leadership and Management, Healthcare Economics and Outcomes Research, Oxford, United Kingdom, ²Becton Dickinson and Company, BDI PI EMEA, Winnersh, United Kingdom, ³Royal Society of Medicine, Library, London, United Kingdom

- P053** **Secondary bladder cancer after radiotherapy for prostate cancer**
Authors: Terao H.¹, Nagasaka H.¹, Yamamoto S.¹, Suzuki A.¹, Usui K.¹, Nakaigawa N.¹, Watanabe K.², Nakamura S.², Narimatsu H.², Kishida T.¹
Institutes: ¹Kanagawa Cancer Center, Dept. of Urology, Yokohama, Japan, ²Kanagawa cancer center, Cancer Prevention and Control Division, Yokohama, Japan
- P054** **Toxicity results of a multicentre randomized phase 3, non-inferiority trial on moderate hypofractionated radiotherapy**
Authors: Fonteyne V.¹, Berghen C.B.², Van Praet VC³, Verbeke S.V.⁴, Villeirs G.V.⁵, Vanneste B.V.¹, Ost P.O.⁶, De Meerleer G.DM², Lumen N.L.³
Institutes: ¹Ghent University Hospital, Dept. of Radiation-Oncology, Ghent, Belgium, ²University Hospital Louvain, Dept. of Radiation-Oncology, Louvain, Belgium, ³Ghent University Hospital, Dept. of Urology, Ghent, Belgium, ⁴Ghent University Hospital, Dept. of Pathology, Ghent, Belgium, ⁵Ghent University Hospital, Dept. of Radiology, Ghent, Belgium, ⁶Ghent University, Dept. of Radiation Oncology and Experimental Cancer Research, Ghent, Belgium
- P055** **The Impact of Omitting Bilateral Systematic Biopsy on the Surgical Planning of Patients undergoing Robot-Assisted Radical Prostatectomy for Prostate Cancer**
Authors: van den Kroonenberg D.L.¹, Stoter J.D.¹, Jager A.¹, Veerman H.¹, Hagens M.J.², Postema A.W.², Hoekstra R.J.³, Oprea-Lager D.E.⁴, van Nieuwenhuijzen J.N.¹, van Leeuwen P.J.², Vis A.N.¹
Institutes: ¹Amsterdam UMC, Urology, Amsterdam, The Netherlands, ²Antoni van Leeuwenhoek, Urology, Amsterdam, The Netherlands, ³Canisius Wilhelmina Hospital, Urology, Nijmegen, The Netherlands, ⁴Amsterdam UMC, Radiology and Nuclear medicine, Amsterdam, The Netherlands
- P056** **Ultra-high single-dose ablative radiation therapy with real-time target motion management for unfavorable localized prostate cancer**
Authors: Panizza D.¹, Faccenda V.¹, Daniotti M.C.¹, Belmonte M.², Lucchini R.², Arcangeli S.², De Ponti E.¹
Institutes: ¹Fondazione IRCCS San Gerardo dei Tintori, Dept. of Medical Physics, Monza, Italy, ²University of Milan Bicocca, School of Medicine and Surgery, Milan, Italy
- P057** **One is better than two: A comparative study of single-arc versus dual-arc planning techniques in linac-based localized prostate cancer stereotactic body radiation therapy**
Authors: Faccenda V.¹, Panizza D.¹, Arcangeli S.², De Ponti E.¹
Institutes: ¹Fondazione IRCCS San Gerardo dei Tintori, Dept. of Medical Physics, Monza, Italy, ²University of Milan Bicocca, School of Medicine and Surgery, Milan, Italy
- P058** **Prostatic SBRT: RayPilot's dosimetric analysis**
Authors: Navarro I., Olivera Vegas J., Penedo Cobos J.M., Vasquez Rivas W.A., Camacho Fuentes C., Pérez Cobos M, del Campo Rodríguez Ponga M.L., Salgado González P., Azinovic I.
Institutes: Hospital Fundación Jiménez Díaz, Dept. of Radiation Oncology, Madrid, Spain
-

- P059** **Pathological outcomes of early vs. late radical prostatectomy after progression in a long-term follow up active surveillance series.**
Authors: Sánchez-Rosendo L., Guijarro A., Gonzalo-Balbás A., Hernández V., Perez- Fernández E., Llorente C.
Institutes: Hospital Universitario Fundación Alcorcón, Dept. of Urology, Alcorcón-Madrid, Spain
- P060** **Minimizing neurovascular bundle dose while maintaining target coverage in prostate radiotherapy**
Authors: Brand V.¹, Rossi L.¹, Milder M.T.W.¹, Tree A.C.², Hoogeman M.S.¹, Froklage F.E.¹, Incrocci L.¹
Institutes: ¹Erasmus MC Cancer Institute - University Medical Center Rotterdam, Dept. of Radiation Oncology, Rotterdam, The Netherlands, ²The Institute of Cancer Research - The Royal Marsden Hospital, Dept. of Radiotherapy and Imaging, London, United Kingdom
- P061** **Improving rectal dosimetry and quality-of-life for patients with prostate cancer undergoing EBRT with BioProtect-ProSpace Balloon**
Authors: Pistis F., Murtas R., Squintu S.Q., Pittau P., Barbara R.
Institutes: Arnas Brotzu, Dept. of Radiotherapy, Cagliari, Italy
- P062** **Clinical outcomes of intensity modulated radiotherapy in patients with high-risk prostate cancer**
Authors: Kim Y.
Institutes: Kyung Hee University Hospital, Dept. of Radiation oncology, Seoul, South Korea
- P063** **Multi-imaging model for local staging and targeted treatment of localized prostate cancer using high-intensity focused ultrasound (HIFU) focal therapy**
Authors: Maffei D.¹, Fasulo V.¹, Moretto S.¹, Adjaye E.N.Y.D.¹, Paciotti M.¹, Avolio P.P.¹, De Carne F.¹, Arena P.¹, Lopci E.², Colombo P.G.³, Balzarini L.⁴, Saita A.R.⁵, Hurle R.⁵, Guazzoni G.F.¹, Buffi N.¹, Casale P.⁵, Lazzeri M.⁵, Lughezzani G.¹
Institutes: ¹Humanitas University, Dept. of Urology, Pieve Emanuele, Italy, ²Humanitas Clinical and Research Hospital - IRCCS, Dept. of Nuclear Medicine, Rozzano, Italy, ³Humanitas University, Dept. of Pathology, Pieve Emanuele, Italy, ⁴Humanitas Clinical and Research Hospital - IRCCS, Dept. of Radiology, Rozzano, Italy, ⁵Humanitas Clinical and Research Hospital - IRCCS, Dept. of Urology, Rozzano, Italy
- P064** **Real-World Treatment and Outcomes in Localized Prostate Cancer**
Authors: Conde Moreno A.J.¹, Juárez L.², Maroto P.³, Puente J.⁴, Carles J.⁵, López Menduina M.A.⁶, Taberna Sanz M.⁶, Valdivieso Shephard J.L.⁶, Casadevall Aguilar D.⁶, Munoz del Toro J.⁷, Calderón J.M.⁷, Alcaraz A.⁸
Institutes: ¹Hospital Universitario La Fe, Dept. of Radiation Oncology, Valencia, Spain, ²Hospital Universitario de Jerez, Dept. of Urology, Jerez, Spain, ³Hospital de la Santa Creu i Sant Pau, Dept. of Medical Oncology, Barcelona, Spain, ⁴Hospital Clínico San Carlos, Dept. of Medical Oncology, Madrid, Spain, ⁵Hospital Vall d'Hebron, Dept. of Medical Oncology, Barcelona, Spain, ⁶Savana Research S.L., Data Science, Madrid, Spain, ⁷Janssen Cilag S.A., Dept. of Medical Affairs, Madrid, Spain, ⁸Hospital Clinic, Dept. of Urology, Barcelona, Spain

- P065** **PSMA PET/CT in Biochemically Recurrent Prostate Cancer: multicenter external validation of a risk prediction nomogram**
Authors: Chamorro Castillo L.¹, Rivero Belenchon I.², Puche Sanz I.³, Morillo Tejedor A.C.¹, Lendinez Cano G.², Moliner Malaxechevarría J.², Carrasco Valiente J.¹, Avstisyan Avetisyan D.³, Moreno Jimenez J.⁴, Anglada Curado F.J.¹, Medina Lopez R.A.², Gomez Gomez E.¹
Institutes: ¹Hospital Universitario Reina Sofía, Dept. of Urology, Córdoba, Spain, ²Hospital Universitario Virgen Del Rocio, Dept. of Urology, Sevilla, Spain, ³Hospital Universitario Virgen De Las Nieves, Dept. of Urology, Granada, Spain, ⁴Hospital Universitario De Jaen, Dept. of Urology, Jaén, Spain
- P066** **Outcomes after biochemical failure in high risk prostate cancer. Long-term data from a phase III trial**
Authors: Nabid A.¹, Carrier N.², Martin A-G.³, Bahary J-P.⁴, Vavassis P.⁵, Vass S.⁶, Bahoric B.⁷, Archambault R.⁸, Vincent F.⁹, Bettahar R.¹⁰, Souhami L.¹¹
Institutes: ¹CIUSSS de l'Estrie - CHUS, Dept. of Radiation Oncology, Sherbrooke, Canada, ²CIUSSS de l'Estrie - CHUS, Centre de recherche du Centre hospitalier universitaire de Sherbrooke, Sherbrooke, Canada, ³Centre Hospitalier Universitaire de Québec, Dept. of Radiation Oncology, Sherbrooke, Canada, ⁴Centre Hospitalier Universitaire de Montréal, Dept. of Radiation Oncology, Montreal, Canada, ⁵Hôpital Maisonneuve-Rosemont, Dept. of Radiation Oncology, Montreal, Canada, ⁶Centre de Santé et de Services Sociaux de Chicoutimi, Dept. of Radiation Oncology, Sherbrooke, Canada, ⁷Jewish General Hospital, Dept. of Radiation Oncology, Montreal, Canada, ⁸Hôpital de Gatineau, Dept. of Radiation Oncology, Gatineau, Canada, ⁹Centre Hospitalier Régional de Trois-Rivières, Dept. of Radiation Oncology, Trois-Rivières, Canada, ¹⁰Centre de Santé et de Services Sociaux Rimouski-Neigette, Dept. of Radiation Oncology, Rimouski, Canada, ¹¹McGill University Health Centre, Dept. of Radiation Oncology, Montreal, Canada
- P067** **How important is upgrading on biochemical recurrence and prognosis after radical prostatectomy in low risk prostate cancer patients who are eligible for active surveillance?**
Authors: Erdem S.¹, Ergul R.², Cetin S.³, Tantekin A.², Ozluk Y.³, Sanli O.¹, Ozcan F.¹
Institutes: ¹Istanbul University Istanbul Faculty of Medicine, Division of Urologic Oncology, Dept. of Urology, Istanbul, Turkey, ²Istanbul University Istanbul Faculty of Medicine, Dept. of Urology, Istanbul, Turkey, ³Istanbul University Istanbul Faculty of Medicine, Dept. of Pathology, Istanbul, Turkey
- P068** **Serum levels of vitamin E (Vit E) in patients with proctitis after radical radiotherapy for localized prostate cancer**
Authors: Marques Guimaraes G.¹, Sanches E.R.¹, Pinto M.R.¹, Nunes T.C.¹, Vieira A.M.T.L.², Penna A.B.R.C.³, Vieira S.R.L.³, Moreira A.C.M.⁴, Cardoso A.C.M.⁴, Martins Júnior R.R.⁴, Nogueira C.⁵, Franca C.A.S.⁴
Institutes: ¹IDOMED, Students Medical School, Angra Dos Reis, Brazil, ²Armys Central Hospital, Dept. of Radiotherapy, Rio de Janeiro, Brazil, ³Clinica De Radioterapia Inga, Dept. of Radioterhapy, Niteroi, Brazil, ⁴IDOMED, Teachers Medical School, Angra Dos Reis, Brazil, ⁵MEDICALNUTRI, NUTRITION, Niteroi, Brazil

- P069** **PSA persistence after prostatectomy – prognosis and the effect of adjuvant radiotherapy**
Authors: Möller A.¹, Nordström T.², Eklund M.², Akre O.¹, Egevad L.³, Aly M.¹
Institutes: ¹Karolonska Institute, Dept. of Molecular Medicine and Surgery, Stockholm, Sweden, ²Karolonska Institute, Dept. of Medical Epidemiology and Biostatistics, Stockholm, Sweden, ³Karolonska Institute, Dept. of Oncology-Pathology, Stockholm, Sweden
- P070** **Unemployment affects patient's choice of adjuvant/salvage therapy after radical prostatectomy**
Authors: Choo S.H., Kim S.I.
Institutes: Ajou University School of Medicine, Dept. of Urology, Suwon-si, South Korea
- P071** **The association between patient- and disease characteristics, and the risk of disease progression in patients with prostate cancer on active surveillance**
Authors: Duijn M.^{1,2}, de Reijke T.M.^{2, 3}, Barwari K.^{2, 4}, Hagens M.J.^{3, 5}, Rynja S.P.⁶, Immerzeel J.², Barentsz J.O.², Jager A.³
Institutes: ¹OLVG, Dept. of Urology, Amsterdam, The Netherlands, ²Andros Clinics, Arnhem, The Netherlands, ³Amsterdam University Medical Centers, University of Amsterdam, Dept. of Urology, Amsterdam, The Netherlands, ⁴Netherlands Cancer Institute (NCI), Dept. of Urology, Amsterdam, The Netherlands, ⁵Prostate Cancer Network the Netherlands, Amsterdam, The Netherlands, ⁶Spaarne Gasthuis, Dept. of Urology, Hoofddorp, The Netherlands
- P072** **Fecal incontinence after moderately hypofractionated volumetric modulated arc therapy: incidence and impact on quality of life in a real-world practice**
Authors: Lozano J.¹, Jovell E.², Colomer M.¹, Paredes S.¹, Galdeano-Rubio M.¹, Romero C.³, Carmona M.³, Solé J.M.¹, Feltes N.¹
Institutes: ¹Consorci Sanitari de Terrassa, Dept. of Radiation Oncology, Terrassa, Spain, ²Consorci Sanitari de Terrassa, Dept. of Epidemiology, Terrassa, Spain, ³Consorci Sanitari de Terrassa, Research and Innovation Area, Terrassa, Spain
- P073** **The Wolverhampton Assessment Tool (WAT): An objective and reproducible PRO to monitor wellbeing and detect clinical progression in prostate cancer patients**
Authors: Sayers I.¹, Rogers J.¹, Menon A.¹, Arunagiri N.¹, Mohindru G.¹, Tovee J.¹, Matheson D.²
Institutes: ¹New Cross Hospital, Dept. of Oncology, Wolverhampton, United Kingdom, ²University of Wolverhampton, Faculty of Education Health and Wellbeing, Wolverhampton, United Kingdom

P074

Genetically-based Cox-NTCP models for late toxicity after prostate cancer RT

Authors: Avuzzi B.¹, Rancati T.², Gioscio E.², Massi M.³, Franco N.R.³, Cicchetti A.², Rosenstein B.⁴, Seibold P.⁵, Azria D.⁶, Choudhury A.⁷, De Ruyscher D.⁸, Lambrecht M.⁹, Sperk E.¹⁰, Talbot C.¹¹, Vega A.¹², Veldeman L.¹³, Webb A.¹⁴, Zunino P.³, Paganoni A.³, Ieva F.³, Manzoni A.³, Gutierrez S.¹⁵, Kerns S.¹⁶, Dunning A.¹⁷, Elliott R.¹⁸, West C.¹⁸, Chang-Claude J.⁵

Institutes: ¹Fondazione IRCCS Istituto Nazionale Tumori, Dept. of Radiation Oncology, Milan, Italy, ²Fondazione IRCCS Istituto Nazionale Tumori, Prostate Cancer Program, Milan, Italy, ³Politecnico di Milano, MOX, Milan, Italy, ⁴Icahn School of Medicine at Mount Sinai, Dept. of Genetics, New York, United States of America, ⁵German Cancer Research Center, Dept. of Epidemiology, Heidelberg, Germany, ⁶Montpellier Cancer Institute, Dept. of Radiotherapy, Montpellier, France, ⁷University of Manchester, Dept. of Radiotherapy, Manchester, United Kingdom, ⁸Maastricht University Medical Center, Dept. of Radiotherapy, Maastricht, The Netherlands, ⁹University Hospitals Leuven, Dept. of Radiotherapy, Leuven, Belgium, ¹⁰Universitätsmedizin Mannheim, Dept. of Radiotherapy, Mannheim, Germany, ¹¹University of Leicester, Dept. of Genetics, Leicester, United Kingdom, ¹²Fundación Pública Galega de Medicina Xenómica, Dept. of Genetics, Santiago de Compostela, Spain, ¹³Ghent University Hospital, Dept. of Radiotherapy, Ghent, Belgium, ¹⁴Univerisity of Leicester, Dept. of Genetics, Leicester, United Kingdom, ¹⁵Val d'Herbron Istitute of Oncology, Dept. of Genetics, Barcelona, Spain, ¹⁶University of Rochester Medical Center, Dept. of Genetics, Rochester, United States of America, ¹⁷University of Cambridge Strangeways Research Labs, Dept. of Genetics, Cambridge, United Kingdom, ¹⁸University of Manchester, Dept. of Radiobiology, Manchester, United Kingdom

P075

Side Effects and Quality of Life in a Post-Prostatectomy Ablative Radiation Therapy (POPART) Multicentric Trial

Authors: Ferrario F.¹, Franzese C.², Vukcaj S.³, Magli A.⁴, Belmonte M.¹, Lucchini R.¹, Purrello G.¹, Faccenda V.⁵, Panizza D.⁵, Andreoli S.⁶, Poli G.L.⁶, Baldaccini D.⁷, Lo Faro L.², Tomatis S.⁷, Cazzaniga L.F.³, Scorsetti M.², Arcangeli S.¹

Institutes: ¹Fondazione IRCCS San Gerardo dei Tintori, University of Milano Bicocca, Dept. of Radiation Oncology, Monza, Italy, ²Humanitas Clinical and Research Center - IRCCS, Humanitas University, Dept. of Radiotherapy and Radiosurgery, Rozzano, Italy, ³ASST Papa Giovanni XXIII, Dept. of Radiation Oncology, Bergamo, Italy, ⁴AULSS 1 Dolomiti, Dept. of Radiation Oncology, Belluno, Italy, ⁵Fondazione IRCCS San Gerardo dei Tintori, Dept. of Medical Physics, Monza, Italy, ⁶ASST Papa Giovanni XXIII, Dept. of Medical Physics, Bergamo, Italy, ⁷Humanitas Clinical and Research Center - IRCCS, Dept. of Radiotherapy and Radiosurgery, Rozzano, Italy

- P076** **Preliminary Outcomes following Single-Dose Ablative Radiotherapy for Unfavorable Prostate Tumors**
Authors: [Belmonte M.](#)¹, [Lucchini R.](#)¹, [Ferrario F.](#)¹, [Gandola D.](#)², [Purrello G.](#)¹, [Talei Franzesi C.](#)², [Faccenda V.](#)³, [Panizza D.](#)³, [Arcangeli S.](#)¹
Institutes: ¹Fondazione IRCCS San Gerardo dei Tintori, University of Milano Bicocca, Dept. of Radiation Oncology, Monza, Italy, ²Fondazione IRCCS San Gerardo dei Tintori, Dept. of Radiology, Monza, Italy, ³Fondazione IRCCS San Gerardo dei Tintori, Dept. of Medical Physics, Monza, Italy
- P077** **Baseline health-related quality of life as a prognostic indicator for survival in men with intermediate risk prostate cancer following radical prostatectomy**
Authors: [Westhofen T.](#), [Buchner A.](#), [Schlenker B.](#), [Rodler S.](#), [Becker A.](#), [Stief C.G.](#), [Kretschmer A.](#)
Institutes: Ludwig-Maximilians-University Munich, Dept. of Urology, Munich, Germany
- P078** **A panel of dysregulated circulating microRNA as a diagnostic biomarker for Prostate Cancer Progression**
Authors: [Manoj A.](#)¹, [Ahmad M.K.](#)¹, [Kumar M.](#)²
Institutes: ¹King Georges Medical University, Biochemistry, Lucknow, India, ²King Georges Medical University, Urology, Lucknow, India
- P079** **Use of PIRADS 2.1 to predict capsular invasion in patients with radiologic T3a prostate cancer**
Authors: [Chung J.H.](#), [Song W.](#), [Jeon S.S.](#)
Institutes: Samsung Medical Center, Dept. of Urology, Seoul, South Korea
- P080** **Beyond Gleason Patterns: Radiomics for cribriform growth differentiation**
Authors: [Fernandez Salamanca M.](#)¹, [Simoes R.](#)², [van der Heide U.](#)², [Deregowska-Cylke M.](#)³, [van Leeuwen P.](#)⁴, [van der Poel H.](#)⁴, [Bekers E.](#)⁵, [Guimaraes M.A.S.](#)⁵, [Schoots I.G.](#)¹
Institutes: ¹Netherlands Cancer Institute, Dept. of Diagnostic Oncology, Amsterdam, The Netherlands, ²Netherlands Cancer Institute, Dept. of Radiation Oncology, Amsterdam, The Netherlands, ³Medical University of Warsaw, Dept. of Clinical Radiology, Warsaw, Poland, ⁴Netherlands Cancer Institute, Dept. of Urology, Amsterdam, The Netherlands, ⁵Netherlands Cancer Institute, Dept. of Pathology, Amsterdam, The Netherlands
- P081** **Real World Utilisation of Androgen Deprivation Therapy Among Urology Practices: Characterising Initiation and Transition to Relugolix for Patients with Prostate Cancer (The REAL ADT Transitions Study)**
Authors: [Ngo A.](#)¹, [Ghandi R.](#)¹, [Yang E.](#)², [Sangha P.](#)¹, [Pruett J.](#)¹, [Fallick M.](#)¹
Institutes: ¹Myovant Sciences, Dept. of Medical Affairs, Brisbane, United States of America, ²Sumitovant Biopharma, Dept. of Medical affairs, New York, United States of America
-

- P082** **Delphi Consensus Project on Prostate-specific Membrane Antigen (PSMA)-Targeted Surgery – outcomes from an international multidisciplinary panel**
Authors: Berrens A.C.¹, Scheltema M.¹, Maurer T.², Hermann K.³, Hamdy F. C.⁴, Knipper S.⁵, Dell'Oglio P.⁶, Mazzone E.⁷, de Barros H. A.¹, Sorger J. M.⁸, van Oosterom M. N.⁹, Stricker P. D.¹⁰, van Leeuwen P. J.¹, Rietbergen D.¹¹, Valdes Olmos R.⁹, Vidal-Sicart S.¹², Carroll P. R.¹³, Buckle T.⁹, van der Poel H. G.¹, van Leeuwen F. W. B.⁹
Institutes: ¹Antoni van Leeuwenhoek Hospital, Dept. of Urology, Amsterdam, The Netherlands, ²Martini-Klinik Prostate Cancer Center, Dept. of Urology, Hamburg, Germany, ³German Cancer Consortium University Hospital Essen, Dept. of Nuclear Medicine, Essen, Germany, ⁴University of Oxford, Nuffield Department of Surgical Sciences, Oxford, United Kingdom, ⁵Vivantes Klinikum am Urban, Dept. of Urology, Berlin, Germany, ⁶ASST Grande Ospedale Metropolitano Niguarda, Dept. of Urology, Milan, Italy, ⁷San Raffaele Scientific Institute, Dept. of Urology, Milan, Italy, ⁸Intuitive Surgical Inc, Sunnyvale, United States of America, ⁹Interventional Molecular Imaging Laboratory, Leiden University Medical Centre, Dept. of Radiology, Leiden, The Netherlands, ¹⁰St Vincents Hospital, Dept. of Urology, Sydney, Australia, ¹¹Leiden University Medical Centre, Dept. of Nuclear Medicine, Leiden, The Netherlands, ¹²Hospital Clínic Barcelona, Dept. of Nuclear Medicine, Barcelona, Spain, ¹³University of California, Dept. of Urology, San Francisco, United States of America
- P083** **Post-metastasis survival in high-risk localised and locally advanced prostate cancer patients undergoing primary treatment in the United States: A retrospective study**
Authors: Freedland S.¹, Fernandes L.², De Solda F.³, Buyukkaramikli N.⁴, Mundle S.D.⁵, McCarthy S.A.⁶, Labson D.⁷, Yang L.⁷, Pan F.⁷, Mir C.⁸
Institutes: ¹Cedars-Sinai Medical Center, Dept. of Urology, Los Angeles, United States of America, ²Janssen Pharmaceutica N.V., Global Commercial Strategy Organisation, Beerse, Belgium, ³Janssen Global Services LLC, Dept. of Global Market Access, Raritan, United States of America, ⁴Janssen Pharmaceutica N.V., Global Commercial Strategy Organisation, Beerse, Belgium, ⁵Janssen Global Services LLC, Dept. of Medical Affairs, Raritan, United States of America, ⁶Janssen Global Services LLC, Compound Development, Raritan, United States of America, ⁷Janssen Global Services LLC, Strategic Market Access, Raritan, United States of America, ⁸IMED Robotic Surgery Unit, Dept. of Urology, Valencia, Spain
- P084** **Clinical and dosimetric correlation of acute and late toxicities in prostate cancer patients treated with hypofractionated radiotherapy**
Authors: Goyal S.¹, Kataria V.¹, Periasamy K.¹, Mavuduru R.², Mehta A.¹, Madan R.¹, Kumar N.¹, Khosla D.¹
Institutes: ¹Post Graduate Institute of Medical Education and Research, Dept. of Radiotherapy, Chandigarh, India, ²Post Graduate Institute of Medical Education and Research, Dept. of Urology, Chandigarh, India

- P085** **The optimal timing of ARAT administration against nmCRPC**
Authors: Matsumoto K., Kosaka T., Takeda T., Fukumoto K., Yasumizu Y., Tanaka N., Morita S., Mizuno R., Asanuma H., Oya M.
Institutes: Keio University School of Medicine, Dept. of Urology, Tokyo, Japan
- P086** **Dosimetric comparison of imrt vs. vmat - Single arc, dual arc and combination of dual and single arc plans for high risk prostate cancers**
Authors: Lyer M.¹, CHOMAL M.¹, KALIYAMOORTHY A.¹, TOMAR S.¹, Sahay J.²
Institutes: ¹RHL Renova Cancer Centre, Dept. of Radiation Oncology, Jaipur, India, ²HCG Cancer Centre, Dept. of Radiation Oncology, Jaipur, India
- P087** **Acute toxicity results from a multicenter randomized phase 3 trial comparing external beam radiotherapy alone with external beam radiotherapy combined with brachytherapy in intermediate/high risk prostate cancer patients**
Authors: Christianen M.E.M.¹, Pieters B.², Bokhorst L.³, Hoekstra C.⁴, Vanneste B.⁵, Van Norden Y.¹, Kolkman-Deurloo I.K.K.¹, Kirkels W.J.⁶, Nout R.A.¹, Aluwini S.⁷
Institutes: ¹Erasmus MC Cancer Institute - University Medical Center Rotterdam, Dept. of Radiation Oncology, Rotterdam, The Netherlands, ²Amsterdam University Medical Center, Dept. of Radiation Oncology, Amsterdam, The Netherlands, ³Haaglanden Medical Center, Dept. of Radiation Oncology, Den Haag, The Netherlands, ⁴Radiotherapygroup, Dept. of Radiation Oncology, Deventer, The Netherlands, ⁵Maastricht University Medical Centre, Dept. of Radiation Oncology, Maastricht, The Netherlands, ⁶Erasmus MC Cancer Institute - University Medical Center Rotterdam, Dept. of Urology, Rotterdam, The Netherlands, ⁷University Medical Center Groningen, Dept. of Radiation Oncology, Groningen, The Netherlands
- P088** **Salvage radiotherapy after prostatectomy; trends and variation in Dutch clinical practice**
Authors: Janssen J.¹, Staal F.H.E.¹, Heesterman B.L.², Aben K.H.², Kiemeny L.A.³, van Oort I.M.⁴, Aluwini S.¹
Institutes: ¹UMC Groningen, Dept. of Radiation Oncology, Groningen, The Netherlands, ²Netherlands Comprehensive Cancer Organisation, Dept. of Research, Utrecht, The Netherlands, ³Radboud University Medical Center, Dept. of Epidemiology, Nijmegen, The Netherlands, ⁴Radboud University Medical Center, Dept. of Urology, Nijmegen, The Netherlands
- P089** **Hypofractionated radiation therapy in COVID-19 pandemic for high risk prostate cancer patients: randomize trial**
Authors: Ishkinin Y.¹, Raimzhanov K.B.¹, Omarova A.K.², Datbayev K.¹, Seitov O.K.¹, Khudaibergenov Z.T.¹, Raimbekov R.B.¹, Akhunova R.U.¹, Makhmutova N.¹
Institutes: ¹Almaty Oncology Center, Dept. of Radiation Oncology, Almaty, Kazakhstan, ²Almaty Oncology Center, Polyclinic, Almaty, Kazakhstan

- P090** **Comparison of dosimetric parameters between whole pelvis vs. prostate only volumetric-modulated arc therapy**
Authors: Raza S.M.¹, Inayat M.¹, Riaz A.²
Institutes: ¹Shaukat Khanum Memorial Cancer Hospital and Research Center, Dept. of Clinical and Radiation Oncology, Lahore, Pakistan, ²Rutgers University, Dept. of Radiation Oncology, New Brunswick, United States of America
- P091** **Biochemical response and overall survival rate among castrate resistant prostate cancer patients treated with docetaxel**
Authors: Mwakipunda L.M., Rugengamanzi E., Banzi M.O., Malangwa G., Lugina E.L.
Institutes: Muhimbili University of Health and Allied Sciences, Dept. of Clinical Oncology, Dar es Salaam, Tanzania
- P092** **Real-life feasibility study of a digital health platform for prostate cancer survivors: Preliminary results from the Greek cohort of the LifeChamps project**
Authors: Sountoulides P.¹, Kartsidis P.², Anagnostopoulou A.², Lagakis P.², Petridis G.C.², Poultourtzidis I.T.², Mavridi M.², Bamidis P.D.², Billis A.S.²
Institutes: ¹Aristotle University of Thessaloniki, Dept. of Urology, Thessaloniki, Greece, ²Aristotle University of Thessaloniki, Lab of Medical Physics and Digital Innovation, Thessaloniki, Greece
- P093** **Mutational profile of hormone-sensitive and castration-resistant metastatic prostate cancer**
Authors: Velasco Balanza C.¹, Iglesias Beiroa A.², Saavedra Centeno M.¹, Sanchez Ramirez A.¹, Albers Acosta E.¹, Celada Luis G.¹, Toquero Diez P.², Zapatero Laborda A.³, Romero Laorden N.², San Jose Manso L.A.¹
Institutes: ¹La Princesa University Hospital, Dept. of Urology, Madrid, Spain, ²La Princesa University Hospital, Dept. of Medical Oncology, Madrid, Spain, ³La Princesa University Hospital, Dept. of Radiation Oncology, Madrid, Spain
- P094** **Local primary tumor and metastasis treatment in patients with newly diagnosed oligometastatic prostate cancer: a prospective multicenter registry (OLIGOS)**
Authors: Porreca A.¹, Lista G.¹, Di Gianfrancesco L.¹, Sepulcri M.², Corsi P.¹, Miglioranza E.¹, Amodeo A.¹, De Marchi D.¹, Vitelli F.D.¹, Krengli M.²
Institutes: ¹Istituto Oncologico Veneto, Dept. of Urology, Castelfranco Veneto, Italy, ²Istituto Oncologico Veneto, Dept. of Radiotherapy, Padova, Italy
- P095** **Durvalumab and radiotherapy without androgen deprivation for oligometastatic prostate cancer**
Authors: Guminski A.¹, Eade T.², Hruby G.², McCowatt S.¹, Kneebone A.²
Institutes: ¹Royal North Shore Hospital, Dept. of Medical Oncology, Sydney, Australia, ²Royal North Shore Hospital, Dept. of Radiation Oncology, Sydney, Australia

P096

Real-world data analysis of clinical characteristics in metastatic hormone-sensitive prostate cancer: Are patients from RCTs the same from real life? Data from the European network of excellence for big data in prostate cancer (PIONEER).

Authors: Gómez Rivas J.¹, Nicoletti R.², Golozar A.³, Steinbeißer C.⁴, De Meulder B.⁵, Snijder R.⁶, Ibañez L.¹, Axelsson S.E.⁴, Ayman H.⁵, Feng Q.⁶, Murtola T.J.⁷, Bjartell A.⁸, Cornford P.⁹, Willemse P.¹⁰, Prinsen P.¹¹, Ní Dow J.¹²

Institutes: ¹Hospital Clinico San Carlos, Dept. of Urology, Madrid, Spain, ²Careggi Hospital, University of Florence, Unit of Urological Robotic Surgery and Renal Transplantation, Florence, Italy, ³Odysseus Data Services, New York, United States of America, ⁴Bayer AG, Berlin, Germany, ⁵Association EISBM, Vourles, France, ⁶Astellas Pharma Europe, Leiden, The Netherlands, ⁷Tampere University, Faculty of Medicine and Health Technology, Tampere, Finland, ⁸Lund University, Dept. of Translational Medicine, Division of Urological Cancers, Faculty of Medicine, Lund, Sweden, ⁹Liverpool University Hospitals NHS Trust, Dept. of Urology, Liverpool, United Kingdom, ¹⁰University Medical Center Utrecht, Dept. of Urology, Utrecht, The Netherlands, ¹¹Philips Research, Eindhoven, The Netherlands, ¹²University of Aberdeen, Academic Urology Unit, Aberdeen, United Kingdom

P097

How does PSMA PET/CT influence the management of prostate cancer patients?

Authors: Minguez Ojeda C.S.¹, Garcia Barreras S.¹, Hervás Morón A.², Ajuria Illaramendi O.³, Tagalos Munoz A.C.¹, Mata Alcaraz M.¹, López Pérez E.¹, Fernandez Conejo G.¹, Sanz Mayayo E.¹, Rodriguez- Patrón R.¹, López Campos F.², Burgos Revilla F.J.¹

Institutes: ¹Hospital Ramon y Cajal, Dept. of Urology, Madrid, Spain, ²Hospital Ramon y Cajal, Dept. of Radiotherapy Oncology, Madrid, Spain, ³Hospital Ramon y Cajal, Dept. of Nuclear Medicine, Madrid, Spain

- P098** **Real-world characterization of disease management and progression in metastatic and nonmetastatic castrate-resistant prostate cancer patients in Portugal: CaPA study**
Authors: Costa P.D.¹, Patrício A.², Barreira J.V.³, Abranches Monteiro L.⁴, Campos Pinheiro L.⁵, Azinhais P.⁶, Sequeira I.⁷, Rabaça C.⁸, Pereira F.⁹, Borges R.¹⁰, Botelho F.¹¹, Reis F.¹², Carvalho J.¹³, Canelas A.¹⁴, Coelho H.¹⁵, Vila F.¹⁶, Dinis R.¹⁷, Dias S.¹⁸, Fialho A.C.¹⁸, Palma dos Reis J.¹⁹
Institutes: ¹Vila Nova de Gaia Hospital Center, Dept. of Urology, Vila Nova de Gaia, Portugal, ²Baixo Vouga Hospital Center, Dept. of Urology, Aveiro, Portugal, ³SAMS Lisbon, Dept. of Oncology, Lisbon, Portugal, ⁴Western Lisbon Hospital Center, Dept. of Urology, Lisbon, Portugal, ⁵University Hospital Center of Central Lisbon, Dept. of Urology, Lisbon, Portugal, ⁶University Hospital Center of Coimbra, Dept. of Urology, Coimbra, Portugal, ⁷ULS Guarda, Dept. of Oncology, Guarda, Portugal, ⁸IPO Coimbra, Dept. of Urology, Coimbra, Portugal, ⁹SESARAM, Dept. of Urology, Funchal, Portugal, ¹⁰Leiria Hospital Center, Dept. of Urology, Leiria, Portugal, ¹¹University Hospital Center of Sao Joao Hospital, Dept. of Urology, Oporto, Portugal, ¹²ULS Matosinhos, Dept. of Urology, Matosinhos, Portugal, ¹³Garcia da Orta Hospital, Dept. of Urology, Almada, Portugal, ¹⁴Setúbal Hospital Center, Dept. of Urology, Setúbal, Portugal, ¹⁵ULS Alto Minho - Viana do Castelo, Dept. of Urology, Viana do Castelo, Portugal, ¹⁶Tamega and Sousa Hospital Center, Dept. of Urology, Guilhufe, Portugal, ¹⁷Espírito Santo Hospital, Dept. of Oncology, Évora, Portugal, ¹⁸Janssen-Cilag Farmaceutica Lda, Medical Department, Porto Salvo, Portugal, ¹⁹Santa Maria Hospital, Dept. of Urology, Lisbon, Portugal
- P099** **Low dose abiraterone in prostate cancer - safety, efficacy and pharmacoeconomic implications**
Authors: Acharya S.
Institutes: Assam Cancer Care Foundation, Dept. of Clinical Oncology, Lakhimpur, India
- P100** **Apalutamide in Metastatic Prostate Cancer real life experience**
Authors: Vieira E Brito D., Alberto J., Ferreira A.F, Pereira M., Godinho R., Jorge Pereira B.A., Rabaça C.R
Institutes: Portuguese Institute of Oncology Coimbra, Urology, Coimbra, Portugal
- P101** **Treatment (tx) patterns and outcomes in the real world (rw) among patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in Europe**
Authors: Castro E.¹, Schlack K.², Niyazov A.³, Houghton K.⁴, Kirker M.³, Derrien Ansquer V.⁵, Bello F.⁶, Jones R.J.⁷
Institutes: ¹Hospital Universitario 12 de Octubre, GU Tumor Unit, Madrid, Spain, ²University Hospital Münster, Dept. of Urology, Madrid, Spain, ³Pfizer, Dept. of Value and Evidence, New York, United States of America, ⁴RTI Health Solutions, Dept. of Health Economics, Manchester, United Kingdom, ⁵RTI Health Solutions, Surveys and Observational Studies, Lyon, France, ⁶RTI Health Solutions, Dept. of Health Economics, Durham, United States of America, ⁷University of Glasgow, Beaton West of Scotland Cancer Centre, Glasgow, United Kingdom

- P102** **Matching-Adjusted Indirect Comparisons (MAICs) of Talazoparib versus Olaparib and Niraparib for First-line (1L) Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)**
Authors: Castro E.¹, Samjoo I.², Wang D.², Walsh S.², Haltner A.², Paganelli S.², Craigie S.², Nazari J.³, Niyazov A.³
Institutes: ¹Hospital Universitario 12 de Octubre, Dept. of Medical Oncology, Madrid, Spain, ²EVERSANA, Dept. of Value and Evidence, Burlington, Canada, ³Pfizer Inc, Dept. of Oncology, New York, United States of America
- P103** **Lost opportunities: The underutilization of castrate-resistant prostate cancer treatment in real-world settings**
Authors: Gatsinga R.¹, Tan Y.G.¹, Chen W.¹, Yang X.Y.¹, Huang H.H.¹, Tuan J.K.L.², Lee M.K.C.², Rajasekaran T.³, Kanesvaran R.³, Tay K.J.¹, Chen K.¹, Yuen S.P.J.¹
Institutes: ¹Singapore General Hospital, Dept. of Urology, Singapore, Singapore, ²National Cancer Center Singapore, Dept. of Radiation Oncology, Singapore, Singapore, ³National Cancer Center Singapore, Dept. of Medical Oncology, Singapore, Singapore

P104

Stereotactic body radiation therapy and abiraterone acetate for patients affected by oligometastatic castrate-resistant prostate cancer: Freedom from biochemical, radiological progression free survival and freedom from following treatment approaches within a randomized phase II trial (ARTO – NCT03449719)

Authors: Francolini G.¹, Detti B.¹, Di Cataldo V.¹, Caini S.², Bruni A.³, Ingrosso G.⁴, D'angelillo R.M.⁵, Alitto A.R.⁶, Augugliaro M.⁷, Triggiani L.⁸, Parisi S.⁹, Facchini G.¹⁰, Banini M.¹, Simontacchi G.¹, Desideri I.¹, Meattini I.¹, Frosini G.¹, Burchini L.¹, Marvaso G.¹¹, Alongi F.¹², Arcidiacono F.¹³, Lancia A.¹⁴, Genovesi D.¹⁵, Franzese C.¹⁶, Timon G.¹⁷, Tagliagambe A.¹⁸, Livi L.¹

Institutes: ¹Radiation Oncology Unit AOU Careggi, Dept. of Oncology, Florence, Italy, ²Institute for Cancer Research Prevention and Clinical Network ISPO, Cancer Risk Factors and Lifestyle Epidemiology Unit, Florence, Italy, ³Radiation Oncology Unit, University Hospital of Modena, Dept. of Oncology and Hematology, Modena, Italy, ⁴Radiation Oncology Section University of Perugia, Dept. of Medicine and Surgery, Perugia, Italy, ⁵Radiation Oncology, University of Rome Tor Vergata, Dept. of Biomedicine and Prevention, Rome, Italy, ⁶UOC di Radioterapia Oncologica Radioterapia Oncologica ed Ematologia Fondazione Policlinico Universitario A. Gemelli IRCCS, Dept. of Diagnostic Imaging, Rome, Italy, ⁷Azienda USL - IRCCS di Reggio Emilia, Dept. of Radiotherapy, Reggio Emilia, Italy, ⁸Brescia University, Dept. of Radiation Oncology, Brescia, Italy, ⁹Radiation Oncology Unit, University of Messina, Dept. of Biomedical Dental Science and Morphological and Functional Images, Messina, Italy, ¹⁰SM delle Grazie Hospital, Medical Oncology Unit, Pozzuoli, Italy, ¹¹IEO European Institute of Oncology - IRCCS, Dept. of Radiation Oncology, Milan, Italy, ¹²IRCCS Sacro Cuore Don Calabria Hospital, Dept. of Advanced Radiation Oncology, Verona, Italy, ¹³S. Maria Hospital, Dept. of Radiation Oncology, Terni, Italy, ¹⁴Fondazione IRCCS Policlinico San Matteo, Dept. of Radiation Oncology, Pavia, Italy, ¹⁵SS. Annunziata Hospital G. D'Annunzio University of Chieti, Dept. of Radiation Oncology, Chieti, Italy, ¹⁶Humanitas Clinical and Research Center - IRCCS, Dept. of Radiotherapy and Radiosurgery, Rozzano, Italy, ¹⁷Azienda USL - IRCCS di Reggio Emilia, Unit of Radiotherapy, Reggio Emilia, Italy, ¹⁸Apuane Hospital Azienda USL Toscana Nord Ovest, Radiotherapy Unit, Massa Carrara, Italy

P105

Is achieving undetectable PSA (uPSA) a prognostic factor for improved overall survival (OS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving intensified treatments?

Authors: Puente J.¹, López Campos F.², Ohlmann C.³, Ríos E.⁴, Santoni M.⁵, Diels J.⁶, Cabrieto J.⁶, Egea M.⁷, Quesada A.⁸, Calderón J.M.⁸, Birtle A.⁹

Institutes: ¹Hospital Clínico San Carlos, Dept. of Medical Oncology, Madrid, Spain, ²Hospital Universitario Ramón y Cajal, Dept. of Radiation Oncology, Madrid, Spain, ³Johanniter Krankenhaus Oberhausen, Dept. of Urology, Bonn, Germany, ⁴Hospital Universitario La Paz, Dept. of Urology, Madrid, Spain, ⁵Ospedale Di Macerata, Dept. of Medical Oncology, Macerata, Italy, ⁶Janssen Pharmaceutica, Dept. of Market Access Analytics, Beerse, Belgium, ⁷Janssen Cilag S.A., Market Access, Madrid, Spain, ⁸Janssen Cilag S.A., Dept. of Medical Affairs, Madrid, Spain, ⁹Royal Preston Hospital, Dept. of Medical Oncology, Preston, Spain

P106

The conundrum of treating metastatic hormone sensitive prostate cancer

Authors: van Elst T.¹, Mehra N.², Vis A.N.³, Wijsman B.P.⁴, Luijendijk D.⁵, van Dodewaard-de Jong J.M.⁶, van den Berg P.L.⁷, Lavalaye J.⁸, Aluwini S.⁹, Bloemendal H.J.², Mulders P.F.A.¹⁰, van Basten J.P.A.¹

Institutes: ¹Canisius Wilhelmina Hospital, Dept. of Urology, Nijmegen, The Netherlands, ²Radboudumc, Dept. of Oncology, Nijmegen, The Netherlands, ³Amsterdam UMC, Dept. of Urology, Amsterdam, The Netherlands, ⁴Elisabeth-TweeSteden Hospital, Dept. of Urology, Tilburg, The Netherlands, ⁵Martini Hospital, Dept. of Urology, Groningen, The Netherlands, ⁶Meander Medical Centre, Dept. of Oncology, Amersfoort, The Netherlands, ⁷Ter Gooi Hospital, Dept. of Oncology, Blaricum, The Netherlands, ⁸St. Antonius Hospital, Dept. of Nuclear Medicine, Nieuwegein, The Netherlands, ⁹University Medical Centre Groningen, Dept. of Radiotherapy, Groningen, The Netherlands, ¹⁰Radboudumc, Dept. of Urology, Nijmegen, The Netherlands

P107

A network meta-analysis on the safety of systemic treatments in metastatic hormone-sensitive prostate cancer patients

Authors: Di Maio M.¹, Gonzalez Billalabeitia E.², Marandino L.³, Maroto P.⁴, Timsit M.O.⁵, Luccarini I.⁶, Van Sanden S.⁶, Hadaschik B.A.⁷

Institutes: ¹A.O. Ordine Mauriziano, Dept. of Oncology, Turin, Italy, ²University Hospital 12 de Octubre, Medical Oncology Department, Madrid, Spain, ³IRCCS San Raffaele Scientific Institute, Dept. of Medical Oncology, Milan, Italy, ⁴Hospital de la Santa Creu i Sant Pau, Medical Oncology Services, Barcelona, Spain, ⁵Georges Pompidou Hospital, Dept. of Urology, Paris, France, ⁶Janssen Pharmaceutica NV, EMEA, Beerse, Belgium, ⁷University Hospital Essen, Dept. of Urology, Essen, Germany

- P108** **Expert consensus recommendations for managing adverse events in patients with metastatic prostate cancer treated with poly(ADP-ribose) polymerase inhibitor (PARPi) + novel hormonal therapy (NHT) combination therapy**
Authors: Shore N.D.¹, Broder M.S.², Barata P.C.³, Crispino T.⁴, Fay A.P.⁵, Lloyd J.⁶, Mellado B.⁷, Matsubara N.⁸, Pfanzer N.⁹, Schlack K.¹⁰, Sieber P.¹¹, Soares A.¹², Dalglish H.¹³, Niyazov A.¹⁴, Shaman S.¹⁵, Zielinski M.¹⁶, Chang J.¹⁷, Agarwal N.¹⁸
Institutes: ¹Carolina Urologic Research Center, Dept. of Urology, Myrtle Beach, United States of America, ²Partnership for Health Analytic Research, President, Beverly Hills, United States of America, ³University Hospitals Seidman Cancer Center, Dept. of Oncology, Cleveland, United States of America, ⁴Southwestern Oncology Group Cancer Research Network, Prostate Cancer Patient Advocate, Las Vegas, United States of America, ⁵PUCRS School of Medicine, Dept. of Medical Oncology, Porto Alegre, Brazil, ⁶University of Utah, Dept. of Oncology, Salt Lake City, United States of America, ⁷Clinical Hospital of Barcelona, Dept. of Medical Oncology, Catalonia, Spain, ⁸National Cancer Center Hospital East, Dept. of Medical Oncology, Chiba, Japan, ⁹NorthShore University Health System, Dept. of Hematology and Medical Oncology, Evanston, United States of America, ¹⁰University of Muenster Medical Center, Dept. of Urology, Münster, Germany, ¹¹Keystone Urology Specialists, Dept. of Urology, Lancaster, United States of America, ¹²Albert Einstein Israelite Hospital, Dept. of Oncology, Sao Paulo, Brazil, ¹³Partnership for Health Analytic Research, Project Manager, Beverly Hills, United States of America, ¹⁴Pfizer Inc., US Oncology, New York, United States of America, ¹⁵Pfizer Inc., Dept. of Oncology, Collegeville, United States of America, ¹⁶Pfizer Inc., Dept. of Medical Affairs, Collegeville, United States of America, ¹⁷Pfizer Inc., Dept. of Oncology Value and Evidence, New York, United States of America, ¹⁸University of Utah, Dept. of Medicine, Salt Lake City, United States of America
- P109** **An evaluation of service diversification in response to increasing therapeutic indications for 2nd generation hormone therapy in prostate cancer**
Authors: Hague A.¹, Yunus I.¹, Yardy A.¹, Carr R.², Przychyna I.¹, Appleyard S.¹, Manetta C.¹, Soultati A.¹
Institutes: ¹East Sussex Healthcare Trust, Dept. of Oncology, Eastbourne, United Kingdom, ²East Sussex Healthcare Trust, Pharmacy, Hastings, United Kingdom
- P110** **Efficacy and safety of SBRT for oligometastatic prostate cancer: An observational study**
Authors: Gomis Sellés E., Munoz Munoz O., Delgado León B.D., Cabrera Roldán P., López Guerra J.L.
Institutes: University Hospital Virgen del Rocío, Radiation Oncology, Seville, Spain

- P111** **New or worsening type 2 diabetes mellitus (T2DM) in men treated with enzalutamide (ENZ) or abiraterone acetate (AA) for metastatic castration-resistant prostate cancer (mCRPC): EVADE study**
Authors: Merseburger A.¹, Bahl A.², Sodatou H.³, Snijder R.⁴, Chillelli A.⁵, Pranzo A.³, Martins K.³, Rozario N.⁴, Crawley D.⁶
Institutes: ¹University Hospital Schleswig-Holstein, Dept. of Urology, Lübeck, Germany, ²University Hospitals Bristol NHS Foundation, Bristol Haematology and Oncology Centre, Bristol, United Kingdom, ³Astellas Pharma Europe Ltd., Dept. of Medical Affairs, Addlestone, United Kingdom, ⁴Astellas Pharma Europe Ltd., Real World Evidence Statistical Science, Addlestone, United Kingdom, ⁵Astellas Pharma Europe Ltd., Dept. of Health Economics Outcomes Research, Addlestone, United Kingdom, ⁶Guys and St Thomas NHS Foundation Trust, Dept. of Medical Oncology, London, United Kingdom
- P112** **Analysis of prostate-specific antigen (PSA) kinetics in the third month of treatment with apalutamide in metastatic castration-sensitive prostate cancer (mCSPC)**
Authors: Sanz Miguelañez J.L.¹, Gutiérrez Gutiérrez E.¹, Alberto Bravo M.J.¹, Marcos Marín D.¹, Pozo Mengual B.¹, Rodríguez Cabello M.A.², Hernández Andrés I.¹, Rodríguez Cabero M.¹, Barriga Guijo R.M.¹, Leal Hernández L.F.¹
Institutes: ¹Hospital Universitario de Guadalajara, Dept. of Urology, Guadalajara, Spain, ²Hospital Universitario La Moraleja, Dept. of Urology, Madrid, Spain
- P113** **Real-world prostate-specific antigen response and outcomes in patients with metastatic hormone-sensitive prostate cancer patients treated with apalutamide: a multicentric study**
Authors: Duarte Mendes A.¹, Vicente R.¹, Freitas R.¹, Gonçalves J.N.², Tomás T.¹, Silva M.¹
Institutes: ¹Hospital Prof. Dr. Fernando Fonseca, Dept. of Medical Oncology, Amadora, Portugal, ²Centro Hospitalar Barreiro Montijo, Dept. of Medical Oncology, Barreiro, Portugal
- P114** **Efficacy and safety of [177Lu]Lu-PSMA-617 in de-novo high-volume metastatic hormone-sensitive prostate cancer: A pilot study**
Authors: Satapathy S.¹, Ballal S.¹, Yadav M.P.¹, Sahoo R.K.², Tripathi M.¹, Bal C.¹
Institutes: ¹All India Institute of Medical Sciences - New Delhi, Nuclear Medicine, New Delhi, India, ²All India Institute of Medical Sciences - New Delhi, Medical Oncology, New Delhi, India
- P115** **The Dynamics of Alkaline Phosphatase in Man with Metastatic Castration-Resistant Prostate Cancer and Bone Metastasis Receiving Enzalutamide: A Survivor Predictor?**
Authors: Vicente R.¹, Mendes A.D.¹, Caleça T.¹, Freitas R.¹, Ferreira R.¹, Prada S.¹, Martins T.¹, Vitorino M.¹, Tomás T.¹, Chaves A.¹, Santos C.²
Institutes: ¹Hospital Professor Doutor Fernando Fonseca, Medical Oncology Department, Amadora, Portugal, ²Hospital de Cascais Dr. José de Almeida, Medical Oncology Department, Cascais, Portugal

- P116** **Characteristics and healthcare resource utilisation (HRU) of patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) on enzalutamide (ENZ) or abiraterone acetate (AA) in England: PROCCO study**
Authors: Merseburger A.¹, Faria R.², Bahl A.³, Attard G.⁴, Snijder R.⁵, Sodatonou H.⁶, Pranzo A.⁶, Martins K.⁶, Rozario N.⁵, Flach C.⁷, Ridsdale-Smith J.⁷, Chilelli A.²
Institutes: ¹Schleswig-Holstein University Hospital, Dept. of Urology, Lübeck, Germany, ²Astellas Pharma Europe Ltd., Dept. of Health Economics Outcomes Research, Addlestone, United Kingdom, ³Bristol Cancer Institute, University Hospitals Bristol, Bristol, United Kingdom, ⁴University College London, Dept. of Medical Oncology, London, United Kingdom, ⁵Astellas Pharma Europe Ltd., RWE Statistical Science, Addlestone, United Kingdom, ⁶Astellas Pharma Europe Ltd., Dept. of Medical Affairs, Addlestone, United Kingdom, ⁷IQVIA Inc., RWES UK, London, United Kingdom
- P117** **Retrospective Study to Describe Characteristics and Treatment Patterns of Patients with Metastatic Castration-resistant Prostates Cancer**
Authors: Gonzalez Hernandez F.¹, Manneh R.², Motta R.¹, Hashem T.³, Jae Young J.⁴, Joshi A.⁵, Bahadir S.⁶, Omar A.⁷, Eid S.⁸
Institutes: ¹AstraZeneca, Dept. of Medical Affairs, Baar, Switzerland, ²Sociedad de Oncologia y Hematologia del Cesar, Dept. of Genitourinary Cancer, Valledupar, Colombia, ³Menoufia University Hospital, Dept. of Oncology, Shibin El Kom, Egypt, ⁴National Cancer Center, Dept. of Urologic Oncology, Goyang-si, South Korea, ⁵Tata Memorial Hospital, Dept. of Oncology, Mumbai, India, ⁶Marmara University School of Medicine, Dept. of Urology, Istanbul, Turkey, ⁷King Faisal Specialist Hospital and Research Center, Dept. of Oncology, Riyadh, Saudi Arabia, ⁸National Cancer Institute Cairo University, Dept. of Oncology, Cairo, Egypt
- P118** **Real-world European study of treatment (tx) patterns in men with metastatic castration-resistant prostate cancer (mCRPC)**
Authors: Barata P.¹, Niyazov A.², Kirker M.², Ribbands A.³, Butcher J.³, Nazari J.⁴, Walley M.³, Castro E.⁵
Institutes: ¹University Hospitals Seidman Cancer Center, Dept. of Medicine Case Comprehensive Cancer Center, Cleveland, United States of America, ²Pfizer, Dept. of Value and Evidence, New York, United States of America, ³Adelphi Real World, Dept. of Oncology, Bollington, United Kingdom, ⁴University of Illinois at Chicago, Dept. of Pharmacy Systems Outcomes and Policy, Chicago, United States of America, ⁵Hospital Universitario 12 de Octubre, GU Tumors Unit, Madrid, Spain
- P119** **Influence of statins in mCRPC patients treated with new antiandrogen therapies**
Authors: Ferreira A.M.¹, Pereira J.A.², Tavares da Silva E.¹, Pedroso Lima J.¹, Quaresma V.¹, Coelho Nunes P.T.¹, Figueiredo A.J.¹
Institutes: ¹Centro Hospitalar e Universitário de Coimbra, Dept. of Urology, Coimbra, Portugal, ²Instituto Portugues de Oncologia de Coimbra, Dept. of Urology, Coimbra, Portugal

- P120** **BIO-Ra score as predictor of prognosis in mCRPC receiving Radium-233**
Authors: Ferreira A.M.¹, Lorigo J.¹, Guerra A.J.¹, Casimiro I.², Tavares da Silva E.¹, Costa G.², Coelho Nunes P.T.¹, Figueiredo A.J.¹
Institutes: ¹Centro Hospitalar e Universitário de Coimbra, Dept. of Urology, Coimbra, Portugal, ²Centro Hospitalar e Universitário de Coimbra, Dept. of Nuclear Medicine, Coimbra, Portugal
- P121** **Prognostic value of neutrophil-to-lymphocyte ratio in mCPRC patients treated with abiraterone, enzalutamide and docetaxel**
Authors: Ferreira A.M., Lorigo J., Tavares da Silva E., Coelho Nunes P.T., Figueiredo A.J.
Institutes: Centro Hospitalar e Universitário de Coimbra, Dept. of Urology, Coimbra, Portugal
- P122** **Is there an optimal number of docetaxel cycles for treatment of metastatic castration-resistant prostate cancer?**
Authors: Furtado I., Gramaça J., Quaresma Ferreira R., Montenegro A., Leao Mendes J., Verdasca F., Escaleira R., Gil L., Gonçalves F., Luz R.
Institutes: Hospital Santo António dos Capuchos, Dept. of Medical Oncology, Lisbon, Portugal
- P123** **Efficacy and Safety with Androgen Receptor Targeted Agents in Older Patients with Metastatic Hormone-Sensitive Prostate Cancer**
Authors: Arevalo R., Gomez Rivas J., Galante Romo M.I., Senovilla Pérez J.L., De la parra I., Infante Hernández S., Mata Deniz P., Moreno Sierra J.S.
Institutes: Hospital clinico San Carlos, Dept. of Urology, Madrid, Spain
- P124** **Prescription patterns in metastatic hormone-sensitive prostate cancer (mHSPC)**
Authors: Duarte Branco V.¹, Pina Cabral T.¹, Lagarto M.¹, Vasques A.C.¹, Ferraz de Liz F.¹, Ferreira F.¹, Cardoso D.¹, Martins A.¹, Lobo-Martins S.²
Institutes: ¹Hospital Sao Francisco Xavier, Dept. of Medical Oncology, Lisbon, Portugal, ²Institut Jules Bordet, Dept. of Medical Oncology, Brussels, Belgium
- P125** **Clinical Outcomes of Metastasis-directed Stereotactic Ablative Radiation Therapy (MDT-SABR) as single intervention added to baseline systemic treatment for Oligometastatic Castration-Resistant Prostate Cancer (mCRPC)**
Authors: Cavalin Silva C.C.S., Souza Fontes Dias M., Masson Domingues P., Machado Coelho T., Wajnsztock Gitelman G., Augusto Rodrigues da Rosa D.
Institutes: Grupo Oncoclinicas, Dept. of Medical Oncology, Rio de Janeiro, Brazil

- P126** **Extended Nodal Radiotherapy for Prostate Cancer Lymph-Nodal Relapse Guided with [11C]-Choline PET/CT: ten-year results in patients enrolled in a prospective trial**
Authors: Fodor A.¹, Brombin C.², Deantoni C.L.¹, Giannini L.¹, Villa S.L.¹, Rancoita P.M.V.², Mangili P.³, Torrisi M.¹, Dell'Oca I.¹, Broggi S.³, Cozzarini C.¹, Mapelli P.⁴, Picchio M.⁵, Del Vecchio A.³, Fiorino C.³, Di Serio M.C.S.², Chiti A.⁵, Di Muzio N.⁶
Institutes: ¹IRCCS San Raffaele Scientific Institute, Dept. of Radiation Oncology, Milan, Italy, ²Vita-Salute San Raffaele University, University Center for Statistics in the Biomedical Sciences, Milan, Italy, ³IRCCS San Raffaele Scientific Institute, Dept. of Medical Physics, Milan, Italy, ⁴IRCCS San Raffaele Scientific Institute, Dept. of Nuclear Medicine, Milan, Italy, ⁵IRCCS San Raffaele Scientific Institute and Vita-Salute San Raffaele University, Dept. of Nuclear Medicine, Milan, Italy, ⁶IRCCS San Raffaele Scientific Institute and Vita-Salute San Raffaele University, Dept. of Radiation Oncology, Milan, Italy
- P127** **Oncological outcomes of patients with oligorecurrent prostate cancer on PMSA PET/CT who underwent stereotactic body radiotherapy**
Authors: de Bie K.C.C.¹, Zuur L.², Meijer D.³, Meijnen P.⁴, Hinnen K.⁵, Oprea-Lager D.E.⁶, van Leeuwen P.J.², Vis A.N.³
Institutes: ¹Amsterdam UMC location Vrije Universiteit Amsterdam, Dept. of Urology, Amsterdam, The Netherlands, ²Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Dept. of Urology, Amsterdam, The Netherlands, ³Amsterdam UMC location Vrije Universiteit Amsterdam, Dept. of Urology, Amsterdam, The Netherlands, ⁴Amsterdam UMC location Vrije Universiteit Amsterdam, Dept. of Radiotherapy, Amsterdam, The Netherlands, ⁵Amsterdam UMC location University of Amsterdam, Dept. of Radiotherapy, Amsterdam, The Netherlands, ⁶Amsterdam UMC location Vrije Universiteit Amsterdam, Dept. of Radiology and Nuclear Medicine, Amsterdam, The Netherlands
- P128** **The influence of the prostate radiotherapy dose in the prediction of complete response in synchronous oligometastatic prostate cancer patients**
Authors: Grujic M., Zivkovic Radojevic M., Milosavljevic N.
Institutes: University of Kragujevac, Faculty of Medical Sciences, Kragujevac, Serbia

- P129** **Real-world data analysis of treatment outcomes for patients with metastatic hormone-sensitive prostate cancer: Development of a survival prediction model. Results from the European network of excellence for big data in prostate cancer (PIONEER)**
Authors: Gómez Rivas J.¹, Nicoletti R.², Golozar A.³, Ayman H.⁴, Steinbeißer C.⁵, Ibañez L.¹, De Meulder B.⁴, Axelsson S.E.⁵, Snijder R.⁶, Feng Q.⁶, Bjartell A.⁷, Cornford P.⁸, Willemse P.⁹, Prinsen P.¹⁰, Murtola T.J.¹¹, N´dow J.¹²
Institutes: ¹Hospital Clinico San Carlos, Dept. of Urology, Madrid, Spain, ²Careggi Hospital, University of Florence, Unit of Urological Robotic Surgery and Renal Transplantation, Florence, Italy, ³Odysseus Data Services, New York, United States of America, ⁴Association EISBM, Vourles, France, ⁵Bayer AG, Berlin, Germany, ⁶Astellas Pharma Europe, Leiden, The Netherlands, ⁷Lund University, Dept. of Translational Medicine, Division of Urological Cancers, Faculty of Medicine, Lund, Sweden, ⁸Liverpool University Hospitals NHS Trust, Dept. of Urology, Liverpool, United Kingdom, ⁹University Medical Center Utrecht, Dept. of Urology, Cancer Center, Utrecht, The Netherlands, ¹⁰Phillips Research, Eindhoven, The Netherlands, ¹¹Tampere University, Faculty of Medicine and Health Technology, Tampere, Finland, ¹²University of Aberdeen, Academic Urology Unit, Aberdeen, United Kingdom
- P130** **Metastatic Prostate cancer (mPCa) and Homologous Recombination Deficiency (HRD) in daily practice: experience of 6 years in a tertiary hospital.**
Authors: Gavira J.¹, Tapia J.C.¹, Romano A.¹, Anguera G.¹, Aguado M.¹, Piedra A.¹, Bosma F.¹, Sanchez S.¹, Sanz J.¹, Molina M.A.¹, Martin C.¹, Algaba F.², Arce Y.², Ramon y Cajal T.¹, Maroto P.¹
Institutes: ¹Hospital de la Santa Creu i Sant Pau, Medical Oncology, Barcelone, Spain, ²Fundació Puigvert, Pathology, Barcelone, Spain
- P131** **Early response evaluation of bone disease with whole-body MRI in metastatic prostate cancer patients**
Authors: Garcia-Ruiz A.¹, Macarro C.¹, Zacchi F.², Mast R.³, de Albert M.³, Roche S.³, Escobar M.³, Morales-Barrera R.², Gonzalez M.², Piulats J.M.⁴, Calvo N.⁵, Garcia Bennett J.⁵, Sanguedolce F.⁶, Carles J.², Mateo J.², Grussu F.¹, Perez-Lopez R.¹
Institutes: ¹Vall d'Hebron Institute of Oncology, Dept. of Radiomics, Barcelona, Spain, ²Vall d'Hebron Institute of Oncology, Oncology Department and Prostate Cancer Translational Research Group, Barcelona, Spain, ³Vall d'Hebron University Hospital, Dept. of Radiology, Barcelona, Spain, ⁴Institut Català d'Oncologia, Dept. of Medical Oncology, L'Hospitalet, Spain, ⁵Hospital Universitari de Bellvitge, Dept. of Radiology, Barcelona, Spain, ⁶Fundació Puigvert, Uro-Oncological Unit, Barcelona, Spain

- P132** **Reliability and efficiency of the CAPRI-3 metastatic prostate cancer registry powered by artificial intelligence**
Authors: Bosch D.¹, Kuppen M.C.P.², Tascilar M.³, Smilde T.J.⁴, Mulders P.¹, Uyl-de Groot C.A.⁵, Oort I.M.¹
Institutes: ¹Radboud University Medical Center, Dept. of Urology, Nijmegen, The Netherlands, ²Maastrro Clinic, Dept. of Radiotherapy, Maastricht, The Netherlands, ³Isala Hospital, Dept. of Medical Oncology, Zwolle, The Netherlands, ⁴Jeroen Bosch Hospital, Dept. of Medical Oncology, 's-Hertogenbosch, The Netherlands, ⁵Erasmus University, Institute for Medical Technology Assessment, Rotterdam, The Netherlands
- P133** **Second line PSMA-targeted salvage treatment in patients with mi N1/M1a-b oligorecurrent PCa**
Authors: Bianchi L.¹, Balestrazzi E.¹, Ceci F.², Costa F.¹, Droghetti M.¹, Pissavini P.¹, Piazza P.¹, Tamburini S.¹, Monti M.¹, Farolfi A.³, Mei R.³, Castellucci P.³, Puliatti S.⁴, Gandaglia G.⁵, Larcher A.⁵, Mottrie A.⁶, Briganti A.⁵, Morganti A.G.⁷, Fanti S.⁸, Montorsi F.⁵, Schiavina R.¹, Brunocilla E.¹
Institutes: ¹IRCCS Azienda Ospedaliero-Universitaria di Bologna, Division of Urology, Bologna, Italy, ²IEO European Institute of Oncology - IRCCS, Division of Nuclear Medicine, Milan, Italy, ³IRCCS Azienda Ospedaliero-Universitaria di Bologna, Dept. of Nuclear Medicine, Bologna, Italy, ⁴University of Modena and Reggio Emilia, Dept. of Urology, Modena, Italy, ⁵IRCCS San Raffaele Scientific Institute Vita-Salute San Raffaele University, Dept. of Urology, Division of Experimental Oncology, Urological Research Institute, Milan, Italy, ⁶Onze-Lieve-Vrouwziekenhuis-Aalst-- ORSI Academy, Dept. of Urology, Melle, Belgium, ⁷IRCCS Azienda Ospedaliero-Universitaria di Bologna, Dept. of Radiation Oncology, Bologna, Italy, ⁸University of Milan, Dept. of Oncology and Hemato-Oncology, Milan, Italy
- P134** **Risk for progression in patients with pathological lymph-node metastatic disease (pN1) who underwent robot-assisted radical prostatectomy and extensive pelvic lymph node dissection.**
Authors: Wever L.¹, Meijer D.², Soeterik T.F.W.¹, Ettema R.H.², Baas D.J.H.³, Dijkman L.M.⁴, Somford D.M.³, van Leeuwen P.J.⁵, Beerlage H.P.², van Basten J.P.A.³, van den Bergh R.C.N.¹, Vis A.N.²
Institutes: ¹St. Antonius Hospital, Dept. of Urology, Nieuwegein, The Netherlands, ²Amsterdam University Medical Centre, Dept. of Urology, Amsterdam, The Netherlands, ³Canisius Wilhelmina Hospital, Dept. of Urology, Nijmegen, The Netherlands, ⁴St. Antonius Hospital, Dept. of Value Based Health Care, Nieuwegein, The Netherlands, ⁵the Netherlands Cancer Institute, Dept. of Urology, Amsterdam, The Netherlands

- P135** **Homologous recombination repair mutation (HRRm) testing patterns among men with metastatic castration-resistant prostate cancer (mCRPC): Interim results from a real-world (rw) study in Europe**
Authors: Castro E.¹, Niyazov A.², Kirker M.², Nazari J.³, Ribbands A.⁴, Butcher J.⁴, Skilling J.⁴, Salmon P.⁴, Barata P.⁵
Institutes: ¹Hospital Universitario 12 de Octubre, Dept. of Medical Oncology, Madrid, Spain, ²Pfizer, Dept. of Value and Evidence, New York, United States of America, ³University of Illinois at Chicago, Dept. of Pharmacy Systems Outcomes and Policy, Chicago, United States of America, ⁴Adelphi Real World, Real World Evidence, Bollington, United States of America, ⁵University Hospitals Seidman Cancer Center, GU Oncology, Cleveland, United States of America
- P136** **Analysis of prognostic factors in patients with metastatic prostate cancer at diagnosis**
Authors: Gonzalo Balbas A., Jimenéz E., SANCHEZ-ROSENDO L., GUIJARRO A., HERNÁNDEZ V., PÉREZ E., LLORENTE C.
Institutes: Hospital Universitario Fundación Alcorcón, Dept. of Urology, Alcorcón-Madrid, Spain
- P137** **Magnitude of PSA decline at 12 weeks and clinical outcomes in first line treatment of metastatic resistant prostate cancer**
Authors: Costa M., Lopes Fernandes C., Silva D., Pinho M., Magalhaes H.
Institutes: Hospital Pedro Hispano, Dept. of Medical Oncology, Matosinhos, Portugal
- P138** **Prevalence of HRR gene mutations in patients with metastatic prostate cancer (mPC): results from a single center in Mexico**
Authors: Staufert Gutierrez J.R., Bautista V.N., Tejeda A., Caballero J.A., Álvarez-Avitia M.N., Jiménez Ríos M.N., Sobrevilla-Moreno N.
Institutes: National Cancer Institute, Genitourinary Tumors Clinic, Mexico City, Mexico
- P139** **Real-world (rw) homologous recombination repair (HRR) mutation testing patterns in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) in five European countries**
Authors: Barata P.¹, Montgomery R.², Gillespie-Akar L.², Ribbands A.², Nazari J.³, Niyazov A.⁴
Institutes: ¹University Hospitals Seidman Cancer Center, Dept. of Medicine Case Comprehensive Cancer Center, Cleveland, United States of America, ²Adelphi Real World, Dept. of Oncology, Bollington, United Kingdom, ³University of Illinois at Chicago, Pharmacy Systems Outcomes and Policy, Chicago, United States of America, ⁴Pfizer, Dept. of Value and Evidence, New York, United States of America

- P140** **Patient-reported pain in men with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) mutations receiving talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA: Results from a phase 3 (TALAPRO-2) study**
Authors: Jones R.¹, De Giorgi U.², Zschabitz S.³, Oldenburg J.⁴, Azad A.⁵, Cislo P.⁶, Chang J.⁷, Healy C.⁸, Niyazov A.⁷, Agarwal N.⁹
Institutes: ¹University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom, ²IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori, Dept. of Oncology, Meldola, Italy, ³University Hospital Heidelberg, Medical Oncology National Center for Tumor Diseases, Heidelberg, Germany, ⁴Akershus University Hospital, Nordbyhagen, Norway, ⁵Peter MacCallum Cancer Centre, Dept. of Medical Oncology, Melbourne, Australia, ⁶Pfizer Inc, Statistics Department, New York, United States of America, ⁷Pfizer Inc, Dept. of Global Access and Value, New York, United States of America, ⁸Pfizer Inc, Clinical Development and Operations, Collegeville, United States of America, ⁹University of Utah, Huntsman Cancer Institute, Salt Lake City, United States of America
- P141** **Cost-effectiveness analysis for prostate cancer bone metastases 3DCRT vs. VMAT techniques**
Authors: Ishkinin Y., Ibrayev R.Z., Raimzhanov K.B., Raimbekov R.B., Omirzak M.S., Latypova B.G., Kuatbek A.K., Munalbayev R.M., Kaldarbekova G.M.
Institutes: Almaty Oncology Center, Dept. of Radiation Oncology, Almaty, Kazakhstan
- P142** **Osteoprotective Treatment in Metastatic Prostate Cancer and Bone related events**
Authors: Arevalo R., Gomez Rivas J., Galante Romo M.I., Senovilla Pérez J.L., Redondo González E., Gutierrez Hidalgo B., Mata Deniz P., Marugan M.J., Moreno Sierra J.S.
Institutes: Hospital clinico San Carlos, Dept. of Urology, Madrid, Spain
- P143** **NEphron Sparing Treatment (NEST) for small renal masses: A feasibility cohort-embedded randomised controlled trial comparing percutaneous cryoablation and robot assisted partial nephrectomy**
Authors: Neves J.B.¹, Warren H.¹, Santiapillai J.¹, Rode N.², Cullen D.², Pavlou M.³, Walkden M.², Patki P.², Barod R.¹, Mumtaz F.¹, Aitchison M.², Bandula S.¹, Pizzo E.⁴, Ranieri V.⁵, Williams N.¹, Wildgoose W.⁶, Gurusamy K.¹, Emberton M.¹, Bex A.¹, Tran M.G.B.¹
Institutes: ¹University College London, Division of Surgery and Interventional Sciences, London, United Kingdom, ²Royal Free Hospital Specialist Centre for Kidney Cancer, Dept. of Urology, London, United Kingdom, ³University College London, Dept. of Statistical Sciences, London, United Kingdom, ⁴University College London, Dept. of Allied Health Research, London, United Kingdom, ⁵Tavistock and Portland Foundation Trust, Dept. of Clinical Psychology, London, United Kingdom, ⁶Patient and Public Representative, London, United Kingdom

- P144** **Complete response in first-line metastatic renal cell carcinoma treated by immunotherapy with or without local treatment of residual disease**
Authors: Boudier P.¹, Moinard-Butot F.¹, Thouvenin J.², Bigot P.³, Maillet D.², Tricard T.⁴, Pierard L.¹, Werle P.⁴, Lindner V.R.⁵, Martin S.¹, Schuster C.¹, Burgy M.¹, Malouf G.¹, Lang H.⁴, Barthelemy P.¹
Institutes: ¹Institut de Cancérologie Strasbourg Europe, Dept. of Medical Oncology, Strasbourg, France, ²Hospices Civils de Lyon, Dept. of Medical Oncology, Pierre-Benite, France, ³Angers University Hospital, Dept. of Urology, Angers, France, ⁴Strasbourg University Hospital, Dept. of Urology, Strasbourg, France, ⁵Strasbourg University Hospital, Dept. of Pathology, Strasbourg, France
- P145** **A monocentric experience about the MET c.3328G>A p.Val1110Ile mutation and its association with papillary and chromophobe Renal Cell Carcinomas: data on histology, multifocality, early onset and the need for Radical Nephrectomy**
Authors: Rinaldi M.¹, Di Gianfrancesco L.¹, Zovato S.², Crestani A.³, Porreca A.¹, Lista G.¹
Institutes: ¹Veneto Institute of Oncology IOV IRCCS, Dept. of Oncological Urology, Padua, Italy, ²Veneto Institute of Oncology IOV IRCCS, UOSD Tumori Ereditari, Padua, Italy, ³Azienda Sanitaria Universitaria Friuli Centrale, Dept. of Urology, Udine, Italy
- P146** **Risk factors for recurrence after curative nephrectomy in non metastatic renal cell carcinoma: A retrospective cohort study**
Authors: Tejada K.
Institutes: National Kidney and Transplant Institute, Section of Medical Oncology, Manila, Philippines
- P147** **Mucinous Tubular and Spindle Cell carcinoma of the kidney – an rare indolent variant or something more?**
Authors: Oliveira J.P.¹, Vilorio A.², Abreu S.¹, Pereira P.³, Martins-Silva C.¹, Silva J.¹, Antunes-Lopes T.¹
Institutes: ¹Centro Hospitalar e Universitário de Sao Joao, Dept. of Urology, Porto, Portugal, ²Faculty of Medicine Porto University, Dept. of Surgery and Physiology, Porto, Portugal, ³Centro Hospitalar e Universitário de Sao Joao, Dept. of Pathology, Porto, Portugal
- P148** **Laparoscopic partial nephrectomy using neuroaxial anesthesia**
Authors: Piana A.¹, Lauria J.¹, Zappalà G.¹, Sidoti F.¹, Chiaradia F.¹, Greco A.¹, Chiaravalloti F.², Porpiglia F.³, Alba S.¹
Institutes: ¹Romolo Hospital, Dept. of Urology, Rocca di Neto, Italy, ²Romolo Hospital, Dept. of Anesthesiology, Rocca di Neto, Italy, ³San Luigi Gonzaga Hospital, Dept. of Urology, Turin, Italy
- P149** **Comparison of oncological and functional outcomes of radical versus partial nephrectomy for cT1b renal cell carcinoma: A two-center, matched analysis**
Authors: Van Den Brink L.¹, van den Kroonenberg D.L.¹, Graafland N.M.², Bex A.², Beerlage H.P.¹, Zondervan P.J.¹
Institutes: ¹Amsterdam University Medical Center, Dept. of Urology, Amsterdam, The Netherlands, ²Netherlands Cancer Institute, Dept. of Urology, Amsterdam, The Netherlands

- P150** **Improving value of care for Renal Cell Carcinoma (RCC) patients: Development of 2 Dutch decision aids**
Authors: Bresser C.C.¹, van Melick H.H.E.¹, van der Nat P.B.², Garvelink M.M.²
Institutes: ¹St. Antonius Hospital, Dept. of Urology, Nieuwegein, The Netherlands, ²St. Antonius Hospital, Dept. of Value Based Healthcare, Nieuwegein, The Netherlands
- P151** **Lenvatinib plus Pembrolizumab as first-line treatment in patients with advanced renal cell carcinoma – real world data from a retrospective multi-center analysis**
Authors: Stelmach R.¹, Schlack K.², Neuberger S.³, Muehle C.⁴, Darr C.⁵, Reichert M.⁶, Flegar L.⁷, Zengerling F.⁸, Casuscelli J.⁹, Cox A.¹⁰, Nestler T.¹¹, Egenolf T.¹², Brehmer B.¹³, Vallet S.¹⁴, Ivanyi P.¹⁵, Rehlinghaus M.¹⁶, Neuberger M.¹⁷, Paffenholz P.¹⁸, Grünwald V.⁵, Zschäbitz S.¹
Institutes: ¹Heidelberg University Hospital, National Center for Tumor Diseases, Heidelberg, Germany, ²University Hospital Muenster, Dept. of Urology, Münster, Germany, ³University Medical Center of Johannes Gutenberg University, Dept. of Urology and Pediatric Urology, Mainz, Germany, ⁴Klinikum Rechts der Isar Technical University Munich, Dept. of Urology, Munich, Germany, ⁵University of Duisburg-Essen and German Cancer Consortium University Hospital Essen, Dept. of Urology, Essen, Germany, ⁶University Medicine Goettingen, Dept. of Urology, Göttingen, Germany, ⁷Philipps-University Marburg, Dept. of Urology, Marburg, Germany, ⁸University Hospital Ulm, Dept. of Urology and Pediatric Urology, Ulm, Germany, ⁹University Hospital Ludwig Maximilian University of Munich, Dept. of Urology, Munich, Germany, ¹⁰University Hospital Bonn, Dept. of Urology, Bonn, Germany, ¹¹Federal Armed Services Hospital Koblenz, Dept. of Urology, Koblenz, Germany, ¹²University Hospital Würzburg, Dept. of Urology and Pediatric Urology, Würzburg, Germany, ¹³Diakonie Hospital, Dept. of Urology, Schwaebisch-Hall, Germany, ¹⁴University Hospital Krems, Dept. of Internal Medicine II, Krems an der Donau, Austria, ¹⁵Claudia-von Schelling Comprehensive Cancer Center, Hannover Medical School, Dept. of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover, Germany, ¹⁶University Hospital Düsseldorf, Dept. of Urology, Düsseldorf, Germany, ¹⁷Medical Faculty Mannheim of the University of Heidelberg, Dept. of Urology and Urological Surgery, Mannheim, Germany, ¹⁸University of Cologne, Faculty of Medicine and University Hospital Cologne, Dept. of Urology, Uro-Oncology, Robot Assisted and Reconstructive Urologic Surgery, Cologne, Germany
- P152** **Creation of a Day Hospital in the Urology service for the Implementation of Immunotherapy: results and management of adverse events**
Authors: Guerra Lacambra M., Melgarejo Segura M.T., Yáñez Castillo Y., Folgueral Corral M.E., Arrabal Polo M.A., Gutiérrez Tejero F., Arrabal Martín M.
Institutes: San Cecilio Clinical University Hospital, Dept. of Urology, Granada, Spain

- P153** **A hypothesis generating analysis of the role of chromosome 3p-related genes as predictors for immunocombinations in metastatic renal cell carcinoma (mRCC)**
Authors: Rosellini M.¹, Mollica V.¹, Coluccelli S.², Giunchi F.³, Ricci C.⁴, Marchetti A.¹, Tassinari E.¹, Fiorentino M.⁴, De Biase D.⁵, Massari F.¹
Institutes: ¹IRCCS Azienda Ospedaliero-Universitaria di Bologna, Dept. of Medical Oncology, Bologna, Italy, ²University of Bologna, Dept. of Medical and Surgical Science, Bologna, Italy, ³IRCCS Azienda Ospedaliero-Universitaria di Bologna, Dept. of Pathology, Bologna, Italy, ⁴Maggiore Hospital-AUSL Bologna, Pathology Unit, Bologna, Italy, ⁵University of Bologna, Dept. of Pharmacy and Biotechnology, Bologna, Italy
- P154** **Characteristics and treatment patterns of patients with advanced/metastatic renal-cell carcinoma treated with first line checkpoint inhibitors. A Real-world experience**
Authors: Zakopoulou R.¹, Koutsoukos K.², Angelidou A.³, Kyriazoglou A.¹, Moutafi M.¹, Andrikopoulou A.², Gavrielatou N.¹, Mpoulouta A.¹, Papatheodoridi A.², Kapodistrias N.³, Binas I.⁴, Emmanouil G.⁵, Dimitriadis I.⁵, Christodoulou C.⁴, Mavroudis D.⁶, Koutras A.³, Zagouri F.², Bamias A.¹
Institutes: ¹Attikon University General Hospital, Second Department of Propedeutic Internal Medicine, Athens, Greece, ²Alexandra Hospital National and Kapodistrian University of Athens, Dept. of Clinical Therapeutics, Athens, Greece, ³University Hospital of Patras, Dept. of Medicine, Division of Oncology, Rio, Greece, ⁴Metropolitan Hospital, Second Department of Medical Oncology, Piraeus, Greece, ⁵MSD Greece, Dept. of Medical Affairs, Athens, Greece, ⁶University Hospital of Heraklion, Dept. of Medical Oncology, Heraklion, Greece
- P155** **Factors affecting acute kidney injury and subsequent renal function recovery after robot-assisted partial nephrectomy for clinical T1a renal masses**
Authors: Takeda T., Tanigawa M., Nishimoto Y., Matsumoto K., Mizuno R., Oya M.
Institutes: Keio University School of Medicine, Dept. of Urology, Tokyo, Japan

P156 **Zanzalintinib (XL092) and nivolumab in non-clear cell renal cell carcinoma: The randomized phase 3 STELLAR-304 study (NCT05678673)**
Authors: Suarez C.¹, Powles T.², Kanesvaran R.³, Lee C-H.⁴, Liu M.⁵, Wang Z.⁶, Bhatt A.⁷, Patel P.⁸, Pal S.⁹
Institutes: ¹Vall d'Hebron Institute of Oncology VHIO Hospital Universitari Vall d'Hebron Vall d'Hebron Barcelona Hospital Campus, Dept. of Medical Oncology, Barcelona, Spain, ²Barts Health NHS Trust Saint Bartholomews Hospital, Dept. of Medical Oncology, London, United Kingdom, ³National Cancer Centre Singapore, Dept. of Medical Oncology, Singapore, Singapore, ⁴Memorial Sloan Kettering Cancer Center, Dept. of Medical Oncology, New York, United States of America, ⁵Bristol Myers Squibb, Dept. of Global Drug Development, New York, United States of America, ⁶Exelixis Inc., Dept. of Biometrics, Alameda, United States of America, ⁷Exelixis Inc., Dept. of Clinical Science, Alameda, United States of America, ⁸Exelixis Inc., Dept. of Clinical Development, Alameda, United States of America, ⁹City of Hope Comprehensive Cancer Center, Dept. of Medical Oncology and Therapeutics Research, Duarte, United States of America

P157 **Real world evidence from a retrospective multi-center analysis for the combination immunotherapy ipilimumab and nivolumab as first-line treatment in advanced renal cell carcinoma**
Authors: Materna L.¹, Schlack K.¹, Stelmach R.², Zschäbitz S.², Neuberger S.³, Aydogdu C.⁴, Casuscelli J.⁴, Egenolf T.⁵, Silberg M.⁶, Steinestel J.⁷, Strauss A.⁸, Kirchhoff F.⁹, Ahrens M.¹⁰, Paffenholz P.¹¹, Cathomas R.¹², Gossler C.¹³, Ivanyi P.¹⁴, Rehlinghaus M.¹⁵, Hilser T.¹⁶, Grünwald V.¹⁶
Institutes: ¹University Hospital Muenster, Dept. of Urology, Münster, Germany, ²National Center for Tumor Diseases, University Hospital Heidelberg, Dept. of Medical Oncology, Heidelberg, Germany, ³University Medical Center of Johannes Gutenberg University Mainz, Dept. of Urology and Pediatric Urology, Mainz, Germany, ⁴University Hospital Ludwig Maximilian University of Munich, Dept. of Urology, Munich, Germany, ⁵University Hospital Wuerzburg, Dept. of Urology and Pediatric Urology, Würzburg, Germany, ⁶Marien Hospital Herne - Ruhr University Bochum, Dept. of Urology, Herne, Germany, ⁷University Hospital Augsburg, Dept. of Urology, Augsburg, Germany, ⁸University Medicine Goettingen, Dept. of Urology, Göttingen, Germany, ⁹Rechts der Isar Medical Center, Technical University Munich, Dept. of Urology, Munich, Germany, ¹⁰University Hospital Frankfurt, Dept. of Oncology, Frankfurt, Germany, ¹¹University Hospital Cologne, Dept. of Urology, Cologne, Germany, ¹²Kantonspital Graubünden, Dept. of Oncology-Hematology, Chur, Switzerland, ¹³Krankenhaus St. Josef - University of Regensburg, Dept. of Urology, Regensburg, Germany, ¹⁴Claudia-von Schelling Comprehensive Cancer Center, Hannover Medical School, Dept. of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover, Germany, ¹⁵University Hospital Duesseldorf, Dept. of Urology, Düsseldorf, Germany, ¹⁶University of Duisburg-Essen and German Cancer Consortium - University Hospital Essen, Dept. of Urology, Essen, Germany

- P158** **Phase II study of avelumab (Ave) plus intermittent axitinib (Axi) in previously untreated patients (pts) with metastatic renal cell carcinoma (mRCC): overall outcome and by IMDC risk class and PDL1 expression**
Authors: Iacovelli R.¹, Ciccicarese C.¹, Brunelli M.², Buti S.³, Zucali P.A.⁴, Fantinel E.⁵, Bimbatti D.⁶, Verzoni E.⁷, Accettura C.⁸, Bonomi L.⁹, Buttigliero C.¹⁰, Cremante M.¹¹, Vitale M.G.¹², Atzori F.¹³, Masini C.¹⁴, Mollica V.¹⁵, Giron Berrios J.R.¹⁶, Perrino M.¹⁷, Giudice G.C.³, Calì A.², Martignoni G.¹⁸, Tortora G.¹
Institutes: ¹Fondazione Policlinico Universitario A. Gemelli IRCCS, Medical Oncology, Rome, Italy, ²University of Verona, Department of Diagnostics and Public Health, Verona, Italy, ³University of Parma, Medical Oncology Unit, Parma, Italy, ⁴Humanitas University, Department of Biomedical Sciences, Pieve Emanuele, Italy, ⁵Azienda Ospedaliera Universitaria Integrata, Medical Oncology, Verona, Italy, ⁶Istituto Oncologico Veneto, Oncology Unit 1, Padua, Italy, ⁷Istituto Nazionale Tumori, Medical Oncology, Milan, Italy, ⁸Vito Fazzi Hospital, Medical Oncology, Lecce, Italy, ⁹ASST Papa Giovanni XXIII, Department of Oncology and Hematology, Bergamo, Italy, ¹⁰University of Turin, Department of Oncology, Turin, Italy, ¹¹IRCCS Ospedale Policlinico San Martino, Medical Oncology Unit 1, Genova, Italy, ¹²Azienda Ospedaliero-Universitaria di Modena, Department of Oncology and Haematology, Modena, Italy, ¹³University Hospital and University of Cagliari, Medical Oncology, Cagliari, Italy, ¹⁴Comprehensive Cancer Centre IRCCS - AUSL Reggio Emilia, Medical Oncology, Reggio Emilia, Italy, ¹⁵IRCCS Azienda Ospedaliero-Universitaria di Bologna, Medical Oncology, Bologna, Italy, ¹⁶Central Hospital of Belcolle, Medical Oncology, Viterbo, Italy, ¹⁷IRCCS Humanitas Research Hospital Humanitas Cancer Center, Medical Oncology, Rozzano, Italy, ¹⁸University of Verona, Department of Diagnostic and Public Health, Verona, Italy
- P159** **The impact of multi- and interdisciplinary tumour board (MTB) meetings on treatment decision making for patients with renal cell carcinoma (RCC): 5-year data analysis**
Authors: Van Den Brink L.¹, Ruiter A.E.C.², Lagerveld B.W.², Graafland N.M.³, Bex A.³, Beerlage H.P.¹, van Moorselaar R.J.M.¹, Zondervan P.J.¹
Institutes: ¹Amsterdam University Medical Center, Dept. of Urology, Amsterdam, The Netherlands, ²Onze Lieve Vrouwe Gasthuis, Dept. of Urology, Amsterdam, The Netherlands, ³Netherlands Cancer Institute, Dept. of Urology, Amsterdam, The Netherlands
- P160** **Clinical characterisation, prognosis, and assessment of predictive score for response to treatment of metastatic renal cells carcinoma with rhabdoid component**
Authors: Vallois L.¹, Lindner V.¹, Barthélémy P.²
Institutes: ¹Haute-pierre University Hospital, Dept. of Pathology, Strasbourg, France, ²ICANS, Dept. of Oncology, Strasbourg, France

- P161** **Avelumab and axitinib in metastatic renal cell carcinoma: Results from a real-world observational study RAVE-Renal**
Authors: Baklanova O.¹, Chubenko V.², Kalpinskiy A.³, Safina S.⁴, Shkurat A.⁵, Lebedinets A.⁵, Parsadanova E.⁶, Turganova M.⁷, Petkau V.⁸, Tovbik N.⁹, Tkacheva E.¹⁰, Anzhiganova Y.¹¹, Novikova O.¹², Zukov R.¹³, Tsimafeyeu I.¹⁴
Institutes: ¹Irkutsk Regional Cancer Center, Dept. of Urology, Irkutsk, Russia, ²Saint-Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Care Oncological, Dept. of Medical Oncology, Saint-Petersburg, Russia, ³P.A. Hertsen Moscow Oncology Research Center - National Medical Research Center of Radiology, Dept. of Oncurology, Moscow, Russia, ⁴Republican Dispensary of Tatarstan, Dept. of Chemotherapy, Kazan, Russia, ⁵SBHI Leningrad Regional Clinical Hospital, Dept. of Medical Oncology, Saint-Petersburg, Russia, ⁶Sakhalin Regional Cancer Center, Outpatient Dept., Yuzhno-Sakhalinsk, Russia, ⁷Novosibirsk Regional Cancer Center, Outpatient Dept., Novosibirsk, Russia, ⁸Sverdlovskiy Regional Oncological Dispensary, Dept. of Medical Oncology, Ekaterinburg, Russia, ⁹Amursky Regional Cancer Center, Dept. of Chemotherapy, Blagoveshchensk, Russia, ¹⁰Primorsky Regional Cancer Center, Dept. of Medical Oncology 2, Vladivostok, Russia, ¹¹A.I. Kryzhanovsky Krasnoyarsk Regional Cancer Center, Dept. of Urogynecological, Krasnoyarsk, Russia, ¹²Khabarovsk Regional Cancer Center, Dept. of Medical Oncology, Khabarovsk, Russia, ¹³V.F. Voyno-Yasenetsky Krasnoyarsk State Medical University, Dept. of Oncology, Krasnoyarsk, Russia, ¹⁴Bureau of Cancer Research - BUCARE, Moscow Office, Moscow, Russia
- P162** **Clinical outcomes of immunotherapy-based first-line regimens in advanced Renal Cell Carcinoma – the Onco-CHUS experience**
Authors: Anido Herranz U.¹, Fernandez-Diaz N.¹, Garcia-Gonzalez J.¹, Cebey-Lopez V.¹, Z. Betancor Y.², Ferreiro-Pantin M.², Fuentes-Losada M.¹, Touris-Lores M.³, Vaamonde-Rodriguez V.⁴, Villaverda-Viano R.⁴, Bernandez-Ferran B.³, Blanco-Parra M.⁵, Lopez-Lopez R.¹, Ruiz-Banobre J.¹
Institutes: ¹Complejo Hospitalario Universitario de Santiago de Compostela, Dept. of Medical Oncology, Santiago de Compostela, Spain, ²Health Research Institute of Santiago de Compostela, Translational Medical Oncology Group, Santiago de Compostela, Spain, ³Complejo Hospitalario Universitario de Santiago de Compostela, Dept. of Pharmacy, Santiago de Compostela, Spain, ⁴Complejo Hospitalario Universitario de Santiago de Compostela, Dept. of Oncology Nursery, Santiago de Compostela, Spain, ⁵Complejo Hospitalario Universitario de Santiago de Compostela, Dept. of Urology, Santiago de Compostela, Spain
- P163** **Systemic Immune Inflammation Index and Survival Outcomes in Metastatic Renal Cell Carcinoma**
Authors: Fraga T., Gomes I., Tavares A., Madeira P., Sousa G.
Institutes: Instituto Portugues de Oncologia de Coimbra, Dept. of Medical Oncology, Coimbra, Portugal
- P164** **Comparison of oncological and functional outcomes of partial nephrectomy versus cryoablation for cT1a renal cell carcinoma**
Authors: Van Den Brink L., Henderickx M.M.E.L., Beerlage H.P., Zondervan P.J.
Institutes: Amsterdam University Medical Center, Dept. of Urology, Amsterdam, The Netherlands

- P165** **A nationwide real-world comparison of old vs. new clinical practice for cytoreductive nephrectomy in metastatic renal cell carcinoma**
Authors: Yildirim H.¹, Bijlsma M.J.², Bins A.D.³, van Oijen M.³, van den Hurk C.⁴, Bex A.⁵, Aben K.K.H.⁴, Zondervan P.J.⁶
Institutes: ¹Amsterdam UMC location University of Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands, ²IKNL, Dept. of Clinical Data Science, Utrecht, The Netherlands, ³Amsterdam UMC location University of Amsterdam, Dept. of Medical Oncology, Amsterdam, The Netherlands, ⁴IKNL, Dept. of Research and Development, Utrecht, The Netherlands, ⁵The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Dept. of Urology, Amsterdam, The Netherlands, ⁶Amsterdam UMC location University of Amsterdam, Dept. of Urology, Amsterdam, The Netherlands
- P166** **Real-world outcomes of cabozantinib treatment after first-line checkpoint inhibitor-based combination therapy for patients with advanced renal cell carcinoma: CARINA study results**
Authors: Nathan P.¹, Allison J.², Charnley N.³, Griffiths R.⁴, Michael A.⁵, Moore K.⁶, Sharma A.¹, Szabados B.⁷, Venugopal B.⁸, Ali J.⁸, Perrot V.⁹, Prendergast A.¹⁰, Ceruso M.¹⁰, Larkin J.¹¹
Institutes: ¹Mount Vernon Cancer Centre, Dept. of Medical Oncology, Northwood, United Kingdom, ²The Christie NHS Foundation Trust, Dept. of Medical Oncology, Manchester, United Kingdom, ³Royal Preston Hospital, Dept. of Clinical Oncology, Preston, United Kingdom, ⁴The Clatterbridge Cancer Centre NHS Foundation Trust, Dept. of Medical Oncology, Liverpool, United Kingdom, ⁵Royal Surrey NHS Foundation Trust, Dept. of Oncology, Guildford, United Kingdom, ⁶Nottingham University Hospitals NHS Trust, Nottingham Cancer Clinical Trials Team, Nottingham, United Kingdom, ⁷Barts Cancer Institute Queen Mary University of London, Dept. of Medical Oncology, London, United Kingdom, ⁸Beatson West of Scotland Cancer Centre, Dept. of Medical Oncology, Glasgow, United Kingdom, ⁹Ipsen, Medical Department, Boulogne-Billancourt, France, ¹⁰Ipsen Biopharm Ltd, Clinical Department, Slough, United Kingdom, ¹¹The Royal Marsden NHS Foundation Trust, Medicine, London, United Kingdom
- P167** **Kidney SBRT for Renal Lesions: a Monoinstitutional Analysis**
Authors: Tummineri R.¹, Fodor A.¹, Deantoni C.L.¹, Losa A.², Maga T.², Broggi S.³, Fiorino C.³, Gaboardi F.², Di Muzio N.G.¹
Institutes: ¹IRCCS Ospedale San Raffaele, Dept. of Radiation Oncology, Milan, Italy, ²IRCCS Ospedale San Raffaele, Dept. of Urology, Milan, Italy, ³IRCCS Ospedale San Raffaele, Dept. of Medical Physics, Milan, Italy
- P168** **Nivolumab as a treatment for metastatic renal cancer in second and successive lines. Experience at our hospital.**
Authors: Garrido M.L., Lopez Lopez L., Tavana Silva B., Perez Nunez S., Vazquez Diez M., Pedraza Lorenzo M., De Sande Gonzalez L.M., Garcia Palomo A., Rodriguez Sanchez A.
Institutes: Leon University Hospital, Dept. of Medical Oncology, Leon, Spain

- P169** **Impact of intraoperative blood transfusions after surgery for renal cell carcinoma**
Authors: Chaker K.¹, Ben Chedly W.¹, Ben Elkadhi S.¹, Bibi M.¹, Mosbahi B.², Fakhfakh H.², El Abed W.², Hriz A.², Rahoui M.¹, Mourad Dali K.¹, Ouanes Y.¹, Nouira Y.¹
Institutes: ¹La Rabta Hospital, Dept. of Urology, Tunis, Tunisia, ²La Rabta Hospital, Dept. of Anesthesia, Tunis, Tunisia
- P170** **Renal cell carcinoma with vena cava thrombus management and results in a tertiary center**
Authors: Faria Costa G.¹, Freitas R.², Alzamora M.A.³, Braga I.², Magalhaes S.², Carvalho J.², Correia J.², Silva V.M.², Lobo F.², Henrique R.³, Morais A.²
Institutes: ¹Unidade Local de Saúde de Matosinhos, Dept. of Urology, Matosinhos, Portugal, ²Instituto Portugues de Oncologia do Porto, Dept. of Urology, Porto, Portugal, ³Instituto Portugues de Oncologia do Porto, Dept. of Pathology, Porto, Portugal
- P171** **Oncocytoma is predominant pathology feature in multifocal bilateral kidney tumors**
Authors: Yakovlev P., Chistyakov V.
Institutes: Clinical hospital Feofaniya, Dept. of Oncourology and Urology, Kyiv, Ukraine
- P172** **Perioperative and long-term oncological outcomes after local tumor ablation for complex (PADUA Score =10) cT1a renal tumors: a multicenter analysis**
Authors: Piazza P.¹, Bianchi L.¹, Luzzago S.², Bandini M.³, Mottaran A.¹, Amirhassankhani S.¹, De Concilio B.⁴, Celia A.⁴, Serra C.⁵, Cappelli A.⁶, Golfieri R.⁶, Musi G.⁷, Gallina A.⁸, Rizzo M.⁹, Liguori G.⁹, Trombetta C.⁹, De Cobelli F.¹⁰, Mauri G.¹¹, Orsi F.¹¹, Capitanio U.³, Schiavina R.¹, De Cobelli O.², Montorsi F.³, Brunocilla E.¹
Institutes: ¹IRCCS Azienda Ospedaliero-Universitaria di Bologna, Dept. of Urology, Bologna, Italy, ²IEO European Institute of Oncology - IRCCS, Dept. of Urology, Bologna, Italy, ³IRCCS Ospedale San Raffaele, Urological Research Institute, Vita-Salute San Raffaele University, Unit of Urology, Milan, Italy, ⁴San Bassiano Hospital - Bassano del Grappa, Dept. of Urology, Bassano del Grappa, Italy, ⁵Interventional Diagnostic and Therapeutic Ultrasound Unit - Sant'Orsola Malpighi Hospital, Medical and Surgical Sciences, Bologna, Italy, ⁶IRCCS Azienda Ospedaliero-Universitaria di Bologna, Dept. of Radiology, Bologna, Italy, ⁷IEO European Institute of Oncology - IRCCS, Dept. of Oncology, Milan, Italy, ⁸Ospedale Regionale di Lugano- Università della Svizzera Italiana, Dept. of Urology, Lugano, Switzerland, ⁹University of Trieste, Dept. of Urology, Trieste, Italy, ¹⁰IRCCS Ospedale San Raffaele, Urological Research Institute, Vita-Salute San Raffaele, Dept. of Radiology, Milan, Italy, ¹¹IEO European Institute of Oncology - IRCCS, Dept. of Radiology, Milan, Italy
- P173** **Percutaneous and Laparoscopic Radiofrequency Ablation in Small Renal Masses**
Authors: Akgül B.¹, Kiyici B.², Tozsın A.¹, Kula O.², Cek H.M.¹, Arda E.¹
Institutes: ¹Trakya University School of Medicine Hospital, Dept. of Urology, Edirne, Turkey, ²Trakya University School of Medicine Hospital, Dept. of Radiology, Edirne, Turkey

- P174** **The efficacy and safety of cone beam computed tomography for percutaneous renal cell carcinoma cryoablation: A single-center long-term follow-up study**
Authors: Duijn M.¹, Ruiter A.E.C.¹, Montauban van Swijndregt A.D.², Lagerveld B.W.¹
Institutes: ¹OLVG, Dept. of Urology, Amsterdam, The Netherlands, ²OLVG, Dept. of Radiology, Amsterdam, The Netherlands
- P175** **Nuclear Grading of Tumor Thrombus as an Unheeded Prognostic Predictor in Non-metastatic Clear Cell Renal Cell Carcinoma: A Multi-cohort Study**
Authors: Le Q.¹, Ge J.¹, Zhou W.¹, Wang L.²
Institutes: ¹Jinling Hospital, Dept. of Urology, Nanjing, China, ²Changhai Hospital, Dept. of Urology, Shanghai, China
- P176** **LDH isozyme as a prognostic factor for patients with metastatic clear cell renal cell carcinoma (mCRCC)**
Authors: Takeda H., Kimura G., Kishi H., Taniuchi M., Miyauchi S., Funato R., Hasegawa H., Shibasaki M., Mikami H., Obayashi K., Akatsuka J., Endo Y., Toyama Y., Kondo Y.
Institutes: Nippon Medical School, Dept. of Urology, Tokyo, Japan
- P177** **Prognostic significance of differentiating Tubulopapillary kidney carcinomas**
Authors: Bedoui M.A., Saadi A., Zaghib S., Mokadem S., Boussaffa H., Hermi A., Ayed H., Bouzouita A., Derouiche A., Chakroun M., Ben Slama M.R.
Institutes: Charles Nicolle Hospital, Dept. of Urology, Tunis, Tunisia
- P178** **Mutational profile of primary clear cell renal cell carcinoma predicts recurrence and potential selection for adjuvant therapy**
Authors: Vlachostergios P.¹, Papathanassiou M.², Anagnostou M.², Tamposis I.³, Mitrakas L.⁴, Zachos I.⁴, Thodou E.², Ioannou M.², Koukoulis G.², Samara M.², Tzortzis V.⁴
Institutes: ¹IASO Thessalias Hospital, Dept. of Medical Oncology, Larissa, Greece, ²University of Thessaly, Faculty of Medicine School of Health Sciences, Dept. of Pathology, Larissa, Greece, ³University of Thessaly, Dept. of Computer Science and Biomedical Informatics, Lamia, Greece, ⁴University of Thessaly, Faculty of Medicine School of Health Sciences, Dept. of Urology, Larissa, Greece
- P179** **Comparison of C-reactive protein kinetics and primary treatment response in synchronous/metachronous metastatic renal cell carcinoma**
Authors: Guer M., Fehr A., Schittko J., Blaschke S., Schostak M.
Institutes: University Hospital Magdeburg, Dept. of Urology, Magdeburg, Germany
- P180** **Beyond IMDC stratification: potential alternative prognostic factors in metastatic renal cells carcinoma**
Authors: Teixeira C.M.T., Marina G.A., Lopes de Almeida C., Baptista Freitas M., Lemos T., Couto M., Costa I., Augusto I., Meireles S., Marques Ribeiro M.J., Barbosa M.
Institutes: Centro Hospitalar e Universitário do Sao Joao, Dept. of Oncology, Porto, Portugal

P181

Proposal and internal validation of a nomogram for the prediction of local recurrence-free survival after percutaneous ablation for ct1 renal masses

Authors: Mottaran A.¹, Nocera L.², Bianchi L.¹, Luzzago S.³, Bandini M.², Piazza P.¹, Celia A.⁴, Serra C.⁵, Cappelli A.⁶, De Cinque A.⁶, Modestino F.⁶, Golfieri R.⁶, Musi G.³, Gallina A.⁷, De Cobelli F.⁸, Mauri G.⁹, Orsi F.⁸, Capitanio U.², Schiavina R.¹, De Cobelli O.³, Montorsi F.², Brunocilla E.¹

Institutes: ¹IRCCS Azienda Ospedaliero-Universitaria di Bologna, Division of Urology, Bologna, Italy, ²IRCCS Ospedale San Raffaele, Urological Research, Vita-Salute San Raffaele University, Unit of Urology, Milan, Italy, ³IEO European Institute of Oncology - IRCCS, Dept. of Urology, Milan, Italy, ⁴San Bassiano Hospital, Dept. of Urology, Bassano del Grappa, Italy, ⁵Sant'Orsola Malpighi Hospital, Interventional Diagnostic and Therapeutic Ultrasound Unit, Dept. of Medical and Surgical Sciences, Bologna, Italy, ⁶IRCCS Azienda Ospedaliero-Universitaria di Bologna, Dept. of Radiology, Bologna, Italy, ⁷Ospedale Regionale di Lugano- Civico USI - Università della Svizzera Italiana, Dept. of Urology, Lugano, Switzerland, ⁸IRCCS Ospedale San Raffaele, Urological Research Institute, Vita-Salute San Raffaele University, Unit of Radiology, Milan, Italy, ⁹IEO European Institute of Oncology - IRCCS, Dept. of Radiology, Milano, Italy

- P182** **IO-Synthesise RCC: relationship between baseline health-related quality of life and clinical outcomes of nivolumab in patients with previously treated metastatic renal cell carcinoma using pooled real-world data from France and Germany**
Authors: Bedke J.¹, Thiery-Vuillemin A.², Grimm M-O.³, Mueller-Huesmann H.⁴, Ivanyi P.⁵, von der Heyde E.⁶, Barthélémy P.⁷, Colomba E.⁸, Albiges L.⁸, Vano Y-A.⁹, Ejzykowicz F.¹⁰, Brellier F.¹¹, Herber M.¹², Grötzinger S.W.¹³, Quentric C.¹⁴, Bennett B.¹⁵, Néré S.¹⁶, Grünwald V.¹⁷, Mouillet G.¹⁸
Institutes: ¹Tübingen University Hospital, Dept. of Urology, Tübingen, Germany, ²CHRU Jean Minjot, Dept. of Medical Oncology, Besançon, France, ³Jena University Hospital, Dept. of Urology, Jena, Germany, ⁴Brüderkrankenhaus St. Josef Paderborn, Dept. of Hematology and Oncology, Paderborn, Germany, ⁵Hannover Medical School, Dept. of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover, Germany, ⁶Onkologische Praxis am Raschplatz, Dept. of Oncology, Hannover, Germany, ⁷Institut de Cancérologie Strasbourg Europe, Dept of Medical Oncology, Strasbourg, France, ⁸Gustave Roussy, Dept of Medical Oncology, Villejuif, France, ⁹Hopital Europeen Georges Pompidou APHP Centre Université Paris Cite, Dept of Medical Oncology, Paris, France, ¹⁰Bristol Myers Squibb, Worldwide Health Economics and Outcomes Research, Princeton, United States of America, ¹¹Bristol Myers Squibb, Center for Observational Research and Data Sciences, Uxbridge, United Kingdom, ¹²Bristol Myers Squibb, Dept. of Medical Oncology, Munich, Germany, ¹³Bristol Myers Squibb, Dept. of Oncology, Munich, Germany, ¹⁴Bristol Myers Squibb, Dept. of Worldwide Medical Oncology, Rueil-Malmaison, France, ¹⁵Bristol Myers Squibb, Worldwide Health Economics and Outcomes Research Patient-reported Outcome Assessments, Uxbridge, United Kingdom, ¹⁶Bristol Myers Squibb, Oncology Field Medical France, Rueil-Malmaison, France, ¹⁷University Hospital Essen, Clinic for Internal Medicine Tumor Research and Clinic for Urology West-German Cancer Center Essen, Essen, Germany, ¹⁸University Hospital of Besançon, Dept of Medical Oncology, Besançon, France
- P183** **Clinical Significance of Primary Tumour Size in Testicular Neoplasms**
Authors: Oliveira B.¹, Gomes A.X.², Metrogos V.², Joao R.², Rosa G.¹, Marialva C.², Ramos R.², Peyroteo I.², Silva E.²
Institutes: ¹Centro Hospitalar Universitário do Algarve, Dept. of Urology, Faro, Portugal, ²IPO Lisboa, Dept. of Urology, Lisbon, Portugal
- P184** **Monitoring of pulmonary function by diffusing capacity of lung for carbon monoxide(DLCO) during BEP therapy for testicular cancer**
Authors: Kishida T., Nagasaka H., Yamamoto S., Suzuki A., Usui K., Terao H., Umemoto S., Nakaigawa N.
Institutes: Kanagawa Cancer Center Hospital, Dept. of Urology, Yokohama, Japan

- P185** **Salvage High-Dose ChemoTherapy (HDCT) in NonSeminomatous Germ Cell Tumors (NSGCT)**
Authors: Israelyan E.¹, Rumyantsev A.¹, Petrova G.², Tyulyandina A.¹, Tryakin A.³, Fedyanin M.⁴, Sekhina O.⁴, Monin I.², Nikiforova N.², Tjulandin S.³
Institutes: ¹N.N.Blokhin National Medical Research Center of Oncology, Dept. of Chemotherapy 4, Moscow, Russia, ²N.N.Blokhin National Medical Research Center of Oncology, Dept. of Bone Marrow and Hematopoietic Stem Cell Transplantation, Moscow, Russia, ³N.N.Blokhin National Medical Research Center of Oncology, Dept. of Chemotherapy 2, Moscow, Russia, ⁴Moscow Medical City Hospital Kommunarka, Dept. of Chemotherapy, Moscow, Russia
- P186** **Overall Response rate with baby-BOP induction chemotherapy in patients with poor-risk, metastatic germ-cell tumors patients: A Retrospective Study in a Mexican hospital.**
Authors: Najar Rodriguez M.A., Martin A., Dip Borunda A.K., Lizcano Aguilar N.J.
Institutes: Hospital de Oncologia Siglo XXI, Dept. of Medical Oncology, Mexico City, Mexico
- P187** **Retroperitoneal Lymph Node Dissection (RPLND) in Testicular Cancer: Emerging Surgical Issue to Offer Cure.**
Authors: Alam S., Abdur R., Waheed W.
Institutes: Multispeciality hospital, Dept. of Urological Oncology, Dhaka, Bangladesh
- P188** **Influence of prognostic group classification of advanced male germ cell tumor on treatment outcomes**
Authors: Ur Rehman S., Rasool Z.
Institutes: BINOR Cancer Hospital Bannu KPK Pakistan, Dept. of Clinical Oncology, Bannu, Pakistan
- P189** **Long-term outcomes and cumulative incidences of hypogonadism (HGN), hypertension (HTN), and dyslipidaemia (DLP) in patients (pts) with clinical stage I seminoma testicular cancer (CS1-STC)**
Authors: Tapia J.C.¹, Anguera G.², Sanchez S.², Romano A.², Gavira J.², Maroto P.²
Institutes: ¹Clinica Corachan, Dept. of Medical Oncology, Barcelona, Spain, ²Hospital de la Santa Creu i Sant Pau, Dept. of Medical Oncology, Barcelona, Spain
- P190** **Studied on the effect of metformin combined with epirubicin on apoptosis of human bladder cancer cell line through PI3K/AKT/mTOR signaling pathway**
Authors: Shen Z.¹, Jiaqi S.¹, Hongyu J.², Hua X.¹, Zheng P.¹, Yu H.¹, Shuyu L.¹, Xinyu Z.¹
Institutes: ¹The Affiliated tumor hospital of Guizhou Medical University, Dept. of Urology, Guiyang, China, ²The Affiliated tumor hospital of Guizhou Medical University, Dept. of Molecular Biology, Guiyang, China

- P191** **Explants from high-grade bladder cancer demonstrate evident 3D-spheroids cellular colonies formation in vitro.**
Authors: Yakovlev P.¹, Garmanchuk L.², Ostrovska G.², Stupak Y.², Skachkova O.³, Gorbach O.³, Stepanov Y.⁴
Institutes: ¹Clinical hospital Feofaniya, Dept. of Oncurology and Urology, Kyiv, Ukraine, ²Taras Shevchenko National University of Kyiv, Dept. of Biomedicine, Kyiv, Ukraine, ³National Cancer Institute of Ukraine, Dept. of Experimental Oncology, Kyiv, Ukraine, ⁴Kavetsky Institute of Experimental Pathology Oncology and Radiobiology NAS of Ukraine, Dept. of Experimental Oncology, Kyiv, Ukraine
- P192** **Intratumoral heterogeneity of upper tract urothelial carcinoma in a mouse model**
Authors: Ishizuya Y., Kawashima A., Yoshimura A., Horibe Y., Tani M., Okuda Y., Oka T., Yamamoto A., Uemura T., Yamamichi G., Yamamoto Y., Kato T., Hatano K., Nonomura N.
Institutes: Graduate School of Medicine Osaka University, Dept. of Urology, Suita, Japan
- P193** **Bladder cancer is associated with immunosuppression and enhanced activity of ectonucleotidases in peripheral blood: a flow cytometry analysis**
Authors: Teixeira Gabriel Furriel F.¹, Pereira M.², Santos A.L.C.³, Silva S.³, Silva I.³, Laranjeira P.³, Ferreira H.², Sampaio Ribeiro G.², Gomes C.L.², Paiva A.³, Parada B.²
Institutes: ¹Leiria Hospital Center, Department of Urology, Leiria, Portugal, ²Faculty of Medicine - University of Coimbra, Coimbra Institute for Clinical and Biomedical Research, Coimbra, Portugal, ³Coimbra Hospital and University Centre, Unit of Operational Management of Cytometry, Coimbra, Portugal
- P194** **Integrated single-cell and spatial transcriptomic profiling reveals higher intratumour heterogeneity and epithelial–fibroblast interactions in recurrent bladder cancer**
Authors: Shi Z.¹, Hao L.², Dong Y.², Pang K.², Zhang P.³, Zhou Y.³, Qin Y.³, Liang Q.², Han C.²
Institutes: ¹Xuzhou Central Hospital and Peixian People's Hospital, Dept. of Urology, XuZhou, China, ²Xuzhou Central Hospital, Dept. of Urology, XuZhou, China, ³Peixian People's Hospital, Dept. of Urology, XuZhou, China
- P195** **Efficacy of the vesical imaging reporting and data system and serum CYFRA 21-1 in diagnosing high-stage bladder cancer**
Authors: Ikuma S., Akatsuka J., Takeda H., Endo Y., Hamasaki T., Kimura G., Kondo Y.
Institutes: Nippon Medical School Hospital, Dept. of Urology, Tokyo, Japan

- P196** **D-asparagine could become a novel blood-based diagnostic marker for urothelial carcinoma patients**
Authors: Kawashima A.¹, Yamamoto A.¹, Kimura T.², Mita M.³, Jingushi K.⁴, Horibe Y.¹, Sassi N.¹, Uemura T.¹, Tani M.¹, Yoshimura A.¹, Oka T.¹, Okuda Y.¹, Yamamichi G.¹, Ishizuya Y.¹, Yamamoto Y.¹, Kato T.¹, Hatano K.¹, Nonomura N.¹
Institutes: ¹Osaka University Graduate School of Medicine, Dept. of Urology, Suita, Japan, ²National Institute of Biomedical Innovation Health and Nutrition, Reverse Translational Project Center for Rare Disease Research, Minoh, Japan, ³KAGAMI Inc, Ibaraki, Japan, ⁴Graduate School of Pharmaceutical Sciences Osaka University, Laboratory of Molecular and Cellular Physiology, Suita, Japan
- P197** **Do the results differ between septuagenaries and octogenarians undergoing radical cystectomy?**
Authors: Oliveira B., Rosa G., Barros P., Cabrita M., Dores M., Coutinho A.
Institutes: Centro Hospitalar Universitário do Algarve, Dept. of Urology, Faro, Portugal
- P198** **Prognostic significance of Serum Cytokeratin 19 Fragments (sCYFRA) in metastatic urothelial carcinoma patients treated with pembrolizumab**
Authors: Endo Y., Kimura G., Akatsuka J., Takeda H., Toyama Y., Obayashi K., Mikami H., Ikuma S., Shibasaki M., Hasegawa H., Funato R., Miyauchi S., Taniuchi M., Kishi H., Kondo Y.
Institutes: Nippon Medical School Hospital, Dept. of Urology, Tokyo, Japan
- P199** **Utilization of Tropomyosin isoform expression pattern in development of a urine-based assay for detection of urothelial bladder cancer**
Authors: Humayun-Zakaria N.¹, Ward D.G.¹, Zeegers M.P.², Cheng K.K.³, Arnold R.¹, Bryan R.T.¹
Institutes: ¹University of Birmingham, Bladder Cancer Research Centre, Birmingham, United Kingdom, ²Maastricht University, Dept. of Complex Genetics, Maastricht, The Netherlands, ³University of Birmingham, Institute of Applied Health Research, Birmingham, United Kingdom
- P200** **Integrative multi-omics analysis depicts the methylome and hydroxymethylome in recurrent bladder cancers and identifies biomarkers for predicting PD-L1 expression**
Authors: Shi Z.¹, Pang K.², Dong Y.², Hao L.², Zhang P.³, Cao Y.³, Liang Q.², Han C.²
Institutes: ¹Xuzhou Central Hospital and Peixian People's Hospital, Dept. of Urology, XuZhou, China, ²Xuzhou Central Hospital, Dept. of Urology, XuZhou, China, ³Peixian People's Hospital, Dept. of Urology, XuZhou, China
- P201** **Expertise Matters: Unveiling the Impact of Surgeon Experience on Second-Look Transurethral Resection of Bladder Cancer – a prospective Study**
Authors: Fernandes C.F.¹, Vale L.V.¹, Ramos P.¹, Sousa J.S.², Oliveira J.O.¹, Silva C.¹, Antunes-Lopes T.A.L.¹, Silva J.¹
Institutes: ¹Centro Hospitalar e Universitário do Sao Joao, Dept. of Urology, Porto, Portugal, ²Centro Hospitalar e Universitario do Sao Joao, General Surgery Department, Porto, Portugal
-

- P202** **High-Risk Non-Muscle Invasive Bladder Cancer associated with Prostate Cancer**
Authors: Geavlete B.¹, Bulai C.¹, Ene C.¹, Ene A.¹, Mares C.¹, Georgescu D.¹, Geavlete P.¹, Popescu R.²
Institutes: ¹St. John Clinical Hospital of Emergency, Dept. of Urology, Bucharest, Romania, ²Carol Davila University of Medicine and Pharmacy, Dept. of Urology, Bucharest, Romania
- P203** **Search for circulating tumor cells in patients with urothelial cancer**
Authors: Kruglova I.A.¹, Zinoviev S. V.², Utkin O.V.³, Denisenko A.N.⁴, Kuznetsova S.A.⁵, Grebennik I.V.⁵
Institutes: ¹State Budgetary Healthcare Institution Nizhny Novgorod City Hospital No. 35, Laboratory, Nizhny Novgorod, Russia, ²State Budgetary Healthcare Institution Nizhny Novgorod Regional Clinical Oncological Dispensary, Dept. of Oncology, Nizhny Novgorod, Russia, ³Federal Budgetary Institution of Science Nizhny Novgorod Research Institute of Epidemiology and Microbiology named after ak. I.N.Blokhina of Rospotrebnadzor, Laboratory Molecular Biology and Biotechnology, Nizhny Novgorod, Russia, ⁴State Budgetary Healthcare Institution Nizhny Novgorod City Hospital No. 35, chief medical officer, Nizhny Novgorod, Russia, ⁵Federal State Budgetary Institution Dmitry Rogachev National Medical Research Center, Laboratory, Moscow, Russia
- P204** **Creating a screening method for known Lynch Syndrome patients to detect Upper Tract Urothelial Carcinoma**
Authors: Figaroa O.J.A.¹, Baard J.¹, van Noesel C.M.J.², Savci C.D.², Bins A.D.³
Institutes: ¹Amsterdam UMC, Dept. of Urology, Amsterdam, The Netherlands, ²Amsterdam UMC, Dept. of Pathology, Amsterdam, The Netherlands, ³Amsterdam UMC, Dept. of Oncology, Amsterdam, The Netherlands
- P205** **Diagnostic roles of immunohistochemical markers, CK20, CD44, AMACR, and p53 in urothelial carcinoma in situ: A meta-analysis and diagnostic test accuracy review**
Authors: Yoo D-S.¹, Min K-W.², Pyo J-S.², Shin H.B.¹, Kim N.Y.³
Institutes: ¹Daejeon Eulji University Hospital, Dept. of Urology, Daejeon, South Korea, ²Uijeongbu Eulji Medical Center, Dept. of Pathology, Gyeonggi-do, South Korea, ³Uijeongbu Eulji Medical Center, Dept. of Internal Medicine, Gyeonggi-do, South Korea
- P206** **Diagnostic and prognostic roles of GATA3 immunohistochemistry in urothelial carcinoma**
Authors: Yoo D.S.¹, Min K-W.², Pyo J-S.², Shin H.B.¹, Kim N.Y.³
Institutes: ¹Daejeon Eulji University Hospital, Dept. of Urology, Daejeon, South Korea, ²Uijeongbu Eulji Medical Center, Dept. of Pathology, Gyeonggi-do, South Korea, ³Uijeongbu Eulji Medical Center, Dept. of Internal Medicine, Gyeonggi-do, South Korea

- P207** **Feasibility to detect the PD-L1 expression by cytoinclusion technique in bladder cancer**
Authors: Di Gianfrancesco L.¹, Montagner I.M.², Tormen D.², Scapinello A.², Crestani A.³, Amodeo A.¹, Corsi P.¹, Lista G.¹, De Marchi D.¹, Miglioranza E.¹, Cargnel C.G.¹, Vitelli F.D.¹, Simonetti F.¹, Porreca A.¹
Institutes: ¹Veneto Institute of Oncology IOV IRCCS, Dept. of Oncological Urology, Padua, Italy, ²Veneto Institute of Oncology IOV IRCCS, Anatomy and Pathological Histology Unit, Padua, Italy, ³Azienda Sanitaria Universitaria Friuli Centrale, Dept. of Urology, Udine, Italy
- P208** **Targeted therapy for advanced/metastatic urothelial carcinoma: Effectiveness of online education in improving knowledge, competence and confidence of oncologists and urologists**
Authors: Harvey-Jones V., Canon M.
Institutes: WebMD, Medscape Oncology Global, London, United Kingdom
- P209** **Clinical use of our ERAS program (PRORAC) 5 years after its implementation**
Authors: Sánchez-Rosendo L.¹, Guijarro A.¹, Macía M.¹, Hernández V.¹, Pérez-Fernández E.², Llorente C.¹
Institutes: ¹Hospital Universitario Fundación Alcorcón, Dept. of Urology, Madrid, Spain, ²Hospital Universitario Fundación Alcorcón, Research Department, Madrid, Spain
- P210** **Cisplatin Eligibility in the Neoadjuvant Setting for Patients with Muscle-Invasive Bladder Cancer: The Optimal Way to Determine Kidney Function**
Authors: Pichler R.¹, Fritz J.², Mari A.³, Cadenar A.³, Von Deimling M.⁴, Del Giudice F.⁵, Costantino L.⁵, Bologna E.⁵, Mori K.⁶, Rana T.⁷, De Santis M.⁷, Klatte T.⁷, Erber B.⁷, Lackner F.¹, Kronbichler A.⁸, Fisch M.⁴, Moschini M.⁹, Pradere B.¹⁰, Mertens L.¹¹
Institutes: ¹Medical University of Innsbruck, Dept. of Urology, Innsbruck, Austria, ²Medical University of Innsbruck, Institute of Medical Statistics and Informatics, Innsbruck, Austria, ³University of Florence, Unit of Oncologic Minimally-Invasive Urology and Andrology, Florence, Italy, ⁴University Medical Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, ⁵Sapienza University of Rome Policlinico Umberto Hospital, Dept. of Maternal Infant and Urologic Sciences, Rome, Italy, ⁶The Jikei University School of Medicine, Dept. of Urology, Tokyo, Japan, ⁷Charité University Hospital, Dept. of Urology, Berlin, Germany, ⁸Medical University of Innsbruck, Dept. of Internal Medicine IV, Innsbruck, Austria, ⁹IRCCS Ospedale San Raffaele and Vita-Salute San Raffaele University, Dept. of Urology, Milan, Italy, ¹⁰La Croix du Sud Hospital, Dept. of Urology, Quint-Fonsegrives, France, ¹¹The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Dept. of Urology, Amsterdam, The Netherlands
- P211** **Endoscopic ablation of UTUC in solitary kidney patients**
Authors: Papadimitriou E., Stamatakos P.V., Paizis T., Mari V., Fragkoulis C., Papadopoulos G., Ntoumas K.
Institutes: General Hospital of Athens Georgios Gennimatas, Dept. of Urology, Athens, Greece
-

- P212** **Oncological outcomes of chemohyperthermia with HIVEC for BCG-unresponsive non-muscle invasive bladder cancer : results from a multicenter national database**
Authors: Pignot G.¹, Baboudjian M.², Masson-Lecomte A.³, Lebacle C.⁴, Tillou X.⁵, Waeckel T.⁵, Duperron C.⁶, Monges A.⁷, Alezra E.⁸, Irani J.⁴, Lechevallier E.², Gravis G.¹, Walz J.¹
Institutes: ¹Institut Paoli-Calmettes, Dept of Oncological Surgery 2, Marseille, France, ²Conception Hospital, Dept of Urology, Marseille, France, ³Saint-Louis Hospital, Dept of Urology, Paris, France, ⁴Bicetre Hospital, Dept of Urology, Le Kremlin-Bicetre, France, ⁵Caen Hospital CHU, Dept of Urology, Caen, France, ⁶Dijon Hospital, Dept of Urology, Dijon, France, ⁷Provence Private Hospital, Dept of Urology, Aix-en-Provence, France, ⁸Bordeaux CHU, Dept of Urology, Bordeaux, France
- P213** **Impact of Complete Tumor Resection on Survival of Muscle-Invasive Bladder Cancer Patients Treated with Neoadjuvant Chemotherapy and Radical Cystectomy**
Authors: Fernandes C.F.¹, Baptista I.², Abreu S.A.¹, Ramos P.¹, Lopes T.A.¹, Silva J.¹, Silva C.¹, Vale L.S.¹
Institutes: ¹Centro Hospitalar e Universitário do Sao Joao, Dept. of Urology, Porto, Portugal, ²Medicine Faculty of Porto University, Dept. of Urology, Porto, Portugal
- P214** **C-reactive protein is a prognostic factor after pembrolizumab for metastatic upper urothelial carcinoma**
Authors: Nagasaka H., Yamamoto S., Suzuki A., Usui K., Terao H., Nakaigawa N., Kishida T.
Institutes: Kanagawa Cancer Center Hospital, Dept. of Urology, Yokohama, Japan
- P215** **Adjuvant Radiotherapy in Bladder Cancers with Ileal Conduit – dosimetric comparison of 3D conformal (3DCRT) and volumetric modulated arc radiotherapy (VMAT)**
Authors: Goyal S.¹, Dey T.¹, Periasamy K.¹, Vias P.¹, Trivedi G.¹, Ghera G.¹, Madan R.¹, Khosla D.¹, Mavuduru R.²
Institutes: ¹Post Graduate Institute of Medical Education and Research, Dept. of Radiotherapy, Chandigarh, India, ²Post Graduate Institute of Medical Education and Research, Dept. of Urology, Chandigarh, India

P216

Neutrophil-to-eosinophil ratio (NER) predicts the efficacy of avelumab in patients with advanced Urothelial Carcinoma (aUC) enrolled in the MALVA study (Meet-URO 25)

Authors: Gambale E.¹, Maruzzo M.², Messina C.³, De Gennaro Aquino I.⁴, Vascotto I.A.¹, Rossi V.⁴, Bimbatti D.², Cavasin N.², Messina M.³, Mennitto A.⁵, Rebuzzi S.E.⁶, Mercinelli C.⁷, Fanelli M.⁸, Sorarù M.⁹, Scolari F.⁴, Mela M.M.⁴, Galli L.⁷, Doni L.⁴, Pillozzi S.⁴, Antonuzzo L.¹

Institutes: ¹University of Florence, Dept. of Experimental and Clinical Medicine, Florence, Italy, ²Istituto Oncologico Veneto, Padova, Italy, ³Ospedale Arnas Civico, Dept. of Clinical Oncology, Palermo, Italy, ⁴Careggi University Hospital, Dept. of Clinical Oncology, Florence, Italy, ⁵University Hospital Maggiore della Carità, Division of Oncology, Novara, Italy, ⁶Ospedale San Paolo, Medical Oncology Unit, Savona, Italy, ⁷Azienda Ospedaliero-Universitaria Pisana, Medical Oncology Unit 2, Pisa, Italy, ⁸University Hospital of Udine, Dept. of Oncology, Udine, Italy, ⁹Ospedale di Camposampiero, U.O. Oncology, Camposampiero, Italy

P217

FOur Cycles of platinum-based chemotherapy in advanced or metastatic Urothelial carcinoma Compared to Six Cycles: A retrospective cohort study (FOCUS, KCSG-GU23-08)

Authors: Kwonoh P.¹, Kim E.J.², Kim I.³, Kim J.Y.⁴, Kim H.⁵, Park I.⁶, Park J.H.⁷, Sohn B.S.⁸, Lee H.J.⁹, Jo J.¹⁰, Huh S.J.¹¹, Lee J.L.⁶

Institutes: ¹Hanyang University Seoul Hospital Hanyang University College of Medicine, Internal Medicine, Seoul, South Korea, ²Kangbuk Samsung Hospital, Dept. of Hematology Oncology, Seoul, South Korea, ³Haeundae Paik Hospita, Dept. of Oncology, Busan, South Korea, ⁴Keimyung University Dongsan Hospital, Dept. of Hemato-Oncology, Daegu, South Korea, ⁵Pusan National University Hospital, Dept. of Hemato-Oncology, Pusan, South Korea, ⁶Asan Medical Center, Dept. of Oncology and Internal Medicine, Seoul, South Korea, ⁷Gil Medical Center, Dept. of Medical Oncology, Incheon, South Korea, ⁸Inje University Sanggye Paik Hospital, Internal Medicine, Seoul, South Korea, ⁹Chungnam National University College of Medicine, Internal Medicine, Daejeon, South Korea, ¹⁰Ewha Womans University Medical Center, Internal Medicine, Seoul, South Korea, ¹¹Dong-A University College of Medicine, Internal Medicine, Pusan, South Korea

P218

Role of thromboprophylaxis during neoadjuvant chemotherapy before radical cystectomy in patients with bladder cancer, results of a multicenter retrospective cohort study

Authors: Antonelli L.¹, Wendel Garcia P.D.², Deforth M.², Afferi L.¹, Esperto F.³, Borghesi M.⁴, Albisinni S.⁵, Pichler R.⁶, Teoh J.Y.C.⁷, Orecchia L.⁸, Soria F.⁹, Marcq G.¹⁰, Alrumayyan M.¹¹, Montes M.A.R.¹², Okoye S.¹³, Campi R.¹⁴, Krajewski W.¹⁵, Mertens L.¹⁶, Culpan M.¹⁷, Poyet C.D.¹⁸, Tully K.H.¹⁹, Umari P.²⁰, Del Giudice F.²¹, Antonelli A.²², Mari A.¹⁴, Claps F.²³, Roumiguié M.²⁴, Schulz G.B.²⁵, Rink M.²⁶, Zamboni S.²⁷, Lavalée L.²⁸, Moschini M.²⁹, Held U.², Fankhauser C.D.¹

Institutes: ¹Luzerner Kantonsspital, Dept. of Urology, Lucerne, Switzerland, ²Biostatistics and Prevention Institute of University of Zurich, Dept. of Biostatistics at the Epidemiology, Zurich, Switzerland, ³Campus Bio-Medico University, Dept. of Urology, Rome, Italy, ⁴IRCCS Ospedale Policlinico S. Martino, Dept. of Urology, Genoa, Italy, ⁵Hopital Universitaire de Bruxelles, Dept. of Urology, Brussels, Belgium, ⁶Medical University of Innsbruck, Dept. of Urology, Innsbruck, Austria, ⁷S.H. Ho Urology Centre, Dept. of Surgery, Hong Kong, China, ⁸Policlinico Tor Vergata Foundation, Urology Unit, Rome, Italy, ⁹Aou Città Della Salute e Della Scienza Di Torino and Torino School of Medicine, Division of Urology and Dept. of Surgical Sciences, Turin, Italy, ¹⁰Claude Huriez Hospital, Dept. of Urology, Lille, France, ¹¹University of Toronto, Dept. of Urology, Toronto, Canada, ¹²Galdakao-Usansolo Hospital, Dept. of Urology, Vizcaya, Spain, ¹³Charité-Universitätsmedizin Berlin, Dept. of Urology, Berlin, Germany, ¹⁴University of Florence and Careggi Hospital, Unit of Urological Robotic Surgery and Renal Transplantation, Florence, Italy, ¹⁵Wroclaw Medical University, Dept. of Minimally Invasive and Robotic Urology, Wroclaw, Poland, ¹⁶Netherlands Cancer Institute, Dept. of Urology, Amsterdam, The Netherlands, ¹⁷Faculty of Medicine at Istanbul Medeniyet University, Dept. of Urology, Istanbul, Turkey, ¹⁸University Hospital Zürich, Dept. of Urology, Zürich, Switzerland, ¹⁹Marien Hospital Herne - Ruhr University Bochum, Dept. of Urology and Neurourology, Bochum, Germany, ²⁰St George University Hospital, Dept. of Urology, London, United Kingdom, ²¹Policlinico Umberto I and Sapienza University, Dept. of Urology, Rome, Italy, ²²University of Verona, Dept. of Urology, Verona, Italy, ²³Cattinara University Hospital, Dept. of Urology, Trieste, Italy, ²⁴Institut Universitaire du Cancer Toulouse Oncopole CHU, Dept. of Urology, Toulouse, France, ²⁵University Hospital, Dept. of Urology, Munich, Germany, ²⁶University Medical Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, ²⁷Università degli studi di Brescia, Dept. of Urology, Brescia, Italy, ²⁸The Ottawa Hospital, Division of Urology at Dept. of Surgery, Ottawa, Canada, ²⁹Urological Research Institute of Vita-Salute San Raffaele, Dept. of Urology and Division of Experimental Oncology, Milan, Italy

P219

Evaluation of the use of postoperative single-shot instillation chemotherapy after TURBT and reasons for not administering it

Authors: Fedorko M., Wasserbauer R., Papirek J., Krsakova E.

Institutes: University Hospital Brno, Dept. of Urology, Brno, Czech Republic

- P220** **Development of a decision support system to reduce the workload of interdisciplinary tumor conferences - using the example of a certified urinary bladder cancer center**
Authors: Weiss C.¹, Sahi D.¹, Stamm P.¹, Hoier D.H.², Groß-Ophoff-Mueller C.³, Hallek M.⁴, Pfister D.⁵, Heidenreich A.⁵, Ohlmann C.⁶, Elter T.⁴
Institutes: ¹Heilig Geist-Krankenhaus, Dept. of Urology, Cologne, Germany, ²Sankt Martinus Krankenhaus, Dept. of Internal Medicine, Düsseldorf, Germany, ³Kliniken der Stadt Köln gGmbH, Dept. of Oncology, Cologne, Germany, ⁴University of Cologne, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Dept. of Internal Medicine I, Cologne, Germany, ⁵University of Cologne, Faculty of Medicine and University Hospital Cologne, Dept. of Urology, Uro-Oncology and Robot Assisted Surgery, Cologne, Germany, ⁶Johanniter-Krankenhaus Bonn-Gronau, Dept. of Urology, Bonn, Germany
- P221** **Real world data from Avelumab in Advanced or Metastatic Urothelial Carcinoma**
Authors: Goncalves L.¹, Gramaça J.², Freitas A.R.³, Dunoës I.⁴, Barroso T.¹, Patel V.¹, Lopes Brás R.¹, Costa A.L.¹, Quintela A.¹, Torres S.¹, Spencer A.S.¹, Costa L.¹
Institutes: ¹Hospital de Santa Maria CHULN, Dept. of Medical Oncology, Lisbon, Portugal, ²Centro Hospitalar Barreiro Montijo, Dept. of Medical Oncology, Lisbon, Portugal, ³Hospital Prof. Doutor Fernando Fonseca, Dept. of Medical Oncology, Lisbon, Portugal, ⁴Hospital do Espírito Santo de Évora, Dept. of Medical Oncology, Évora, Portugal
- P222** **Patterns of care and outcomes with bladder preservation for patients with muscle-invasive bladder cancer treated in Tanzania: A retrospective cohort study.**
Authors: Banzi M.¹, Nnko G.¹, Rugengamanzi E.¹, Malangwa G.¹, Makupa G.¹, Dharsee N.², Van Loon K.³, Miller A.⁴, Raza Khaki A.⁵, Lugina E.²
Institutes: ¹Muhimbili University of Health and allied Sciences, Clinical Oncology, Dar Es Salaam, Tanzania, ²Ocean Road Cancer Institute, Clinical Oncology, Dar Es Salaam, Tanzania, ³University of California San Francisco, Medical Oncology, California, United States of America, ⁴Illawarra Cancer Care Centre, Radiation Oncology, Wollongong, Australia, ⁵Stanford University, School of Medicine, Stanford, United States of America
- P223** **Management of High-Risk Urothelial Cancer: A Comparative Study of Intravesical BCG and Hyperthermic Mitomycin**
Authors: Ferreira Gomes I.S., Fraga T., Magalhaes J., Tavares A., Madeira P., Sousa G.
Institutes: Instituto Portugues De Oncologia De Coimbra Francisco Gentil, Dept. of Medical Oncology, Coimbra, Portugal
- P224** **Pembrolizumab Versus Atezolizumab in The Treatment of Advanced Urothelial Cancer: A Single Institution Experience**
Authors: Makady N.F.¹, Saadeldin I.M.¹, Mokhtar M.¹, Edesa W.A.¹, Smith K.², Enting D.²
Institutes: ¹Cairo University Hospitals, Dept. of Clinical Oncology, Cairo, Egypt, ²Guy's and St Thomas' NHS Foundation Trust, Dept. of Medical Oncology, London, United Kingdom

- P225** **A real world study of avelumab first-line maintenance in advanced urothelial carcinoma**
Authors: Guedes H., Marinho J., Silva S., Neto E., Guedes A., Moreira Pinto A., Custódio S.
Institutes: Centro Hospitalar Vila Nova de Gaia Espinho, Dept. of Medical Oncology, Porto, Portugal
- P226** **Delay of radical cystectomy in patients treated with neoadjuvant chemotherapy is associated with worse oncological outcomes**
Authors: Nuijens S.T.¹, van Osch F.H.M.², Hoogstraten L.M.C.³, Witjes J.A.¹, Aben K.K.H.³, Hermans T.J.N.⁴
Institutes: ¹Radboud University Medical Centre, Dept. of Urology, Nijmegen, The Netherlands, ²VieCuri Medical Centre, Dept. of Clinical Epidemiology, Venlo, The Netherlands, ³Netherlands Comprehensive Cancer Organisation, Dept. of Research and Development, Utrecht, The Netherlands, ⁴VieCuri Medical Centre, Dept. of Urology, Venlo, The Netherlands
- P227** **Interim results from a real-world ambispective study RAVE-Bladder: avelumab first-line maintenance therapy in patients with metastatic urothelial carcinoma**
Authors: Anzhiganova Y.¹, Gridneva Y.², Sultanbayev A.³, Gluzman M.⁴, Shkurat A.⁵, Lebedinets A.⁵, Ivanov A.⁶, Karabina E.⁷, Parsadanova E.⁸, Turganova M.⁹, Petkau V.¹⁰, Keln A.¹¹, Tovbik N.¹², Murzina Y.¹³, Vodolazskiy V.¹⁴, Orlova R.⁴, Zukov R.¹⁵, Volkova M.², Tsimafeyeu I.¹⁶
Institutes: ¹A.I. Kryzhanovsky Krasnoyarsk Regional Cancer Center, Dept. of Urogynecological, Krasnoyarsk, Russia, ²Oncology Clinical Hospital No. 1, Dept. of Oncology 8, Moscow, Russia, ³Republican Clinical Oncological Dispensary of Bashkortostan, Dept. of Medical Oncology, Ufa, Russia, ⁴Saint-Petersburg State University, Medical Department, Saint-Petersburg, Russia, ⁵SBHI Leningrad Regional Clinical Hospital, Dept. of Medical Oncology, Saint-Petersburg, Russia, ⁶Center for Immune and Targeted Therapy, Dept. of Medical Oncology, Moscow, Russia, ⁷Tula Regional Cancer Center, Dept. of Medical Oncology, Tula, Russia, ⁸Sakhalin Regional Cancer Center, Outpatient Dept., Yuzhno-Sakhalinsk, Russia, ⁹Novosibirsk Regional Cancer Center, Outpatient Dept., Novosibirsk, Russia, ¹⁰Sverdlovskiy Regional Oncological Dispensary, Dept. of Medical Oncology, Ekaterinburg, Russia, ¹¹Tyumen State Medical University, Dept. of Oncology, Tyumen, Russia, ¹²Amursky Regional Cancer Center, Dept. of Chemotherapy, Blagoveshchensk, Russia, ¹³Birobidzhan Regional Cancer Center, Dept. of Medical Oncology, Jewish Autonomous Oblast, Russia, ¹⁴Omsk Regional Cancer Center, Dept. of Oncology, Omsk, Russia, ¹⁵V.F. Voyno-Yasenetsky Krasnoyarsk State Medical University, Dept. of Oncology, Krasnoyarsk, Russia, ¹⁶Bureau of Cancer Research - BUCARE, Moscow Office, Moscow, Russia

- P228** **Neoadjuvant versus adjuvant chemotherapy in muscle-invasive bladder cancer: The RealBLADDER study. Results on behalf of the GOIRC**
Authors: Gambale E.¹, Giorgione R.¹, Vascotto I.A.¹, De Gennaro Aquino I.¹, Scolari F.¹, Mela M.M.¹, Catalano M.¹, Roviello G.¹, Doni L.¹, Galli L.², Baldazzi V.³, Atzori F.⁴, Masini C.⁵, Scagliarini S.⁶, Pillozzi S.¹, Basso U.⁷, Antonuzzo L.¹
Institutes: ¹Careggi University Hospital, Dept. of Clinical Oncology, Florence, Italy, ²Azienda Ospedaliero-Universitaria Pisana, Medical Oncology Unit 2, Pisa, Italy, ³P.O. Santa Maria Annunziata., Medical Oncology Unit, Florence, Italy, ⁴Policlinico Monserrato, Medical Oncology Unit, Cagliari, Italy, ⁵AUSL Reggio Emilia, Medical Oncology Unit, Reggio Emilia, Italy, ⁶Azienda Ospedaliera Antonio Cardarelli, Medical Oncology Unit, Naples, Italy, ⁷Istituto Oncologico Veneto, Medical Oncology Unit, Padova, Italy
- P229** **A comparison of the incidence of 90-days complications in patients undergoing open radical cystectomy and robot-assisted radical cystectomy for bladder cancer; results from a nationwide real-world database registry**
Authors: van Ginkel N.¹, Meijer D.¹, Nieuwenhuijzen J.¹, Boormans J.L.², van Beek S.C.³, Vis A.N.¹
Institutes: ¹Amsterdam UMC, Dept. of Urology, Amsterdam, The Netherlands, ²Erasmus University Medical Centre, Dept. of Urology, Rotterdam, The Netherlands, ³St. Antonius Hospital, Dept. of Urology, Nieuwegein, The Netherlands
- P230** **Avelumab as maintenance treatment in advanced urothelial cancer. A Single Oncological Centre's Experience**
Authors: Alevizopoulos N., Alexandris D., Oreopoulos V., Dimitriadou A., Maragkouli H., Kitsou M.
Institutes: Evaggelismos General Hospital, Dept. of Oncology, Athens, Greece
- P231** **Efficacy and tolerance of intravesical BCG treatment in non-muscle invasive bladder cancer according to age and comorbidities**
Authors: Macía-Díaz M., Guijarro Cascales A., Gonzalo Balbás A., Jiménez Alcaide E.B., Llorente Abarca C.
Institutes: Hospital Universitario Fundación Alcorcón, Dept. of Urology, Madrid, Spain

- P232** **Intraoperative outcomes from The Italian Radical Cystectomy Registry: more than 1000 robotic-assisted, laparoscopic, and open surgeries**
Authors: Di Gianfrancesco L.¹, Crestani A.², Artibani W.³, Busetto G.M.⁴, Carrieri G.⁴, Antonelli A.⁵, Bianchi L.⁶, Brunocilla E.⁶, Bocciardi A.M.⁷, Carini M.⁸, Celia A.⁹, Cochetti G.¹⁰, Gallina A.¹¹, Mearini E.¹⁰, Minervini A.¹², Schiavina R.⁶, D'Agostino D.¹³, Romagnoli D.³, Porreca A.¹
Institutes: ¹Veneto Institute of Oncology IOV IRCCS, Dept. of Urology, Padua, Italy, ²Azienda Sanitaria Universitaria Friuli Centrale, Dept. of Urology, Udine, Italy, ³Policlinico Abano Terme, Dept. of Urology, Abano Terme, Italy, ⁴University of Foggia, Urology and Renal Transplantation Unit, Dept. of Medical and Surgical Sciences, Foggia, Italy, ⁵Azienda Ospedaliera Universitaria Integrata, Dept. of Urology, Verona, Italy, ⁶IRCCS Azienda Ospedaliero-Universitaria di Bologna, Dept. of Urology, Bologna, Italy, ⁷Grande Ospedale Metropolitano Niguarda, Complex Structure Urology ASST, Milan, Italy, ⁸Careggi Hospital, Unit of Oncologic Minimally-Invasive Urology and Andrology, Florence, Italy, ⁹San Bassiano Hospital, Dept. of Urology, Bassano Del Grappa, Italy, ¹⁰University of Perugia, Dept. of Urology, Perugia, Italy, ¹¹IRCCS San Raffaele Scientific Institute, Dept. of Urology and Division of Experimental Oncology, Milan, Italy, ¹²Careggi Hospital, University of Florence, Dept. of Urology, Florence, Italy, ¹³Ospedale Villa Salus, Dept. of Urology, Mestre, Italy
- P233** **Audit of outcomes of bladder perforation during Transurethral resection of Bladder Tumour (TURBT)**
Authors: Lohana D., Waleed A., Javed M.A., Nandwani G.M.
Institutes: Ninewells hospital, Dept. of Urology, Dundee, United Kingdom
- P234** **Comparing toxicity and short term outcomes of Hyperthermic Intravesical Chemotherapy with Mitomycin-C versus Intravesical Chemotherapy with Mitomycin-C alone in the management of intermediate risk non-muscle invasive bladder cancer**
Authors: Ramos Rodriguez E., Garcia Carceles N., Ferrández Jiménez M., Domingo Latorre D., Albertus A., García Seguí A., Soler Lopez C., Gómez Pérez L.
Institutes: Hospital Universitario de Elche, Dept. of Urology, Elche, Spain
- P235** **Impact of adjuvant chemotherapy in suboptimal neoadjuvant dose-dense MVAC followed by radical cystectomy for muscle-invasive bladder cancer**
Authors: Jo J.¹, LEE D.H.²
Institutes: ¹Ewha Womans University Mokdong Hospital, Dept. of Oncology, Seoul, South Korea, ²Ewha Womans University Mokdong Hospital, Dept. of Urology, Seoul, South Korea

- P236** **Avelumab first-line (1L) maintenance therapy for advanced urothelial cancer: real-world early clinical experience in the UK**
Authors: Jones R.J.¹, Shah Y.², Birtle A.³, Challapalli A.⁴, Chan J.⁵, Enting D.⁶, Hudson A.⁷, Linch M.⁸, Otter S.⁹, Protheroe A.¹⁰, Sharma A.¹¹, Turner R.¹, Kularatne B.¹², Elia C.¹³, Rice W.¹³
Institutes: ¹University of Glasgow, The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom, ²Merck Serono Ltd, Affiliate of Merck KGaA, Feltham, United Kingdom, ³Lancashire Teaching Hospitals, Rosemere Cancer Centre, Preston, United Kingdom, ⁴University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, United Kingdom, ⁵The Clatterbridge Cancer Center NHS Foundation Trust, The Clatterbridge Cancer Center NHS Foundation Trust, Liverpool, United Kingdom, ⁶Guy's and St Thomas' NHS Foundation Trust, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom, ⁷The Christie NHS Foundation Trust, The Christie NHS Foundation Trust, Manchester, United Kingdom, ⁸University College London, Cancer Centre, London, United Kingdom, ⁹Royal Surrey County Hospital, Royal Surrey NHS Foundation Trust, Guildford, United Kingdom, ¹⁰Churchill Hospital, Oxford University Hospitals, Oxford, United Kingdom, ¹¹Lister Hospital and Mount Vernon Cancer Centre, East and North Hertfordshire NHS Trust, Middlesex, United Kingdom, ¹²Pfizer, Pfizer, Surrey, United Kingdom, ¹³IQVIA, Real World Solutions, London, United Kingdom
- P237** **Retroperitoneal versus transperitoneal laparoscopic radical nephroureterectomy in the management of upper urinary tract urothelial carcinoma: A double-center perioperative outcomes comparison**
Authors: Araújo A.S., Morais N., Valente P., Vivas C., Araújo P., Castro H., Vila F., Lindoro J.
Institutes: Centro Hospitalar do Tamega e Sousa, Dept. of Urology, Penafiel, Portugal
- P238** **Neoadjuvant chemotherapy for patients diagnosed with muscle-invasive bladder cancer. Is bladder preservation a valid option for the complete responders?**
Authors: Ntoumas G.¹, Stamatakos P.V.², Fragkoulis C.², Papadopoulos G.², Stathouros G.², Ntoumas K.²
Institutes: ¹Aretaio Hospital, Dept. of Radiology, Athens, Greece, ²GNA G. Gennimatas, Dept. of Urology, Athens, Greece
- P239** **Neoadjuvant cisplatin-based chemotherapy (NAC) in Muscle-invasive bladder cancer (MIBC): Real-world data**
Authors: Montenegro M.A., Gao N., Leao Mendes J., Furtado I., Quaresma Ferreira R., Escalreira R., Verdasca F., Seladas M., Fernandes V.L., Gonçalves F., Gil L.C., Gramaça J., da Luz R.
Institutes: Centro Hospitalar Universitário de Lisboa Central, Dept. of Medical Oncology, Lisbon, Portugal
- P240** **Atezolizumab (Atz) outcomes in platinum pretreated advanced urothelial carcinoma patients: a retrospective review of a 5-year period at a tertiary center.**
Authors: Iruarrizaga Ovejas E., Novo Sukia E., Iza Rodriguez E., Mane Martinez J.M., Fernandez Rodriguez R.
Institutes: Hospital Universitario de Cruces, Dept. of Medical Oncology, Barakaldo, Spain

- P241** **Atezolizumab as treatment of urothelial carcinoma in second line of metastatic disease. Experience in our institution.**
Authors: López L., Garrido Onecha M.A.L., Távora B., Pérez S.L., Vázquez M., Medina S., Castanón C., López A., García Palomo A.S., Rodríguez Sánchez N.
Institutes: Complejo Asistencial Universitario de León, Dept. of Urology, León, Spain
- P242** **A rare case of embryonal rhabdomyosarcoma of urinary bladder in an adult patient successfully managed with neoadjuvant vincristine, doxorubicin and cyclophosphamide followed by surgery: A case report and literature review**
Authors: Tejada K., Lola C.
Institutes: National Kidney and Transplant Institute, Section of Medical Oncology, Manila, Philippines
- P243** **NBI-assisted Digital Flexible Ureteroscopy in the Management of Upper Tract Urothelial Carcinoma**
Authors: Geavlete B.¹, Iordache V.F.¹, Ene C.V.¹, Bulai C.A.¹, Popescu R.I.², Mares C.¹
Institutes: ¹St. John Clinical Hospital of Emergency, Dept. of Urology, Bucharest, Romania, ²Carol Davila University of Medicine and Pharmacy, Dept. of Urology, Bucharest, Romania
- P244** **COVID-19 pandemic and non-muscle-invasive bladder cancer: impact on follow-up and disease recurrence**
Authors: Portugal Gaspar F., Silva A.B, Lopes F.A., Monteiro L.A.
Institutes: Hospital Egas Moniz CHLO, Dept. of Urology, Lisbon, Portugal
- P245** **Uromonitor-V2®: Clinical Validation and Performance Assessment of a Urinary Biomarker for Recurrence in Non-Muscle Invasive Bladder Cancer Patients**
Authors: Ramos P.¹, Silva J.¹, Botelho F.¹, Manso M.¹, Vale L.¹, Martins-Silva C.¹, Brás J.², Dias C.², Bessa-Gonçalves M.², Pacheco-Figueiredo L.³
Institutes: ¹Sao Joao University Hospital Center, Dept. of Urology, Porto, Portugal, ²Universidade do Porto, Institute for Research and Innovation in Health i3S, Porto, Portugal, ³School of Medicine University of Braga, Life and Health Sciences Research Institute ICVS, Braga, Portugal
- P246** **Cardiac and Intramuscular Metastases Post Nephroureterectomy for Metachronous Urothelial Carcinoma**
Authors: Hiok Yang C., Wan Ying C., Wong J.
Institutes: National Cancer Centre, Dept. of Oncologic Imaging, Singapore, Singapore
- P247** **Do FGFR2 and 3 proteins have a role in the prognosis of urothelial bladder carcinoma?**
Authors: Alhanafy A.¹, serag El-dien M.², fathy mahmoud S.², shawky holah N.²
Institutes: ¹Menoufia University Faculty of Medicine, Dept. of Clinical Oncology and Nuclear Medicine, Shibin El Kom, Egypt, ²Menoufia University Faculty of Medicine, Dept. of Pathology, Shibin El Kom, Egypt

- P248** **Building a Machine Learning-based Survival Model for Predicting Oncological Outcomes in High-Grade T1 Bladder Tumor: Optimizing the Selection of Suitable Candidates for Radical Cystectomy**
Authors: Minguez Ojeda C.S., Subiela Henriquez J.D., Mata Alcaraz M., Tagalos Munoz A., López Perez E., Artilles Medina A., Brasero Burgos J., Sanchez Gonzalez A., Jimenez Cidre M.A., Burgos Revilla F.J.
Institutes: Hospital Ramon y Cajal, Dept. of Urology, Madrid, Spain
- P249** **Radical cystectomy in elderly patients: Perioperative morbidity and mortality**
Authors: Nouioui M.A., Saadi A., Bedoui M.A., Zaghib S., Mokadem S., Boussaffa H., Hermi A., Ayed H., Bouzouita A., Derouiche A., Chakroun M., Ben Slama M.R.
Institutes: Charles Nicolle Hospital, Dept. of Urology, Tunis, Tunisia
- P250** **Clinico-pathological characterization and treatment analysis of micropapillary bladder carcinoma**
Authors: Bedoui M.A., Saadi A., Zaghib S., Mokadem S., Boussaffa H., Hermi A., Ayed H., Bouzouita A., Derouiche A., Chakroun M., Ben Slama M.R.
Institutes: Charles Nicolle Hospital, Dept. of Urology, Tunis, Tunisia
- P251** **Inhibitory coreceptors in variant histologies of bladder cancer – the next chapter in urooncology?**
Authors: Rodler S.¹, Ledderose S.², Waidelich R.¹, Casuscelli J.¹, Stief C.¹, Eismann L.¹
Institutes: ¹Klinikum der Universität München, Dept. of Urology, Munich, Germany, ²Klinikum der Universität München, Dept. of Pathology, Munich, Germany
- P252** **The long term 5 years' oncologic impact of narrow band imaging – en bloc bipolar plasma resection hybrid approach versus the standard diagnostic and treatment protocol – A matched-paired, index-control cohort long-term clinical comparison**
Authors: Geavlete B.¹, Ene C.¹, Bulai C.¹, Popescu R.², Mares C.¹, Geavlete P.¹
Institutes: ¹Saint John Emergency Clinical Hospital, Dept. of Urology, Bucharest, Romania, ²Carol Davila University of Medicine and Pharmacy, Dept. of Urology, Bucharest, Romania
- P253** **Adjuvant immunotherapy bladder score (AIOB): a new score to identify the ideal candidate for adjuvant (adj) immunotherapy (IO) in patients (pts) undergoing radical cystectomy (RC) for muscle invasive bladder cancer (MIBC)**
Authors: Foschi N.¹, Ciccicarese C.², Russo P.¹, Marino F.¹, Ragonese M.¹, Rossi F.¹, Filomena G.B.¹, Maioriello G.¹, Anghelone A.², Tortora G.², Iacovelli R.²
Institutes: ¹Fondazione Policlinico Universitario A.Gemelli, Dept. of Urology, Rome, Italy, ²Fondazione Policlinico Universitario A.Gemelli, Dept. of Oncology, Rome, Italy
- P254** **Prognostic factors for urachal carcinoma**
Authors: Suzuki A., Nagasaka H., Shotaro Y., Usui K., Terao H., Nakaigawa N., Kishida T.
Institutes: Kanagawa Cancer Center, Dept. of Urology, Yokohama, Japan

- P255** **Multi-center study of progression factors and intravesical recurrence in patients with urothelial carcinoma of the upper urinary tract**
Authors: Garcia Morales L.¹, Contreras Matos F.J.², Puche Sanz I.², Morillo Tejedor A.C.¹, Mellado Castellero A.¹, Anglada Curado F.J.¹, Gómez Gómez E.¹
Institutes: ¹Reina Sofía University Hospital, Dept. of Urology, Córdoba, Spain, ²Virgen de las Nieves University Hospital, Dept. of Urology, Granada, Spain
- P256** **Prognostic relevance of Platelet-to-Lymphocyte Ratio in patients with Muscle-Invasive Bladder Cancer Patients: real world data from a retrospective multicenter analysis**
Authors: Pecoraro G.¹, Scagliarini S.², Puglia L.¹, Alberico G.¹, Amato A.R.¹, Migliaccio F.¹, Di Costanzo F.¹, Ribera D.¹, Verde A.¹, D'Ambrosio A.¹, Buonaiuto R.¹, Salomone F.¹, Viggiano A.¹, Peddio A.¹, Romano F.J.², Servetto A.¹, Bianco R.¹, Formisano L.¹
Institutes: ¹Azienda Ospedaliera Universitaria Federico II, Dept. of Oncohematology, Naples, Italy, ²Azienda Ospedaliera di Rilievo Nazionale Antonio Cardarelli, Dept. of Oncohematology, Naples, Italy
- P257** **Surveillance of Non-Muscle Invasive Bladder Cancer with Blue Light Cystoscopy: A Systematic Review and Meta-Analysis**
Authors: Sari Motlagh R.¹, Ghoreifi A.², Yanagisawa T.¹, Kawada T.¹, Sascha A.³, Merseburger A.S.⁴, Abufaraj M.⁵, Djaladat H.², Daneshmand S.², Shariat S.F.¹
Institutes: ¹Medical University of Vienna, Dept. of Urology, Vienna, Austria, ²Keck School of Medicine-University of Southern California, Dept. of Urology, Los Angeles, United States of America, ³Medical University of Graz, Dept. of Urology, Graz, Austria, ⁴Campus Lübeck-University Hospital Schleswig-Holstein, Dept. of Urology, Lübeck, Germany, ⁵Jordan University Hospital-the University of Jordan, Special Surgery-Division of Urology, Amman, Jordan
- P258** **Squamous cell carcinoma of the bladder and upper urinary tract (SCCBUT): a retrospective cohort analysis**
Authors: Gomez D.¹, Morales-Barrera R.¹, Salvà de Torres C.¹, Suárez C.¹, Marmolejo-Castaneda D.¹, Navarro Garcés V.², Mast R.³, Roche S.³, Semidey M.A.E.⁴, Raventos C.⁵, Mateo J.¹, González M.¹, Carrión A.⁵, Lozano F.⁵, de Torres I.S.⁴, Trilla E.⁵, Maldonado X.⁶, Carles J.¹
Institutes: ¹Vall d'Hebron University Hospital, Dept. of Medical Oncology, Barcelona, Spain, ²Vall d'Hebron Institute of Oncology-VHIO, Data Science-ODysSey, Barcelona, Spain, ³Vall d'Hebron University Hospital, Dept. of Radiology, Barcelona, Spain, ⁴Vall d'Hebron University Hospital, Dept. of Pathology, Barcelona, Spain, ⁵Vall d'Hebron University Hospital, Dept. of Urology, Barcelona, Spain, ⁶Vall d'Hebron University Hospital, Dept. of Radiation Oncology, Barcelona, Spain

P259

Enhancing Predictions of the EAU21 Scoring Model in High-Grade Non-Muscle Invasive Bladder Carcinoma Treated with BCG using Explainable Machine Learning Survival Ensemble

Authors: Subiela Henriquez J.D.¹, Krajewski W.², Aumatell J.L.³, González-Padilla D.⁴, Lopez J.⁵, Gomez-Rivas J.⁶, Gallioli A.⁷, Moschini M.⁸, Cimadamore A.⁹, D Andrea D.¹⁰, Mertens L.¹¹, Alvarez-Maestro M.¹², Pradere B.¹³, Marcq G.¹⁴, Afferi L.¹⁵, Basile G.⁸, Cano J.¹⁶, Guerrero-Ramos F.¹⁷, Lopez-Perez E.¹, Montorsi F.⁸, Dominguez-Escrig J.L.¹⁸, Artiles-Medina A.¹, Sanchez-Gonzalez A.¹, Brasero-Burgos J.¹, Yuen-Chun Teoh J.¹⁹, Rajwa P.¹⁰, Nowak U.², Rodríguez-Faba O.⁷, Del Giudice F.²⁰, Laukhtina E.²¹, Ploussard G.¹³, Tully K.²², Szydelko T.², Gomez-Dos Santos V.¹, Jimenez Cidre M.A.¹, Burgos Revilla F.J.¹

Institutes: ¹Hospital Universitario Ramón y Cajal IRYCIS Universidad de Alcalá, Dept. of Urology, Madrid, Spain, ²Center of Excellence in Urology, Dept. of Minimally Invasive Robotic Urology, Wroclaw, Poland, ³Hospital Universitario Rey Juan Carlos, Dept. of Urology, Mostoles, Spain, ⁴Clínica Universidad de Navarra, Dept. of Urology, Madrid, Spain, ⁵Datons, Data Science, Salamanca, Spain, ⁶Hospital Clínico San Carlos, Dept. of Urology, Madrid, Spain, ⁷Fundació Puigvert, Dept. of Urology, Barcelona, Spain, ⁸Vita-Salute San Raffaele University, Dept. of Urology, Milan, Italy, ⁹Polytechnic University of the Marche Region, Dept. of Pathology, Ancona, Italy, ¹⁰Medical University of Vienna, Dept. of Urology, Vienna, Austria, ¹¹The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Dept. of Urology, Amsterdam, The Netherlands, ¹²Hospital Universitario La Paz, Dept. of Urology, Madrid, Spain, ¹³La Croix Du Sud Hospital, Dept. of Urology, Quint-Fonsegrives, France, ¹⁴Claude Huriez Hospital, Dept. of Urology, Lille, France, ¹⁵Luzerner Kantonsspital, Dept. of Urology, Luzern, Switzerland, ¹⁶Hospital Universitario Gregorio Marañon, Dept. of Urology, Madrid, Spain, ¹⁷Hospital Universitario 12 de Octubre, Dept. of Urology, Madrid, Spain, ¹⁸Fundación Instituto Valenciano de Oncología, Dept. of Urology, Valencia, Spain, ¹⁹The Chinese University of Hong Kong, Dept. of Urology, Shatin, Hong Kong, ²⁰Sapienza University of Rome, Dept. of Maternal Infant and Urologic Sciences, Rome, Italy, ²¹Sechenov Universit, Institute for Urology and Reproductive Health, Moscow, Russia, ²²Marien Hospital Herne, Dept. of Urology and Neurourology, Herne, Germany

P260

Absence of Tumor (T0) on Second Transurethral Resection (ReTURB) Positively Impact Recurrence and Progression Risk Dynamics in a Contemporary Series of High-grade T1 Non-muscle Invasive Bladder Carcinoma Treated With Adequate Bacillus Calmette-Guérin

Authors: Subiela Henriquez J.D.¹, Krajewski W.², Tukiendorf A.³, Aumatell J.⁴, González-Padilla D.⁵, Gomez-Rivas J.⁶, Gallioli A.⁷, Moschini M.⁸, Cimadamore A.⁹, D Andrea D.¹⁰, Mertens L.¹¹, Alvarez-Maestro M.¹², Pradere B.¹³, Marcq G.¹⁴, Afferi L.¹⁵, Basile G.⁸, Cano J.¹⁶, Guerrero-Ramos F.¹⁷, Lopez-Perez E.¹, Montorsi F.⁸, Dominguez-Escrig J.L.¹⁸, Artiles-Medina A.¹, Sanchez-Gonzalez A.¹, Brasero-Burgos J.¹, Yuen-Chun Teoh J.¹⁹, Rajwa P.¹⁰, Nowak U.², Rodríguez-Faba O.⁷, Del Giudice F.²⁰, Ploussard G.¹³, Tully K.²¹, Laukhtina E.²², Gomez-Dos Santos V.¹, Szydelko T.², Jimenez Cidre M.¹, Burgos Revilla F.J.¹

Institutes: ¹Hospital Universitario Ramón y Cajal IRYCIS Universidad de Alcalá, Dept. of Urology, Madrid, Spain, ²Center of Excellence in Urology, Dept. of Minimally Invasive Robotic Urology, Wroclaw, Poland, ³Opole University, Institute of Health Science, Opole, Poland, ⁴Hospital Universitario Rey Juan Carlos, Dept. of Urology, Mostoles, Spain, ⁵Clínica Universidad de Navarra, Dept. of Urology, Madrid, Spain, ⁶Hospital Clínico San Carlos, Dept. of Urology, Madrid, Spain, ⁷Fundació Puigvert, Dept. of Urology, Barcelona, Spain, ⁸Vita-Salute San Raffaele University, Dept. of Urology, Milan, Italy, ⁹Polytechnic University of the Marche Region, Dept. of Pathology, Ancona, Italy, ¹⁰Medical University of Vienna, Dept. of Urology, Vienna, Austria, ¹¹The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Dept. of Urology, Amsterdam, The Netherlands, ¹²Hospital Universitario La Paz, Dept. of Urology, Madrid, Spain, ¹³La Croix Du Sud Hospital, Dept. of Urology, Quint-Fonsegrives, France, ¹⁴Claude Huriez Hospital, Dept. of Urology, Lille, France, ¹⁵Luzerner Kantonsspital, Dept. of Urology, Luzern, Switzerland, ¹⁶Hospital Universitario Gregorio Marañón, Dept. of Urology, Madrid, Spain, ¹⁷Hospital Universitario 12 de Octubre, Dept. of Urology, Madrid, Spain, ¹⁸Fundación Instituto Valenciano de Oncología, Dept. of Urology, Valencia, Spain, ¹⁹The Chinese University of Hong Kong, Dept. of Urology, Shatin, Hong Kong, ²⁰Sapienza University of Rome, Dept. of Maternal Infant and Urologic Sciences, Rome, Italy, ²¹Marien Hospital Herne, Dept. of Urology and Neurourology, Herne, Germany, ²²Sechenov University, Institute for Urology and Reproductive Health, Moscow, Russia

P261

A systematic review of upper urinary tract recurrence predictors after radical cystectomy

Authors: Kardoust Parizi M.¹, Margulis V.², Lotan Y.², Shariat S.F.¹

Institutes: ¹Medical University of Vienna, Dept. of Urology, Vienna, Austria, ²University of Texas Southwestern Medical Center, Dept. of Urology, Dallas, United States of America

P262

Treatment Strategies and Clinical Outcomes in patients with Localized and Advanced Bladder Cancer: Real-World Data from a Single Spanish Institution.

Authors: Sánchez-Camacho A., Torres Zurita A., Vázquez Montero L., Flores Raposo J., Nogales Fernández E., Virizuela Echaburu J.A.

Institutes: Hospital Virgen Macarena, Dept. of Medical Oncology, Seville, Spain

- P263** **The feasibility of MicroRNA-Based Approach in Prognostic Stratification in Bladder Cancer Patients**
Authors: Di Gianfrancesco L.¹, Cavallari I.², Ciminale V.², Crestani A.³, Amodeo A.¹, Corsi P.¹, Lista G.¹, De Marchi D.¹, Miglioranza E.¹, Cargnel C.G.¹, Vitelli F.D.¹, Simonetti F.¹, Porreca A.¹
Institutes: ¹Veneto Institute of Oncology IOV IRCCS, Dept. of Oncological Urology, Padua, Italy, ²Veneto Institute of Oncology IOV IRCCS, UOC Immunology and Molecular Oncological Diagnostics IDMO, Padua, Italy, ³Azienda Sanitaria Universitaria Friuli Centrale, Dept. of Urology, Udine, Italy
- P264** **The prognostic value of pre-neoadjuvant chemotherapy prognostic nutritional index, systemic inflammatory response index and neutrophil-to-lymphocyte ratio in muscle invasive bladder cancer**
Authors: Ramos M.J.¹, Costa M.², Marques Monteiro M.³, Castanheira de Oliveira M.³, Pinho M.², Magalhaes H.², Febra J.¹, Simoes J.¹, Araújo A.¹
Institutes: ¹Centro Hospitalar Universitário de Santo António, Dept. of Medical Oncology, Porto, Portugal, ²Hospital Pedro Hispano, Dept. of Medical Oncology, Matosinhos, Portugal, ³Centro Hospitalar Universitário de Santo António, Dept. of Urology, Porto, Portugal
- P265** **The role of nodal yield in patients with bladder cancer submitted to neoadjuvant chemotherapy and radical cystectomy**
Authors: Costa M.¹, Ramos M.J.², Monteiro M.M.³, Lopes Fernandes C.¹, Silva D.¹, Faria-Costa G.⁴, Reis F.C.⁴, Oliveira M.C.³, Simoes J.², Febra J.², Pinho M.¹, Magalhaes H.¹
Institutes: ¹Hospital Pedro Hispano, Dept. of Medical Oncology, Matosinhos, Portugal, ²Centro Hospitalar Universitário de Santo António, Dept. of Medical Oncology, Porto, Portugal, ³Centro Hospitalar Universitário de Santo António, Dept. of Urology, Porto, Portugal, ⁴Hospital Pedro Hispano, Dept. of Urology, Porto, Portugal
- P266** **Gender Influence on Efficacy and Immune-Related Adverse Events of Immune Checkpoint Inhibitors in Metastatic Urothelial Cancer Patients**
Authors: Aydogdu C.¹, Diedrichsen S.¹, Berg E.¹, Tamalunas A.¹, Götz M.¹, Rodler S.¹, Heinemann V.², Stief C.G.¹, Casuscelli J.¹
Institutes: ¹Ludwig-Maximilians-University Hospital, Dept. of Urology, Munich, Germany, ²Ludwig-Maximilians-University Hospital, Dept. of Medicine III, Munich, Germany
- P267** **Quality of life in patients with Non-Muscle Invasive Bladder Cancer (NMIBC) subjected to intravesical instillations with BCG induction**
Authors: Cano Velasco J.¹, Moreno Cortés J.C.¹, Lafuente Puentedura A.¹, Polanco Pujol L.¹, Subiela Henriquez J.D.², Aragón Chamizo J.¹, Mayor de Castro J.¹, Pastor Cordero A.¹, Herranz Amo F.¹, Hernández Fernández C.¹
Institutes: ¹Hospital General Universitario Gregorio Marañon, Dept. of Urology, Madrid, Spain, ²Hospital Universitario Ramón y Cajal, Dept. of Urology, Madrid, Spain

- P268** **Development of Health related Quality of Life in patients with muscle-invasive bladder cancer**
Authors: Nuijens S.T.¹, Hoogstraten L. M. C.², Terpstra N.B.³, Meijer R. P.⁴, Kiemeny L. A.³, Witjes J.A.¹, Aben K. K. H.²
Institutes: ¹Radboud University Medical Centre, Dept. of Urology, Nijmegen, The Netherlands, ²Netherlands Comprehensive Cancer Organisation, Research and Development, Utrecht, The Netherlands, ³Radboud University Medical Centre, Dept. of Health Evidence, Nijmegen, The Netherlands, ⁴University Medical Centre Utrecht, Dept. of Oncological Urology, Utrecht, The Netherlands
- P269** **Visceral adiposity as a predictor for prolonged operating time of transperitoneal laparoscopic adrenalectomy**
Authors: Taniuchi M.¹, Yanagi M.¹, Kiriya T.², Akatsuka J.¹, Endo Y.¹, Takeda H.¹, Hamasaki T.³, Kondo Y.¹
Institutes: ¹Nippon Medical School Hospital, Dept. of Urology, Bunkyo-ku, Japan, ²Nippon Medical School Hospital, Dept. of Radiology, Bunkyo-ku, Japan, ³Nippon Medical School, Musashikosugi Hospital, Dept. of Urology, Kawasaki, Japan
- P270** **Which factors have an impact on fertility outcomes of microsurgical varicocelelectomy?**
Authors: Shomarufov A.B., Akilov F.A., Mukhtarov S.T.
Institutes: Tashkent Medical Academy, Urology, Tashkent, Uzbekistan
- P271** **Case report: Uncommon presentation of metastatic endometrial cancer with synchronous adrenal and renal involvement**
Authors: Dama M., Yorulmaz E.M., Donmez K., Gorgel S.N., Akin Y.
Institutes: Izmir Katip Celebi University, Dept. of Urology, Izmir, Turkey
- P272** **Inadequate PROs and HRQoL reporting in phase III advanced genitourinary tumors RCTs**
Authors: Di Costanzo F.¹, Salomone F.¹, Vitale F.¹, Amato A.R.¹, Alberico G.¹, Migliaccio F.¹, Pecoraro G.¹, Verde A.¹, Ribera D.¹, D'Ambrosio A.¹, Napolitano F.¹, Scagliarini S.², Rossetti S.³, Puglia L.², Di Napoli M.³, Crocetto F.⁴, Bianco R.¹, Servetto A.¹, Formisano L.¹
Institutes: ¹AOU Federico II, Dept. of Medical Oncology, Naples, Italy, ²AORN Cardarelli, Dept. of Medical Oncology, Naples, Italy, ³IRCCS Pascale, Dept. of Medical Oncology, Naples, Italy, ⁴AOU Federico II, Dept. of Urology, Naples, Italy
- P273** **Awareness About Genitourinary Cancer in North Africa – Social Listening Analytics**
Authors: Yekrou D.¹, Guettouche M.G.², Magdy M.³
Institutes: ¹Centre de Lutte Contre le Cancer CLCC de Sidi Bel Abbés, Dept. of Oncology, Sidi Bel Abbes, Algeria, ²Pfizer, Dept. of Medical Affairs, Algiers, Algeria, ³Pfizer, Dept. of Medical Affairs, Cairo, Egypt
- LB01** **Propensity score matched analysis of functional outcome in 5000 cases of robot-assisted radical prostatectomy versus high-intensity focused ultrasound**
Authors: Song S.H., Byun S.S., Lee H.
Institutes: Seoul National University Bundang Hospital, Dept of. Urology, Seongnam, South Korea

- LB02** **Grade heterogeneity in high grade urothelial carcinomas: Does it have an impact on the survival of patients with intermediate/high risk NMIBC who received adequate adjuvant BCG therapy?**
Authors: Karaburun M.C.¹, Serbes E.D.², Akpınar C.¹, Obaid K.¹, Gogus C.¹, Kiremitci S.², Enneli D.², Baltacı S.¹, Suer E.¹
Institutes: ¹Ankara University, Dept. of Urology, Ankara, Turkey, ²Ankara University, Dept. of Pathology, Ankara, Turkey
- LB03** **Predictors of morbidity in inguinal lymph node staging for penile cancer**
Authors: Rodrigues V., Oliveira J., Teixeira de Sousa J., Silva C., Antunes Lopes T., Vale L.
Institutes: Centro Hospitalar e Universitario Sao Joao, Urology, Porto, Portugal
- LB04** **The prostatype® test, a novel genomic classifier, accurately predicts Adverse Pathology (AP) at Radical Prostatectomy (RP)**
Authors: Berglund E., Gaal S., Andriole G.
Institutes: Prostatype Genomics, Research and Development, Solna, Sweden
- LB05** **Effect of obesity-associated inflammatory factor IL-6 on the vitality of prostate cancer cells via SRD5A1**
Authors: Wu X.W., Chiu K-F.P., Ng C-F.
Institutes: The Chinese University of Hong Kong, SH HO Urology Center, Shatin, Hong Kong
- LB06** **Mechanism of IL-6/STAT3 regulation of SRD5A1 in prostate cancer cells**
Authors: Wu X.W., Chiu K-F.P., Ng C-F.
Institutes: The Chinese University of Hong Kong, SH HO Urology Center, Shatin, Hong Kong

New standards and novel approaches in advanced prostate cancer

Plenary Session 13

**05 November
2023
08:45 - 10:15**

**Location
Chairs**

Auditorium
U. Vogl, Bellinzona (CH)
V. Fonteyne, Ghent (BE)
W.L. Loidl, Linz (AT)
D. Oprea-Lager, Amsterdam (NL)

08:45 - 08:55

The role of local treatment in M1a disease

A. Briganti, Milan (IT)

08:55 - 09:05

Intensification of systemic treatment for men with de novo M1 disease

K. Fizazi, Villejuif (FR)

09:05 - 09:15

De-escalating strategies in HSPC: who, when, how?

B. Tombal, Brussels (BE)

09:15 - 09:30

Discussion

09:30 - 09:40

Lu-PSMA in mCRPC men not taxane pre-treated

A. Farolfi (IT)

09:40 - 09:50

PARP inhibitors for mCRPC: for all or for BRCA patients only?

E. Castro, Madrid (ES)

09:50 - 10:00

Novel targeted approaches in mCRPC

J. De Bono, London (GB)

10:00 - 10:15

Discussion

Special guest lecture

**05 November
2023
10:45 - 11:00**

**Location
Chair**

Auditorium
F. Sanguedolce, Barcelona (ES)

10:45 - 11:00

The future of healthcare

Presenter

S. Ahmed, London (GB)

Multidisciplinary case discussions in metastatic prostate cancer

Plenary Session 14

**05 November
2023
11:00 - 12:00**

Location Auditorium
Moderator E. Castro, Madrid (ES)

11:00 - 11:30

G. Baciarello, Rome (IT)
P. Blanchard, Villejuif (FR)
J. Walz, Marseille (FR)
T. Barrett, Cambridge (GB)
K. Goffin, Leuven (BE)
**Multidisciplinary case
discussion: Metastatic early
recurrent disease**

**Case
presenter** R. Flippot, Villejuif
(FR)

11:30 - 12:00

G. Baciarello, Rome (IT)
P. Blanchard, Villejuif (FR)
J. Walz, Marseille (FR)
T. Barrett, Cambridge (GB)
K. Goffin, Leuven (BE)
**Multidisciplinary case
discussion: Sequencing in
mCRPC**

**Case
presenter** R. Flippot, Villejuif
(FR)

Take home messages

Take home messages

05 November 2023 12:00 - 12:25	Location	Auditorium
12:00 - 12:05	Pathology M. Colecchia, Milan (IT)	
12:05 - 12:10	Radiation Oncology V. Fonteyne, Ghent (BE)	
12:10 - 12:15	Urology W.L. Loidl, Linz (AT)	
12:15 - 12:20	Radiology T. Barrett, Cambridge (GB)	
12:20 - 12:25	Medical Oncology E. Castro, Madrid (ES)	

Closing remarks

Closing remarks

**05 November
2023
12:25 - 12:30**

**Location
Chairs**

Auditorium
C. Porta, Bari (IT)
P. Blanchard, Villejuif (FR)
A. Stenzl, Tübingen (DE)

Abstract session

ESUI Abstract Session

Location

Chairs

F. Sanguedolce, Barcelona (ES)

P. Martino, Bari (IT)

O01

MRI in penile cancer: Correlating examination and histopathology with imaging

Authors: Gupta M.¹, Gupta S.¹, Aggarwal G.¹, Bansal V.², SHARMA H.³

Institutes: ¹Tata Medical Center, Dept. of Urologic Surgery, Kolkata, India, ²Tata medical center, Dept. of Surgical Oncology, Kolkata, India, ³Alfala School of Medical Sciences, Dept. of Surgical Oncology, Faridabad, India

O02

Outcomes of Cytoreductive Radical Prostatectomy for Oligometastatic Prostate Cancer on PSMA-PET: Results of a Multicenter, European Study

Authors: Rajwa P.¹, Robesti D.², Chaloupka M.³, Zattoni F.⁴, Giesen A.⁵, Huebner N.A.⁶, Krzywon A.⁷, Mischczyk M.⁸, Moll M.⁹, Stando R.¹⁰, Cisero E.¹¹, Semko S.¹², Checucci E.¹³, Devos G.⁵, Apfelbeck M.³, Gatti C.¹³, Marra G.¹⁴, van den Bergh R.C.N.¹⁵, Goldner G.⁹, Rasul S.¹⁶, Ceci F.¹⁷, Dal Moro F.⁴, Porpiglia F.¹¹, Gontero P.¹⁴, Bjartell A.¹⁸, Stief C.³, Heidenreich A.¹², Joniau S.⁵, Briganti A.², Shariat S.F.⁶, Gandaglia G.²

Institutes: ¹Medical University of Silesia, Dept. of Urology, Zabrze, Poland, ²IRCCS San Raffaele Scientific Institute, Unit of Urology, Milan, Italy, ³Ludwig-Maximilians-University Munich, Dept. of Urology, Munich, Germany, ⁴University of Padua, Dept. of Surgery Oncology and Gastroenterology, Padua, Italy, ⁵University Hospitals Leuven, Dept. of Urology, Leuven, Belgium, ⁶Medical University of Vienna, Dept. of Urology, Vienna, Austria, ⁷Maria Sklodowska-Curie National Research Institute of Oncology, Dept. of Biostatistics and Bioinformatics, Gliwice, Poland, ⁸Maria Sklodowska-Curie National Research Institute of Oncology, IIIrd Department of Radiotherapy and Chemotherapy, Gliwice, Poland, ⁹Medical University of Vienna, Dept. of Radiation Oncology, Vienna, Austria, ¹⁰Holy Cross Cancer Center, Dept. of Radiotherapy, Kielce, Poland, ¹¹University of Turin, Division of Urology, Turin, Italy, ¹²University Cologne, Dept. of Urology, Cologne, Germany, ¹³Candiolo Cancer Institute, Dept. of Surgery, Turin, Italy, ¹⁴Città della Salute e della Scienza University of Turin, Dept. of Urology, Turin, Italy, ¹⁵St. Antonius Hospital, Dept. of Urology, Utrecht, The Netherlands, ¹⁶Medical University of Vienna, Dept. of Biomedical Imaging and Image-Guided Therapy, Vienna, Austria, ¹⁷IEO European Institute of Oncology - IRCCS, Division of Nuclear Medicine, Milan, Italy, ¹⁸Lund University, Dept. of Urology, Malmö, Sweden

O03

Complete biochemical response below 0.1 ng/ml predicts long-term therapy-free survival of prostate cancer patients treated with salvage lymph node dissection via PSMA-radioguided surgery

Authors: Knipper S.¹, Lischewski F.², Koehler D.³, Eiber M.⁴, van Leeuwen F.W.B.⁵, de Barros H.⁶, Berrens A-C.⁶, van Leeuwen P.⁶, van der Poel H.⁶, Ambrosini F.¹, Falkenbach F.¹, Budäus L.¹, Steuber T.¹, Graefen M.¹, Tennstedt P.¹, Gschwend J.E.², Horn T.², Heck M.M.², Maurer T.¹

Institutes: ¹Martini-Klinik Prostate Cancer Center, Dept. of Urology, Hamburg, Germany, ²Technical University of Munich, Dept. of Urology, Munich, Germany, ³University Hospital Hamburg-Eppendorf, Dept. of Nuclear Medicine, Hamburg, Germany, ⁴Technical University of Munich, Dept. of Nuclear Medicine, Munich, Germany, ⁵Leiden University Medical Center, Dept. of Radiology, Leiden, The Netherlands, ⁶Antoni van Leeuwenhoek Hospital the Netherlands Cancer Institute, Dept. of Urology, Amsterdam, The Netherlands

O04

A MULTI-centre feasibility study to assess the use of 99m Tc-sestaMIBI SPECT/CT in the diagnosis of kidney tumours (MULTI-MIBI study)

Authors: Warren H.¹, Wagner T.², El-Sheikh S.³, Barod R.¹, Patki P.⁴, Mumtaz F.¹, Bex A.¹, Campain N.⁵, Rogers P.⁶, O'Brien T.⁷, Hassan F.⁸, Stewart G.⁹, Mendichovszky I.¹⁰, Dizdarevic S.¹¹, Alanbuki A.¹², Wah T.¹³, Scarsbrook A.¹³, Wildgoose W.¹⁴, Vindrola-Padros C.¹, Pizzo E.¹⁵, Dehbi H.M.¹⁶, Gurusamy K.¹, Emberton M.¹, Tran M.G.B.¹

Institutes: ¹University College London, Division of Surgery and Interventional Sciences, London, United Kingdom, ²Royal Free Hospital, Dept. of Nuclear Medicine, London, United Kingdom, ³Royal Free Hospital Specialist Centre for Kidney Cancer, Dept. of Pathology, London, United Kingdom, ⁴Royal Free Hospital Specialist Centre for Kidney Cancer, Dept. of Urology, London, United Kingdom, ⁵Royal Devon University Hospitals, Dept. of Urology, Exeter, United Kingdom, ⁶Royal Devon University Hospitals, Dept. of Radiology, London, United Kingdom, ⁷Guy's and St Thomas' NHS Foundation Trust, Dept. of Urology, London, United Kingdom, ⁸Guy's and St Thomas' NHS Foundation Trust, Dept. of Nuclear Medicine, London, United Kingdom, ⁹Cambridge University Hospitals, Dept. of Urology, Cambridge, United Kingdom, ¹⁰Cambridge University Hospitals, Dept. of Radiology and Nuclear Medicine, Cambridge, United Kingdom, ¹¹University Hospitals Sussex NHS Foundation Trust, Dept. of Nuclear Medicine, Brighton, United Kingdom, ¹²University Hospitals Sussex NHS Foundation Trust, Dept. of Urology, Brighton, United Kingdom, ¹³Leeds Teaching Hospitals Trust, Dept. of Radiology, Leeds, United Kingdom, ¹⁴Patient and Public Representative, London, United Kingdom, ¹⁵University College London, Dept. of Applied Health Research, London, United Kingdom, ¹⁶University College London, Comprehensive Clinical Trials Unit Institute of Clinical Trials and Methodology, London, United Kingdom

- P010** **Pre-magnetic resonance imaging (MRI) prostate-specific antigen density (PSAD) risk-stratification to avoid MRIs, biopsies and detection of low-risk prostate cancer: Results of the MR-PROPER study**
Authors: Dudaie M.¹, Haifler M.², Dotan E.¹, Barnea I.¹, Shaked N.¹
Institutes: ¹Tel Aviv University, Dept. of Biomedical Engineering, Tel Aviv, Israel, ²Meir Medical Center, Dept. of Urology, Kfar Saba, Israel
- O06** **The diagnostic value of fibroblast activation protein inhibitor positron emission tomography/computed tomography in genitourinary malignancies – a systematic review**
Authors: Hagens M.J.¹, van Leeuwen P.J.¹, Boellaard T.N.², Schoots I.G.², van der Poel H.G.¹, Mertens L.S.¹
Institutes: ¹Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Dept. of Urology, Amsterdam, The Netherlands, ²Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Dept. of Radiology, Amsterdam, The Netherlands